Independence Holding (IHC) 10-K 16 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Mar. 06, 2020	Jun. 30, 2019
Details
Registrant CIK	0000701869
Fiscal Year End	--12-31
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2019
Document Transition Report	false
Entity File Number	001-32244
Entity Registrant Name	INDEPENDENCE HOLDING COMPANY
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-1407235
Entity Address, Address Line One	96 CUMMINGS POINT ROAD
Entity Address, City or Town	STAMFORD
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06902
City Area Code	203
Local Phone Number	358-8000
Title of 12(b) Security	Common Stock, $1.00 par value
Trading Symbol	IHC
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 192,788
Entity Common Stock, Shares Outstanding		14,850,921
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Investments
Short-term Investments	$ 50	$ 1,050
Securities Purchased under Agreements to Resell	107,157	12,063
Debt Securities, Available-for-sale	384,974	453,464
Equity Securities, FV-NI	3,747	5,166
Other Investments	15,208	13,192
Investments	511,136	484,935
Cash and Cash Equivalents, at Carrying Value	21,094	26,173
Premiums Receivable, Net	26,244	24,412
Reinsurance Recoverables, Including Reinsurance Premium Paid	362,969	368,731
Goodwill	60,165	50,697
Other Assets	72,695	82,568
Assets, Total	1,054,303	1,037,516
Liabilities
Liability for Claims and Claims Adjustment Expense	164,802	160,115
Liability for Future Policy Benefit, before Reinsurance	201,205	208,910
Deposit Contracts, Liabilities	140,951	141,635
Unearned Premiums	7,282	5,557
Policyholder Account Balance	12,049	10,939
Reinsurance Payable	5,016	3,613
Other Liabilities	61,049	53,133
Liabilities	592,354	583,902
Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount	2,237	2,183
TOTAL LIABILITIES AND EQUITY	1,054,303	1,037,516
STOCKHOLDERS' EQUITY:
Preferred Stock, Value, Issued	0	0
Common Stock, Value, Issued	18,625	18,625
Additional Paid in Capital, Common Stock	122,717	124,395
Accumulated Other Comprehensive Income (Loss), Net of Tax	1,212	(8,310)
Treasury stock, at cost; 3,760,517 and 3,747,210 shares	69,724	66,392
Retained Earnings (Accumulated Deficit)	386,864	380,431
TOTAL IHC STOCKHOLDERS' EQUITY	459,694	448,749
Stockholders' Equity Attributable to Noncontrolling Interest	18	2,682
TOTAL EQUITY	$ 459,712	$ 451,431

Consolidated Balance Sheets - P

Consolidated Balance Sheets - Parenthetical - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Details
Preferred Stock, Par or Stated Value Per Share	$ 1	$ 1
Preferred Stock, Shares Authorized	100,000	100,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par or Stated Value Per Share	$ 1	$ 1
Common Stock, Shares Authorized	23,000,000	23,000,000
Common Stock, Shares, Issued	18,625,458	18,625,458
Common Stock, Shares, Outstanding	14,864,941	14,878,248
Treasury Stock, Shares	3,760,517	3,747,210

Consolidated Income Statement

Consolidated Income Statement - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues
Premiums Earned, Net	$ 338,741	$ 321,248
Net Investment Income	15,643	15,021
Insurance Commissions and Fees	14,003	18,900
Other Income	2,002	(3,361)
Gain (Loss) on Investments	4,705	(1,033)
Revenues	374,448	350,775
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale	646	0
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Portion in Other Comprehensive Loss, before Tax, Including Portion Attributable to Noncontrolling Interest	0	0
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings	646	0
Operating Expenses
Policyholder Benefits and Claims Incurred, Net	174,121	144,206
Selling, General and Administrative Expense	174,979	169,028
Benefits, Losses and Expenses	349,100	313,234
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	25,348	37,541
Income Tax Expense (Benefit)	12,659	8,488
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	12,689	29,053
Net Income (Loss) Attributable to Nonredeemable Noncontrolling Interest	119	352
Net Income (Loss) Attributable to Redeemable Noncontrolling Interest	174	219
Net Income (Loss) Attributable to Parent	$ 12,396	$ 28,482
Earnings Per Share, Basic	$ 0.83	$ 1.92
Weighted Average Number of Shares Outstanding, Basic	14,903	14,812
Earnings Per Share, Diluted	$ 0.83	$ 1.89
Weighted Average Number of Shares Outstanding, Diluted	14,976	15,104

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 12,689	$ 29,053
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax	12,070	(4,272)
Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax	2,548	(910)
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	9,522	(3,362)
Other Comprehensive Income (Loss), Net of Tax	9,522	(3,362)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	22,211	25,691
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest
Net Income (Loss) Attributable to Noncontrolling Interest	293	571
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest	0	0
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	293	571
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ 21,918	$ 25,120

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($) $ in Thousands	Total	COMMON STOCK, AMOUNT	PAID-IN CAPITAL	ACCUMULATED OTHER COMPREHENSIVE INCOME(LOSS)	TREASURY STOCK, AT COST	RETAINED EARNINGS	TOTAL IHC STOCKHOLDERS' EQUITY	NON-CONTROLLING INTERESTS
Treasury Stock, Shares					(3,735,173)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2017	$ 434,243	$ 18,625	$ 124,538	$ (4,598)	$ (63,404)	$ 356,383	$ 431,544	$ 2,699
Common Stock, Shares, Issued at Dec. 31, 2017		18,625,458
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest	28,834					28,482	28,482	352
Other Comprehensive Income (Loss), Net of Tax	(3,362)			(3,362)			(3,362)	0
Treasury Stock, Value, Acquired, Cost Method	$ (4,019)				$ (4,019)		(4,019)	0
Treasury Stock, Shares, Acquired	(135,311)				(135,311)
Dividends, Common Stock, Cash	$ (4,468)					(4,468)	(4,468)	0
Sharebased Compensation Effect On Stockholders Equity	888		(143)		$ 1,031		888	0
Sharebased Compensation Effect On Stockholders Equity, Shares Issued					123,274
Distributions to noncontrolling interests	(272)						0	(272)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2018	$ 451,431	$ 18,625	124,395	(8,310)	$ (66,392)	380,431	448,749	2,682
Common Stock, Shares, Issued at Dec. 31, 2018	18,625,458	18,625,458
Treasury Stock, Shares	(3,747,210)				(3,747,210)
Cumulative Effect of New Accounting Principle in Period of Adoption	$ (413)			(350)		34	(316)	(97)
Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest	12,515					12,396	12,396	119
Other Comprehensive Income (Loss), Net of Tax	9,522			9,522			9,522	0
Treasury Stock, Value, Acquired, Cost Method	$ (4,051)				$ (4,051)		(4,051)	0
Treasury Stock, Shares, Acquired	(108,646)				(108,646)
Dividends, Common Stock, Cash	$ (5,963)					(5,963)	(5,963)	0
Sharebased Compensation Effect On Stockholders Equity	105		(614)		$ 719		105	0
Sharebased Compensation Effect On Stockholders Equity, Shares Issued					95,339
Distributions to noncontrolling interests	(403)						0	(403)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Dec. 31, 2019	$ 459,712	$ 18,625	122,717	$ 1,212	$ (69,724)	$ 386,864	459,694	18
Common Stock, Shares, Issued at Dec. 31, 2019	18,625,458	18,625,458
Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests	$ (3,413)		(1,033)				(1,033)	(2,380)
Other	$ (31)		$ (31)				$ (31)	$ 0
Treasury Stock, Shares	(3,760,517)				(3,760,517)

Consolidated Statement of Sto_2

Consolidated Statement of Stockholders' Equity - Parenthetical - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Common Stock, Dividends, Per Share, Declared	$ 0.40	$ 0.30

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS PROVIDED BY (USED BY) OPERATING ACTIVITIES:
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 12,689	$ 29,053
Net Cash Provided by (Used in) Operating Activities	39,174	36,017
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect	(6,176)	(1,390)
Adjustments to reconcile net income to net change in cash from
Deferred Policy Acquisition Costs, Amortization Expense	1,036	982
Gain (Loss) on Investments	4,705	(1,033)
Gain (Loss) on Disposition of Other Assets	3,589	0
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings	646	0
Income (Loss) from Equity Method Investments	1,304	(2,111)
Impairment losses on equity method and other investments	3,562	2,275
Provision for Loan and Lease Losses	4,185	0
Depreciation, Depletion and Amortization, Nonproduction	3,198	2,852
Deferred Income Tax Expense (Benefit)	7,432	4,063
Other Noncash Income (Expense)	(8,261)	(6,644)
Increase (Decrease) in Operating Capital
Increase (Decrease) in Insurance Liabilities	2,111	(15,660)
Increase (Decrease) in Premiums Receivable	1,832	2,462
Increase (Decrease) in Reinsurance Recoverable	(5,762)	(11,862)
Change in Claim Fund Balances	1,393	(249)
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable	2,285	1,112
Increase (Decrease) in Other Operating Assets and Liabilities, Net	1,956	7,599
Net Cash Provided by (Used in) Investing Activities
Payments for (Proceeds from) Short-term Investments	(1,000)	999
Proceeds from (Payments for) Securities Purchased under Agreements to Resell	(95,094)	(1,794)
Proceeds from Sale of Debt and Equity Securities, FV-NI, Held-for-investment	2,018	698
Proceeds from Sale of Debt Securities, Available-for-sale	161,239	72,905
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	86,460	32,813
Payments to Acquire Debt Securities, Available-for-sale	168,540	126,529
Payments to Acquire Businesses, Net of Cash Acquired	7,952	0
Proceeds from Sale, Maturity and Collection of Investments	5,223	0
Payments to Acquire Other Investments	8,000	0
Other investing activities	3,491	4,784
Net Cash Provided by (Used in) Investing Activities	(27,137)	(27,690)
Net Cash Provided by (Used in) Financing Activities
Payments for Repurchase of Common Stock	4,057	4,140
Net Change Annuities and Investment Certificates	(1,575)	(1,432)
Payments of Ordinary Dividends, Common Stock	5,231	3,712
Payments to Noncontrolling Interests	4,700	0
Proceeds from Stock Options Exercised	269	856
Payment, Tax Withholding, Share-based Payment Arrangement	2,397	905
Proceeds from (Payments for) Other Financing Activities	(522)	(384)
Net Cash Provided by (Used in) Financing Activities	(18,213)	(9,717)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Beginning Balance	30,807	32,197
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Ending Balance	$ 24,631	$ 30,807

Organization, Consolidation, Ba

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies	Note 1. Organization, Consolidation, Basis of Presentation and Accounting Policies (A) Business and Organization Independence Holding Company, a Delaware corporation (“IHC”), is a holding company principally engaged in the life and health insurance business through: (i) its insurance companies, Standard Security Life Insurance, Madison National Life, and Independence American; and (ii) its marketing and administrative companies, including IHC Specialty Benefits Inc., IHC Brokerage Group, Inc., My1HR and a majority interest in PetPartners. Standard Security Life, Madison National Life and Independence American are sometimes collectively referred to as the “Insurance Group”. IHC and its subsidiaries (including the Insurance Group) are sometimes collectively referred to as the "Company", or “IHC”, or are implicit in the terms “we”, “us” and “our”. Geneve Corporation, a financial holding company, and its affiliated entities, held approximately 62% of IHC's outstanding common stock at December 31, 2019. (B) Consolidation In May 2019, IHC purchased the remaining issued and outstanding units of HealthInsurance.org, LLC (“HIO”) from noncontrolling interests for total consideration valued at $4,700,000, making HIO a wholly owned subsidiary. The carrying value of the noncontrolling interest on the transaction date was $2,380,000. As a result of the equity transaction, $1,033,000 was charged to paid-in capital representing the difference between the fair value of the consideration paid and the carrying amount of noncontrolling interest on the transaction date, net of a deferred tax benefit. (C) Basis of Presentation The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of IHC and its consolidated subsidiaries. All significant intercompany transactions have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect: (i) the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements; and (ii) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. (D) Cash, Cash Equivalents and Short-Term Investments Cash equivalents are carried at cost which approximates fair value, and include principally interest-bearing deposits at brokers, money market instruments and U.S. Treasury securities with original maturities of less than 91 days. Investments with original maturities of 91 days to one year are considered short-term investments and are carried at cost, which approximates fair value. (E) Securities Purchased Under Agreements to Resell Securities purchased under agreements to resell ("resale agreements") are carried at the amounts at which the securities will be subsequently resold as specified in the agreements. Resale agreements are utilized to invest excess funds on a short-term basis. At December 31, 2019, the Company had $107,157,000 invested in resale agreements, all of which settled on January 2 , default by the counterparties. (F) Investment Securities (i) (a) (b) (ii) (iii) (iv) The Company periodically reviews and assesses the vendor’s qualifications and the design and appropriateness of its pricing methodologies. Management will on occasion challenge pricing information on certain individual securities and, through communications with the vendor, obtain information about the assumptions, inputs and methodologies used in pricing those securities, and corroborate it against documented pricing methodologies. Validation procedures are in place to determine completeness and accuracy of pricing information, including, but not limited to: (i) review of exception reports that (a) identify any zero or un-priced securities; (b) identify securities with no price change; and (c) identify securities with significant price changes; (ii) performance of trend analyses; (iii) periodic comparison of pricing to alternative pricing sources; and (iv) comparison of pricing changes to expectations based on rating changes, benchmarks or control groups. In certain circumstances, pricing is unavailable from the vendor and broker-pricing information is used to determine fair value. In these instances, management will assess the quality of the data sources, the underlying assumptions and the reasonableness of the broker quotes based on the current market information available. To determine if an exception represents an error, management will often have to exercise judgment. Procedures to resolve an exception vary depending on the significance of the security and its related class, the frequency of the exception, the risk of material misstatement, and the availability of information for the security. These procedures include, but are not limited to; (i) a price challenge process with the vendor; (ii) pricing from a different vendor; (iii) a reasonableness review; and (iv) a change in price based on better information, such as an actual market trade, among other things. Management considers all facts and relevant information obtained during the above procedures to determine the proper classification of each security in the Fair Value Hierarchy. (v) The Company reviews its investment securities regularly and determines whether other-than-temporary impairments have occurred. The factors considered by management in its regular review to identify and recognize other-than-temporary impairment losses on fixed maturities include, but are not limited to: the length of time and extent to which the fair value has been less than cost; the Company's intent to sell, or be required to sell, the debt security before the anticipated recovery of its remaining amortized cost basis; the financial condition and near-term prospects of the issuer; adverse changes in ratings announced by one or more rating agencies; subordinated credit support; whether the issuer of a debt security has remained current on principal and interest payments; current expected cash flows; whether the decline in fair value appears to be issuer specific or, alternatively, a reflection of general market or industry conditions including the effect of changes in market interest rates. If the Company intends to sell a debt security, or it is more likely than not that it would be required to sell a debt security before the recovery of its amortized cost basis, the entire difference between the security's amortized cost basis and its fair value at the balance sheet date would be recognized by a charge to total other-than-temporary impairment losses in the Consolidated Statement of Income. If a decline in fair value of a debt security is judged by management to be other-than-temporary and; (i) the Company does not intend to sell the security; and (ii) it is not more likely than not that it will be required to sell the security prior to recovery of the security’s amortized cost, the Company assesses whether the present value of the cash flows to be collected from the security is less than its amortized cost basis. To the extent that the present value of the cash flows generated by a debt security is less than the amortized cost basis, a credit loss exists. For any such security, the impairment is bifurcated into (a) the amount of the total impairment related to the credit loss, and (b) the amount of the total impairment related to all other factors. The amount of the other-than-temporary impairment related to the credit loss is recognized by a charge to total other-than-temporary impairment losses in the Consolidated Statement of Income, establishing a new cost basis for the security. The amount of the other-than-temporary impairment related to all other factors is recognized in other comprehensive income (loss). It is reasonably possible that further declines in estimated fair values of such investments, or changes in assumptions or estimates of anticipated recoveries and/or cash flows, may cause further other-than-temporary impairments in the near term, which could be significant. In assessing corporate debt securities for other-than-temporary impairment, the Company evaluates the ability of the issuer to meet its debt obligations and the value of the company or specific collateral securing the debt position. For mortgage-backed securities where loan level data is not available, the Company uses a cash flow model based on the collateral characteristics. Assumptions about loss severity and defaults used in the model are primarily based on actual losses experienced and defaults in the collateral pool. Prepayment speeds, both actual and estimated, are also considered. The cash flows generated by the collateral securing these securities are then determined with these default, loss severity and prepayment assumptions. These collateral cash flows are then utilized, along with consideration for the issue’s position in the overall structure, to determine the cash flows associated with the mortgage-backed security held by the Company. In addition, the Company evaluates other asset-backed securities for other-than-temporary impairment by examining similar characteristics referenced above for mortgage-backed securities. The Company evaluates U.S. Treasury securities and obligations of U.S. Government corporations, U.S. Government agencies, and obligations of states and political subdivisions for other-than-temporary impairment by examining the terms and collateral of the security. For the purpose of other-than-temporary impairment evaluations, redeemable preferred stocks are evaluated in a manner similar to debt securities. Subsequent increases and decreases, if not an other-than-temporary impairment, in the fair value of fixed maturities available-for-sale that were previously impaired, are recorded in other comprehensive income (loss). In certain circumstances, due to cash flow requirements, market conditions or changes in the condition of a specific security, the Company may deem it prudent to sell a security before the anticipated recovery of its remaining amortized cost basis. (G) Other Investments Other investments primarily consist of limited partnership interests carried on the equity method, which approximates the Company's equity in the underlying net assets of the partnership. Equity income or loss on partnership interests is credited or charged, as appropriate, to the Consolidated Statements of Income. Decreases in investment values are evaluated to determine if factors indicate the decrease is other than temporary. Evidence of a loss in value might include, but is not limited to, the absence of an ability to recover the carrying amount of the investment or the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. Impairment losses on equity method investments are recognized in the Consolidated Statements of Income in the period when evidence indicates a decrease in the value of the investment has occurred that is other than temporary. Improvements are capitalized while repair and maintenance costs are charged to operations as incurred. Depreciation of property and equipment has been provided on the straight-line method over the estimated useful lives of the respective assets. Amortization of leasehold improvements has been provided on the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Any impairment of long-lived assets would be charged to expense. The Company had no impairments of long-lived assets in either 2019 or 2018. Goodwill carrying amounts are evaluated for impairment, at least annually on December 31 each year, at the reporting unit level that is equivalent to an operating segment. If the fair value of a reporting unit is less than its carrying amount, further evaluation is required to determine if a write-down of goodwill is required. In determining the fair value of each reporting unit, we used an income approach, applying a discounted cash flow method that included a residual value. Based on historical experience, we make assumptions as to: (i) expected future performance and future economic conditions, (ii) projected operating earnings, (iii) projected new and renewal business as well as profit margins on such business, and (iv) a discount rate that incorporated an appropriate risk level for the reporting unit. Any impairment of goodwill would be charged to expense. Other intangible assets are amortized to expense over their estimated useful lives and are subject to impairment testing. Any impairment of other intangible assets would be charged to expense. Policy Benefits and Claims The Company maintains loss reserves to cover its estimated liability for unpaid losses and loss adjustment expenses, where material, including legal, other fees, and costs not associated with specific claims but related to the claims payment function), for reported and unreported claims incurred as of the end of each accounting period. These loss reserves are based on actuarial assumptions. Many factors could affect these reserves, including economic and social conditions, frequency and severity of claims, medical trend resulting from the influences of underlying cost inflation, changes in utilization and demand for medical services, and changes in doctrines of legal liability and damage awards in litigation. Therefore, the Company’s reserves are necessarily based on estimates, assumptions and analysis of historical experience. The Company’s results depend upon the variation between actual claims experience and the assumptions used in determining reserves and pricing products. Reserve assumptions and estimates require significant judgment and, therefore, are inherently uncertain. The Company cannot determine with precision the ultimate amounts that will be paid for actual claims or the timing of those payments. The Company's estimate of loss represents management's best estimate of the Company's liability at the balance sheet date. All of the Company’s short-duration contracts are generated from its accident, health, disability and pet insurance business, and are accounted for based on actuarial estimates of the amount of loss inherent in that period’s claims, including losses incurred for which claims have not been reported. Short-duration contract loss estimates rely on actuarial observations of ultimate loss experience for similar historical events. Specialty Health For the Specialty Health business, incurred but not reported (“IBNR”) claims liabilities plus expected development on reported claims are calculated using standard actuarial methods and practices. The “primary” assumption in the determination of Specialty Health reserves is that historical Claim Development Patterns are representative of future Claim Development Patterns. Factors that may affect this assumption include changes in claim payment processing times and procedures, changes in time delay in submission of claims, and the incidence of unusually large claims. Liabilities for policy benefits and claims for specialty health medical and disability coverage are computed using completion factors and expected Net Loss Ratios derived from actual historical premium and claim data. The reserving analysis includes a review of claim processing statistical measures and large claim early notifications; the potential impacts of any changes in these factors are not material. The Company has business that is serviced by third-party administrators. From time to time, there are changes in the timing of claims processing due to any number of factors including, but not limited to, system conversions and staffing changes during the year. These changes are monitored by the Company and the effects of these changes are taken into consideration during the claim reserving process. Other than these considerations, there have been no significant changes to methodologies and assumptions from the prior year. While these calculations are based on standard methodologies, they are estimates based on historical patterns. To the extent that actual claim payment patterns differ from historical patterns, such estimated reserves may be redundant or inadequate. The effects of such deviations are evaluated by considering claim backlog statistics and reviewing the reasonableness of projected claim ratios. Other factors which may affect the accuracy of policy benefits and claim estimates include the proportion of large claims which may take longer to adjudicate, changes in billing patterns by providers and changes in claim management practices such as hospital bill audits. Disability and Paid Family Leave The Company’s disability business is primarily comprised of New York short-term disability (“DBL”) and group disability. With respect to DBL, the liability for policy benefits and claims for the most recent quarter of earned premium is established using a Net Loss Ratio methodology. The Net Loss Ratio is determined by applying the completed prior four quarters of historical Net Loss Ratios to the last quarter of earned premium. Policy benefits and claims associated with the premium earned prior to the last quarter are established using a completion factor methodology. The completion factors are developed using the historical payment patterns for DBL. The NYSDFS can order the Company to refund a portion of the premium, to each policyholder, to meet the mandated minimum loss ratio requirements. The Company adjusts this premium refund reserve each year based on its loss ratio in relation to the mandated minimum loss ratio requirements. With respect to PFL, policy benefits and claims associated with the premiums earned are established using a completion factor methodology. As this is the second year of this product, the completion factors used were based on the PFL payment patterns developed during 2018 and 2019. Since the NYSDFS established a risk adjustment program, the Company is required to record in its financial statements an accrual for a potential payment to, or recovery from, the risk adjustment program depending on how its loss ratio compares to the industry wide loss ratio. To determine the amount of this risk adjustment, knowledge of industry wide performance is necessary. The NYSDFS does not share the industry loss ratio data for the current reporting year until the following year. However, the Company uses Future Policy Benefits The liability for future policy benefits consists of the liabilities related to insured events for the Company’s long-duration contracts, primarily its life and annuity products. For traditional life insurance products, the Company computes the liability for future policy benefits primarily using the net premium method based on anticipated investment yield, mortality, and withdrawals. These methods are widely used in the life insurance industry to estimate the liabilities for future policy benefits. Inherent in these calculations are management and actuarial judgments and estimates that could significantly impact the ending reserve liabilities and, consequently, operating results. Actual results may differ, and these estimates are subject to interpretation and change. Management believes that the Company's methods of estimating the liabilities for future policy benefits provided appropriate levels of reserves at December 31, 2019. Changes in the Company's future policy benefits estimates are recorded through a charge or credit to its earnings. Funds on Deposit Funds received (net of mortality and expense charges) for certain long-duration contracts (principally deferred annuities and universal life policies) are credited directly to a policyholder liability account, funds on deposit. Withdrawals are recorded directly as a reduction of respective policyholders' funds on deposit. Amounts on deposit were credited at annual rates ranging from 3.0% to 6.0% in both 2019 and 2018. Other Policyholders’ Funds Other policyholders’ funds represent interest-bearing liabilities arising from the sale of products, such as universal life, interest-sensitive life and annuities. Policyholder funds are primarily comprised of The provision for deferred income taxes is based on the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recognized by applying enacted statutory tax rates to temporary differences between amounts reported in the Consolidated Financial Statements and the tax bases of existing assets and liabilities in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is recognized for the portion of deferred tax assets that, in management's judgment, is not likely to be realized. A liability for uncertain tax positions is recorded when it is more likely than not that a tax position will not be sustained upon examination by taxing authorities. The effect on deferred income taxes of a change in tax rates or laws is recognized in income tax expense in the period that includes the enactment date. The Company uses a portfolio approach to release income tax effects from accumulated other comprehensive income. The portfolio approach involves a strict period-by-period cumulative incremental allocation of income taxes to the change in unrealized gains and losses reflected in other comprehensive income. Under this approach, the net cumulative tax effect is ignored. The net change in unrealized gains or losses recorded in accumulated other comprehensive income under this approach would be eliminated only on the date the entire inventory of available-for-sale securities is sold or otherwise disposed of. Interest and penalties, if any, are included in income tax expense in the Consolidated Statements of Income. Amounts paid for or recoverable under reinsurance contracts are included in total assets or total liabilities as due from reinsurers or due to reinsurers. The cost of reinsurance related to long-duration contracts is accounted for over the life of the underlying reinsured policies using assumptions consistent with those used to account for the underlying policies. Premiums from short-duration medical insurance contracts are intended to cover expected claim costs resulting from insured events that occur during a fixed period of short duration. The Company has the ability to not renew the contract or to revise the premium rates at the end of each annual contract period to cover future insured events. Insurance premiums from annual health contracts are collected monthly and are recognized as revenue evenly as insurance protection is provided. Premiums related to long-term and short-term disability contracts are recognized on a pro rata basis over the applicable contract term. Traditional life insurance products consist principally of products with fixed and guaranteed premiums and benefits, primarily term and whole life insurance products. Revenue from these products are recognized as premium when due. Compensation costs for equity awards, such as stock options and non-vested restricted stock, are measured based on grant-date fair value and are recognized in the Consolidated Statements of Income over the requisite service period (which is usually the vesting period). For such awards with only service conditions, the Company recognizes the compensation cost on a straight-line basis over the requisite service period for the entire award. Recently Adopted Accounting Standards In July 2018, the FASB issued guidance to simplify several aspects of accounting for nonemployee share-based compensation. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In March 2017, the FASB issued guidance requiring premium amortization on callable debt securities to be amortized to the earliest call date to more closely align the amortization period with expectations incorporated in market pricing of the underlying securities. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In February 2016, the FASB issued guidance that requires lessees to recognize the assets and liabilities that arise from leases, including operating leases, on the statement of financial position. The Company elected the following practical expedients permitted within the new standard:  an accounting policy election to recognize the lease payments for short-term leases in profit or loss on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred;  practical expedients for leases that commenced before the effective date to not reassess: (i) whether any expired or existing contracts are or contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases;  a practical expedient to use hindsight in determining the lease term and in assessing impairment of the entity’s right-of-use assets.  an accounting policy election to not separate non-lease components from lease components and instead to account for them together as a single lease component. The Company selected the new transition method by applying the new lease requirements on January 1, 2019, without adjustment to the financial statements for periods prior to adoption. As a result, on January 1, 2019, the Company recognized right-of-use assets of $7,010,000 for operating leases, reduced other liabilities by $687,000 to reclassify the unamortized balances of previously deferred operating lease incentives, and recognized operating lease liabilities of $7,697,000 in its Consolidated Balance Sheet. The adoption of this guidance did not have a material effect on the Company’s consolidated results of operations or cash flows. Recently Issued Accounting Standards Not Yet Adopted In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The guidance eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities related to changes in ownership of equity method investments and foreign subsidiaries. The guidance also simplifies aspects of accounting for franchise taxes, the requirement to allocate current and deferred tax expense to legal entities not subject to tax in its separate financial statements, enacted changes in tax laws or rates, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The amendments in this guidance are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements. In October 2018, the FASB issued guidance for determining whether a decision making fee is a variable interest and requires reporting entities to consider indirect interests held through related parties under common control on a proportional basis rather than as the equivalent of a direct interest. The amendments in this guidance are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments in this guidance should be applied retrospectively through a cumulative effect adjustment to retained earnings at the beginning of the earliest period presented. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued guidance to improve existing measurements, presentation and disclosure requirements for long-duration contracts issued by insurance entities. The amendments in this guidance requires an entity to (1) review and update assumptions used to measure cash flows at least annually as well as update the discount rate assumption at each reporting date; (2) measure market risk benefits associated with deposit contracts at fair value; (3) disclose liability rollforwards and information about significant inputs, judgements assumptions, and methods used in measurement. Additionally, it simplifies the amortization of deferred acquisition costs and other balances on a constant level basis over the expected term of the related contracts. In 2019, the FASB delayed the original effective dates. For smaller reporting companies, the amendments in this guidance are now effective for fiscal years beginning

Earnings Per Share _Text Block_

Earnings Per Share [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Earnings Per Share	Note 2. Income Per Common Share Included in the diluted earnings per share calculation for the years ended December 31, 2019 and 2018 are 73,000 and 292,000 of incremental common shares, respectively, primarily from the dilutive effect of share-based payment awards.

Cash and Cash Equivalents Discl

Cash and Cash Equivalents Disclosure	12 Months Ended
	Dec. 31, 2019
Notes
Cash and Cash Equivalents Disclosure	Note 3. Cash, Cash Equivalents and Restricted Cash The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Balance Sheets to the amounts shown in the Consolidated Statements of Cash Flows for the periods indicated (in thousands): December 31, 2019 2018 Cash and cash equivalents $ 21,094 $ 26,173 Restricted cash included in other assets 3,537 4,634 Total cash, cash equivalents and restricted cash $ 24,631 $ 30,807 Restricted cash includes insurance premiums collected from insureds that are pending remittance to insurance carriers and/or payment of insurance claims and commissions to third party administrators. These amounts are required to be set aside by contractual agreements with the insurance carriers and are included in other assets on the Consolidated Balance Sheets.

Investments in Debt and Marketa

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure	Note 4. Investment Securities The cost (amortized cost with respect to certain fixed maturities), gross unrealized gains, gross unrealized losses and fair value of fixed maturities available-for-sale are as follows for the periods indicated (in thousands): December 31, 2019 GROSS GROSS AMORTIZED UNREALIZED UNREALIZED FAIR COST GAINS LOSSES VALUE FIXED MATURITIES AVAILABLE-FOR-SALE: Corporate securities $ 161,369 $ 1,832 $ (1,178) $ 162,023 CMOs – residential (1) 5,328 54 - 5,382 U.S. Government obligations 50,340 257 (48) 50,549 GSEs (3) 6,230 - (107) 6,123 States and political subdivisions 153,439 1,512 (943) 154,008 Foreign government obligations 6,719 172 (2) 6,889 Total fixed maturities $ 383,425 $ 3,827 $ (2,278) $ 384,974 December 31, 2018 GROSS GROSS AMORTIZED UNREALIZED UNREALIZED FAIR COST GAINS LOSSES VALUE FIXED MATURITIES AVAILABLE-FOR-SALE: Corporate securities $ 202,194 $ 701 $ (5,406) $ 197,489 CMOs - residential (1) 6,092 - (252) 5,840 U.S. Government obligations 63,231 1 (423) 62,809 Agency MBS - residential (2) 3 - - 3 GSEs (3) 6,596 - (110) 6,486 States and political subdivisions 172,860 302 (5,228) 167,934 Foreign government obligations 7,039 51 (46) 7,044 Redeemable preferred stocks 5,970 - (111) 5,859 Total fixed maturities $ 463,985 $ 1,055 $ (11,576) $ 453,464 (1) (2) (3) The amortized cost and fair value of fixed maturities available-for-sale at December 31, 2019, by contractual maturity, are shown below (in thousands). Expected maturities will differ from contractual maturities because borrowers may have the right to call or prepay obligations with or without call or prepayment penalties. AMORTIZED FAIR COST VALUE Due in one year or less $ 16,095 $ 16,094 Due after one year through five years 183,263 185,045 Due after five years through ten years 102,605 103,320 Due after ten years 69,904 69,010 Fixed maturities with no single maturity date 11,558 11,505 $ 383,425 $ 384,974 The following tables summarize, for all fixed maturities available-for-sale in an unrealized loss position, the aggregate fair value and gross unrealized loss by length of time those securities that have continuously been in an unrealized loss position for the periods indicated (in thousands): December 31, 2019 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses Corporate securities $ 18,151 $ 455 $ 32,301 $ 723 $ 50,452 $ 1,178 U.S. Government obligations - - 7,167 48 7,167 48 GSEs - - 6,173 107 6,173 107 States and political subdivisions 29,872 114 29,462 829 59,334 943 Foreign government obligations - - 1,603 2 1,603 2 Fixed maturities in an unrealized loss position $ 48,023 $ 569 $ 76,706 $ 1,709 $ 124,729 $ 2,278 Number of fixed maturities in an unrealized loss position 18 43 61 December 31, 2018 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses Corporate securities $ 46,988 $ 1,045 $ 108,738 $ 4,361 $ 155,726 $ 5,406 CMOs - residential 847 37 4,993 215 5,840 252 U.S. Government obligations 6,138 15 31,693 408 37,831 423 GSEs - - 6,478 110 6,478 110 States and political subdivisions 33,021 522 113,297 4,706 146,318 5,228 Foreign government obligations - - 2,835 46 2,835 46 Redeemable preferred stocks 5,859 111 - - 5,859 111 Fixed maturities in an unrealized loss position $ 92,853 $ 1,730 $ 268,034 $ 9,846 $ 360,887 $ 11,576 Number of fixed maturities in an unrealized loss position 47 115 162 Substantially all of the unrealized losses on fixed maturities available-for-sale at December 31, 2019 and 2018 relate to investment grade securities and are attributable to changes in market interest rates. Because the Company does not intend to sell, nor is it more likely than not that the Company will have to sell such investments before recovery of their amortized cost bases, which may be maturity, the Company does not consider these investments to be other-than-temporarily impaired at December 31, 2019. The following table summarizes the Company’s net investment income for the years indicated (in thousands): 2019 2018 Fixed maturities $ 14,128 $ 13,826 Equity securities 386 595 Cash, cash equivalents and other short-term investments 1,004 308 Other 239 420 Investment income, gross 15,757 15,149 Investment expenses (114) (128) Net investment income $ 15,643 $ 15,021 Net investment gains (losses) are as follows for years indicated (in thousands): 2019 2018 Realized gains (losses): Fixed maturities available-for-sale $ 4,105 $ (775) Equity securities (13) (7) Total realized gains (losses) on debt and equity securities 4,092 (782) Unrealized gains (losses) on equity securities 613 (249) Gains (losses) on debt and equity securities 4,705 (1,031) Gains (losses) on other investments - (2) Net investment gains (losses) $ 4,705 $ (1,033) For the years ended December 31, 2019 and 2018, the Company realized gross gains of $5,144,000 and $531,000, respectively, and gross losses of $1,039,000 and $1,306,000, respectively, from sales, maturities and prepayments of fixed maturities available-for-sale. We recognize other-than-temporary impairment losses on fixed maturities available-for-sale in earnings in the period that we determine: 1) we intend to sell the security; 2) it is more likely than not that we will be required to sell the security before recovery of its amortized cost basis; or 3) the security has a credit loss. Any non-credit portion of the other-than-temporary impairment loss is recognized in other comprehensive income (loss). The Company recognized other-than-temporary impairment losses of $646,000 on certain fixed maturities available-for-sale securities in the year ended December 31, 2019. The Company determined that it was more likely than not that we would sell the securities before the recovery of their amortized cost basis. The Company did not recognize any other-than-temporary impairments on available for sale securities in 2018.

Fair Value Disclosures _Text Bl

Fair Value Disclosures [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Fair Value Disclosures	Note 5. Fair Value Disclosures For all financial and non-financial assets and liabilities accounted for at fair value on a recurring basis, the Company utilizes valuation techniques based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market expectations. These two types of inputs create the following fair value hierarchy: Level 1 Level 2 Level 3 The following section describes the valuation methodologies we use to measure different assets and liabilities at fair value. Fixed maturities available-for-sale: Fixed maturities available-for-sale included in Level 2 are comprised of our portfolio of government securities, agency mortgage-backed securities, corporate fixed income securities, foreign government obligations, collateralized mortgage obligations, municipals and GSEs that were priced with observable market inputs. Level 3 debt securities consist of municipal tax credit strips. The valuation method used to determine the fair value of municipal tax credit strips is the present value of the remaining future tax credits (at the original issue discount rate) as presented in the redemption tables in the Municipal Prospectuses. This original issue discount is accreted into income on a constant yield basis over the term of the debt instrument. Further, we retain independent pricing vendors to assist in valuing certain instruments. Equity securities: Equity securities included in Level 1 are equity securities with quoted market prices. The following tables present our financial assets measured at fair value on a recurring basis for the periods indicated (in thousands): December 31, 2019 Level 1 Level 2 Level 3 Total FINANCIAL ASSETS: Fixed maturities available-for-sale: Corporate securities $ - $ 162,023 $ - $ 162,023 CMOs - residential - 5,382 - 5,382 US Government obligations - 50,549 - 50,549 GSEs - 6,123 - 6,123 States and political subdivisions - 152,479 1,529 154,008 Foreign government obligations - 6,889 - 6,889 Total fixed maturities - 383,445 1,529 384,974 Equity securities: Common stocks 2,864 - - 2,864 Nonredeemable preferred stocks 883 - - 883 Total equity securities 3,747 - - 3,747 Total Financial Assets $ 3,747 $ 383,445 $ 1,529 $ 388,721 December 31, 2018 Level 1 Level 2 Level 3 Total FINANCIAL ASSETS: Fixed maturities available-for-sale: Corporate securities $ - $ 197,489 $ - $ 197,489 CMOs - residential - 5,840 - 5,840 US Government obligations - 62,809 - 62,809 Agency MBS - residential - 3 - 3 GSEs - 6,486 - 6,486 States and political subdivisions - 166,225 1,709 167,934 Foreign government obligations - 7,044 - 7,044 Redeemable preferred stocks 5,859 - - 5,859 Total fixed maturities 5,859 445,896 1,709 453,464 Equity securities: Common stocks 2,366 - - 2,366 Nonredeemable preferred stocks 2,800 - - 2,800 Total equity securities 5,166 - - 5,166 Total Financial Assets $ 11,025 $ 445,896 $ 1,709 $ 458,630 The following table presents the changes in fair value of our Level 3 financial assets for the years indicated (in thousands): 2019 2018 States and Total States and Total Political Level 3 Political Level 3 Subdivisions Assets Subdivisions Assets Beginning balance $ 1,709 $ 1,709 $ 1,876 $ 1,876 Gains (losses) included in other comprehensive income (loss): Net unrealized gains (losses) (26) (26) (30) (30) Repayments and amortization of fixed maturities (154) (154) (137) (137) Balance at end of period $ 1,529 $ 1,529 $ 1,709 $ 1,709 The following table provides carrying values, fair values and classification in the fair value hierarchy of the Company’s financial instruments, that are not carried at fair value but are subject to fair value disclosure requirements, for the periods indicated (in thousands): December 31, 2019 December 31, 2018 Level 1 Level 2 Level 1 Level 2 Fair Fair Carrying Fair Fair Carrying Value Value Value Value Value Value FINANCIAL ASSETS: Short-term investments 50 - 50 1,050 - 1,050 Securities purchased under agreements to resell 107,157 - 107,157 12,063 - 12,063 FINANCIAL LIABILITIES: Funds on deposit $ - $ 141,010 $ 140,951 $ - $ 141,662 $ 141,635 Other policyholders’ funds - 12,049 12,049 - 10,939 10,939 The following methods and assumptions were used to estimate the fair value of the financial instruments that are not carried at fair value in the Consolidated Financial Statements: Securities purchased under agreements to resell Securities purchased under agreements to resell are carried at the amounts at which the securities will be subsequently resold, which approximates fair value. Short-term Investments Investments with original maturities of 91 days to one year are considered short-term investments and are carried at cost, which approximates fair value. Funds on Deposit The Company has two types of funds on deposit. The first type is credited with a current market interest rate, resulting in a fair value which approximates the carrying amount. The second type carries fixed interest rates which are higher than current market interest rates. The fair value of these deposits was estimated by discounting the payments using current market interest rates. The Company's universal life policies are also credited with current market interest rates, resulting in a fair value which approximates the carrying amount. Both types of funds on deposit are included in Level 2 of the fair value hierarchy. Other Policyholders’ Funds Other policyholders’ funds are primarily credited with current market interest rates resulting in a fair value which approximates the carrying amount.

Investments in and Advances to

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Investments in and Advances to Affiliates, Schedule of Investments	Note 6. Other Investments, Including Variable Interest Entities Other investments consist of the following for the periods indicated (in thousands): December 31, 2019 2018 Equity method investments $ 10,171 $ 12,308 Equity investments carried at cost less impairments 5,000 850 Other investments and securities, at cost 37 34 $ 15,208 $ 13,192 Equity Method Investments Equity income (loss) from equity method investments for the years ended December 31, 2019 and 2018 was $1,304,000 and $(2,111,000), respectively. Included in equity method investments above is our investment in Ebix Health Exchange, an administration exchange for health insurance. Ebix Health Exchange administers various lines of health insurance for IHC’s insurance subsidiaries. In the fourth quarter of 2019, the Company determined that, due to recurring losses historically and uncertainty for future profitability, there was sufficient evidence to indicate that the carrying value of the Company’s investment in Ebix Health Exchange was no longer recoverable. As a result, the Company recorded an other-than-temporary impairment loss of $3,712,000 which is included in other income on the Consolidated Statement of Income for the year ended December 31, 2019. At December 31, 2019, the carrying value of the Company’s equity investment in Ebix Health Exchange is $0 compared to $6,425,000 at December 31, 2018. The Company recorded equity losses of $2,713,000 and $1,763,000, respectively, from its investment for the years ended December 31, 2019 and 2018. In 2019, the Company also: (i) acquired substantially all of the assets and liabilities of a sales and customer service call center that was previously accounted for as an equity method investment (See Note 7 for more information); (ii) paid $3,000,000 for an equity interest in a lead generation company that will be accounted for as an equity method investment; and (iii) received an aggregate $1,772,000 of distributions from equity method investments. Equity Investments Carried at Cost Less Impairments In March 2019, the Company’s equity investment in Pets Best Insurance Services, LLC, carried at a cost of $500,000, was acquired by an unaffiliated entity and the Company realized a gain of $3,589,000 on the sale, which is included in Other Income in the Consolidated Statement of Income for the year ended December 31, 2019. In the fourth quarter of 2019, the Company paid $5,000,000 for an equity interest in FIGO, a leading insuretech brand company in the pet insurance space focused on referral partners as well as direct-to-consumer and employer benefit channels. In the fourth quarter of 2018, the Company recorded an impairment loss amounting to $2,275,000 related to an equity investment, previously carried at cost, as a result of a bona fide offer to purchase the investment for less than the carrying amount. The impairment loss is included in other income on the Consolidated Statements of Income for the year ended December 31, 2018. The subsequent sale was completed in 2019. Variable Interest Entities Other investments at December 31, 2019 and 2018, shown in the table above, include $5,075,000 and $2,874,000, respectively, of noncontrolling interests in certain limited partnerships that we have determined to be Variable Interest Entities (“VIEs”). The aforementioned VIEs are not required to be consolidated in the Company’s consolidated financial statements as we are not the primary beneficiary since we do not have the power to direct the activities that most significantly impact the VIEs’ economic performance. The Company will periodically reassess whether it is the primary beneficiary in any of these investments. The reassessment process will consider whether it has acquired the power to direct the most significant activities of the VIEs through changes in governing documents or other circumstances. The Company’s maximum loss exposure is limited to the combined $5,075,000 carrying value in these equity investments and the Company has no future funding obligations to them. Related Party Transactions At December 31, 2019 and 2018, the Company’s Consolidated Balance Sheets include $5,000 and $1,842,000, respectively, of notes and other amounts receivable from Ebix Health Exchange, and include $250,000 and $910,000, respectively, of administrative fees and other expenses payable to Ebix Health Exchange, which are included in other assets and accounts payable, accruals and other liabilities, respectively. Recurring losses reported by Ebix Health Exchange, and uncertainty regarding their future profitability, made the collectability of the outstanding notes receivable from Ebix Health Exchange doubtful and as a result, the Company recorded a provision for losses related to these notes in the amount of $1,773,000, which is included in selling, general and administrative expenses on the Consolidated Statement of Income for the year ended December 31, 2019. For the years ended December 31, 2019 and 2018, the Company’s Consolidated Statements of Income include administrative fee expenses to Ebix Health Exchange, which are included in fee income and selling, general and administrative expenses, of $2,180,000 and $7,779,000, respectively. Selling, general and administrative expense for the year ended December 31, 2019 includes approximately $6,940,000 of expense related to the purchase of leads from an affiliated lead generation company.

Business Combination Disclosure

Business Combination Disclosure	12 Months Ended
	Dec. 31, 2019
Notes
Business Combination Disclosure	Note 7. Acquisitions In 2019 the Company made several business acquisitions as follows: In January 2019, the Company acquired all of the stock of My1HR, a web-based entity with a state-of-the-art insurance quoting and cloud-based enrollment platform, INSX Cloud. In general, companies that provide insurance through user-centric platforms, or create efficiencies in the insurance industry through technological advances, are referred to as “insuretech” companies. The Company acquired My1HR for its quoting and cloud-based enrollment platforms as part of an effort to expand our “insuretech” footprint through our agencies, which generate leads and sell our products through our owned call center and career advisors. In April 2019, the Company purchased substantially all of the assets and liabilities of a sales and customer service call center. The Company acquired the call center in order to capitalize on technology-driven trends in the purchase of health insurance directly by consumers. Prior to the purchase, the Company owned an equity interest in the call center. Immediately preceding the transaction, the Company determined the fair value of its equity interest to be $720,000 using a market approach and, as a result, recorded a loss of $237,000 which is included in other income on the Consolidated Statement of Income. The aggregate fair value of consideration transferred for these acquisitions was $8,534,000 cash. The following table presents the aggregate acquisition-date fair values of the identifiable assets acquired and liabilities assumed in these transactions (in thousands): Cash $ 582 Intangible assets 1,500 Other assets 1,341 Total identifiable assets 3,423 Other liabilities 3,637 Total liabilities 3,637 Net identifiable assets (liabilities) acquired $ (214) In connection with these acquisitions, the Company recorded $9,468,000 of goodwill and $1,500,000 of intangible assets (see Note 8). The amount of goodwill and certain other intangibles entitled to an amortization deduction for income tax purposes is $10,921,000. Goodwill reflects the synergies with our insurance carriers. My1HR has an existing distribution network and offers increased distribution sources for IHC carrier products through its quoting and cloud based enrollment platforms designed specifically for producers in the small group employer market and individual ACA and ancillary market. This new quoting and enrollment system will support group and individual products for all IHC carriers as well as select group ACA and level funded health coverages from leading national health plans. The acquisition of the call center is expected to expand our existing call center reach and increase sales of IHC-underwritten health insurance. Goodwill was calculated as the sum of (i) the aggregate acquisition-date fair value of total cash consideration transferred of $8,534,000, (ii) the aggregate acquisition-date fair value of equity interests immediately before the acquisition of $720,000; and (iii) the net identifiable liabilities of $214,000 assumed. Enterprise values were determined either by an independent appraisal using a discounted cash flow model based upon the projected future earnings or by a market approach net of any control premiums. Acquisition-related costs, primarily legal and consulting fees, were not material and are included in selling, general and administrative expenses in the Consolidated Statement of Income. For the period from the acquisition dates to December 31, 2019, the Company’s Consolidated Statement of Income includes revenues and net income of $3,876,000 and $(838,000), respectively, from these acquisitions. Pro forma adjustments to present the Company’s consolidated revenues and net income as if the acquisition dates were January 1, 2018 are not material and accordingly are omitted.

Goodwill and Intangible Assets

Goodwill and Intangible Assets Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Goodwill and Intangible Assets Disclosure	Note 8. Goodwill and Other Intangible Assets The carrying amount of goodwill is $60,165,000 and $50,697,000 at December 31, 2019 and, 2018, respectively, all of which is attributable to the Specialty Health segment. In 2019, the Company recorded $9,468,000 of goodwill in connection with business acquisitions discussed in Note 7. The Company has net other intangible assets of $13,379,000 and $13,163,000 at December 31, 2019 and 2018, respectively, which are included in other assets in the Consolidated Balance Sheets. These intangible assets consist of: (i) finite-lived intangible assets, principally the fair value of acquired agent and broker relationships, which are subject to amortization; and (ii) indefinite-lived intangible assets which consist of the estimated fair value of insurance licenses that are not subject to amortization. The gross carrying amounts of these other intangible assets are as follows for the periods indicated (in thousands): December 31, 2019 December 31, 2018 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Amount Amortization Finite-lived Intangible Assets: Agent and broker relationships $ 18,753 $ 14,474 $ 17,253 $ 13,419 Domain 1,000 325 1,000 225 Software systems 780 332 780 203 Total finite-lived $ 20,533 $ 15,131 $ 19,033 $ 13,847 December 31, 2019 2018 Indefinite-lived Intangible Assets: Insurance licenses $ 7,977 $ 7,977 Total indefinite-lived $ 7,977 $ 7,977 As discussed in Note 7, in connection with business acquisitions in 2019, the Company recorded $1,500,000 of intangible assets associated with the Specialty Health segment. The intangible assets primarily represent the fair value of broker and agent relationships and are being amortized over a weighted average period of 17 years. Amortization expense was $1,284,000 and $1,506,000 for the years ended December 31, 2019 and 2018, respectively. Estimated amortization expense for each of the next five years is as follows (in thousands): Amortization Year Expense 2020 $ 1,033 2021 848 2022 723 2023 623 2024 497

Lessee, Operating Leases

Lessee, Operating Leases	12 Months Ended
	Dec. 31, 2019
Notes
Lessee, Operating Leases	Note 9. Leases Certain subsidiaries of the Company are obligated under operating lease agreements for office space and office equipment. The Company had right-of-use assets amounting to $6,672,000 and corresponding lease liabilities of $7,243,000 related to its operating leases, which are included in other assets and other liabilities, respectively, in the Consolidated Balance Sheet on December 31, 2019. The weighted average discount rate used to measure lease liabilities was 6.70%. The leases have remaining lease terms of 1 to 8 years, some of which include options to extend the leases for up to 5 years. The weighted average remaining lease term is 5 years. Variable lease costs consist primarily of the Company’s proportionate share of real estate taxes and operating expenses related to leased premises. The following table summarizes information pertaining to our lease obligations for the year ended as indicated (in thousands): 2019 Operating lease costs $ 2,277 Short-term lease costs 194 Variable lease costs 456 Total lease costs $ 2,927 Other information: Operating cash flows from operating leases $ (2,392) Right-of-use assets obtained for operating leases $ 1,688 Total rental expense for the year ended December 31, 2018 for operating leases was $2,300,000. The Company assumed $435,000 of right-of-use assets in connection with acquisitions in 2019, as discussed in Note 7. Maturities of operating lease liabilities at December 31, 2019 were as follows: Due in the next year $ 2,381 Due in two years 1,750 Due in three years 1,715 Due in four years 889 Due in five years 619 Due in remaining years 1,079 Total payments due 8,433 Present value discount (1,190) Operating lease liability $ 7,243

Reinsurance _Text Block_

Reinsurance [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Reinsurance	Note 10. Reinsurance The Insurance Group reinsures portions of certain business in order to limit the assumption of disproportionate risks. Amounts not retained are ceded to other companies on an automatic or facultative basis. In addition, the Insurance Group participates in various coinsurance treaties on a quota share or excess basis. The Company is contingently liable with respect to reinsurance in the unlikely event that the assuming reinsurers are unable to meet their obligations. The ceding of reinsurance does not discharge the primary liability of the original insurer to the insured. The effects of reinsurance on premiums earned and insurance benefits, claims and reserves are shown below for the periods indicated (in thousands). ASSUMED CEDED GROSS FROM OTHER TO OTHER NET AMOUNT COMPANIES COMPANIES AMOUNT Premiums Earned December 31, 2019 Accident and health $ 287,529 $ 5 $ 22,538 $ 264,996 Life and annuity 54,825 998 33,061 22,762 Property and liability 51,046 - 63 50,983 $ 393,400 $ 1,003 $ 55,662 $ 338,741 December 31, 2018 Accident and health $ 281,787 $ 112 $ 20,632 $ 261,267 Life and annuity 55,303 577 37,360 18,520 Property and liability 41,846 - 385 41,461 $ 378,936 $ 689 $ 58,377 $ 321,248 Insurance benefits, claims and reserves December 31, 2019 $ 215,477 $ 2,681 $ 44,037 $ 174,121 December 31, 2018 $ 188,319 $ 1,111 $ 45,224 $ 144,206

Liability for Future Policy Ben

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Liability for Future Policy Benefits and Unpaid Claims Disclosure	Note 11. Policy Benefits and Claims Policy benefits and claims is the liability for unpaid loss and loss adjustment expenses. It is comprised of unpaid claims and estimated IBNR reserves. Summarized below are the changes in the total liability for policy benefits and claims for the periods indicated (in thousands). 2019 2018 Balance at beginning of year $ 160,115 $ 168,683 Less: reinsurance recoverable 38,122 42,136 Net balance at beginning of year 121,993 126,547 Amount incurred, related to: Current year 196,124 166,899 Prior years (20,294) (19,907) Total incurred 175,830 146,992 Amount paid, related to: Current year 115,319 97,168 Prior years 54,695 54,378 Total paid 170,014 151,546 Net balance at end of year 127,809 121,993 Plus: reinsurance recoverable 36,993 38,122 Balance at end of year $ 164,802 $ 160,115 Since unpaid loss and loss adjustment expenses are estimates, actual losses incurred may be more or less than the Company’s previously developed estimates and is referred to as either unfavorable or favorable development, respectively. The overall net favorable development of $20,294,000 in 2019 related to prior years consists of favorable developments of $5,879,000 in Specialty Health reserves, $11,681,000 in the group disability reserves, $2,449,000 in the other individual life, annuities and other reserves, and $285,000 in Medical Stop-Loss reserves. Specialty Health net favorable development occurred primarily in the short-term medical and occupational accident lines of business. Group Disability net favorable development was primarily due to DBL and group LTD lines of business. LTD business experienced better than expected claim development in terms of duration and net payments. The net favorable development of the DBL line is mainly due to favorable adjustments to prior year premium refund reserves in addition to better than expected claims experience. The overall net favorable development of $19,907,000 in 2018 related to prior years consists of favorable developments of $10,716,000 in the Specialty Health reserves, $6,332,000 in group disability reserves, $2,575,000 in the group term life, other life, annuities and other reserves, and $284,000 in Medical Stop-Loss reserves. Specialty Health had net favorable development primarily from: (i) the release of reserves due to emerging favorable experience on hospital indemnity plan business written in 2017 on increased sales volume of this product; (ii) short-term medical business as inventory levels decreased during 2018 and paid claim activity was below the levels anticipated; and, (iii) favorable development in other lines of Specialty Health business. Specialty Health Segment The following tables provide undiscounted information about net incurred and paid claims development by accident year for significant short-duration contract liabilities for policy benefits and claims in our Specialty Health segment. All amounts are shown net of reinsurance. In addition, the tables present the total IBNR plus expected development on reported claims by accident year and the cumulative number of reported claims (in thousands, except number of reported claims). Refer to Note 1 for information on the methods we use to estimate IBNR plus expected development, as well as changes to those methodologies and assumptions. Five years of claims development data is presented for lines that are included in our Specialty Health segment since a majority of the claims are fully developed in that time. Certain information about incurred and paid claims is presented as supplementary information and unaudited where indicated. Specialty Health Segment –Claims Development December 31, 2019 Incurred Claims and Claim Adjustment Expenses, Net of Reinsurance Incurred But Cumulative For the years ended December 31, Not Reported Number of Accident 2015 2016 2017 2018 Plus Expected Reported Year (unaudited) (unaudited) (unaudited) (unaudited) 2019 Development Claims ( Actual ) 2015 $ 104,497 100,988 101,241 100,642 $ 101,260 $ 293 467,232 2016 85,426 86,446 86,244 85,399 1,161 538,382 2017 87,070 77,214 77,194 1,275 628,748 2018 74,652 69,206 4,259 661,819 2019 82,926 33,257 537,636 Total $ 415,985 Specialty Health Segment –Claims Development Cumulative Paid Claims and Claim Adjustment Expenses, Net of Reinsurance For the years ended December 31, Accident 2015 2016 2017 2018 Year (unaudited) (unaudited) (unaudited) (unaudited) 2019 2015 $ 70,090 94,757 97,603 99,364 $ 100,967 2016 45,454 78,611 82,983 84,238 2017 49,289 73,667 75,918 2018 46,574 64,947 2019 49,670 Total $ 375,740 Outstanding policy benefits and claims payable before 2015, net of reinsurance 266 Total policy benefits and claims, net of reinsurance $ 40,511 The claim frequency information consists of the count of claims submitted. Each claim was counted as one claim whether or not multiple claim lines were submitted with that claim, and each claim was counted whether or not it resulted in a liability. For those portions of business that did not have claim records readily available, a reasonable count assumption was made based on a comparison to the known records of a similar business type. Cumulative claim count information is not a precise tool for calculating claim severity. Factors, such as changes in provider billing practices, the mix of services, benefit designs or processing systems could impact this type of analysis. The Company does not necessarily use the cumulative number of reported claims disclosed above in its claims analysis but has provided this information to comply with accounting standards. The following is supplementary information about the average historical policy claims duration for the Specialty Health segment as of December 31, 2019: Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (unaudited) Year 1 Year 2 Year 3 Year 4 Year 5 Specialty Health Segment 62.7% 30.3% 3.6% 1.6% 1.6% The liability for policy benefits and claims associated with the Company’s health insurance lines are embedded within the Specialty Health segment. The table below summarizes the components of the change in the liability for policy benefits and claims that are specific to the health insurance claims that are included in our Specialty Health segment for the periods indicated (in thousands). Specialty Health Segment Health Insurance Claims 2019 2018 Balance at beginning of year $ 26,068 $ 32,904 Less: reinsurance recoverable 851 762 Net balance at beginning of year 25,217 32,142 Amount incurred, related to: Current year 51,479 47,143 Prior years (3,517) (9,000) Total incurred 47,962 38,143 Amount paid, related to: Current year 25,738 24,422 Prior years 17,295 20,646 Total paid 43,033 45,068 Net balance at end of year 30,146 25,217 Plus: reinsurance recoverable 1,113 851 Balance at end of year $ 31,259 $ 26,068 The liability for the IBNR plus expected development on reported claims associated with the Company’s health insurance claims was $30,146,000 at December 31, 2019. The incurred claims and claim adjustment expenses, net, for the 2013 accident year include the acquisition of $15,384,000 of disability policy benefits and claims liabilities from a Receivership. Claim frequency information consists of the count of unique claims where a benefit has been paid, whether that benefit was paid for one month or multiple months. Any claims where a benefit has not been paid are not in the count. Cumulative claim count information is not a precise tool for calculating claim severity. Changes in reinsurance and other factors, such as those described in Note 1, could impact this type of analysis with regards to our group disability business. The Company does not necessarily use the cumulative number of reported claims disclosed above in its claims analysis but has provided this information to comply with accounting standards. Unpaid claim liabilities related to our group disability policies is presented at present value. The following is additional information on unpaid claims liabilities presented at present value (in thousands): Carrying Value of Aggregate Amount Unpaid Claim Liabilities of Discount December 31, December 31 2019 2018 2019 2018 Group disability $ 56,756 $ 57,510 $ 10,382 $ 10,764 Discount rates for each of the years ended December 31, 2019 and 2018 ranged from 3% to 6%. Insurance benefits, claims and reserves on the Consolidated Statements of Income for the years ended December 31, 2019 and 2018 include the accretion of interest amounting to $1,524,000 and $1,617,000, respectively. The following is supplementary information about the average historical claims duration for our group disability business as of December 31, 2019: Group Disability Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (unaudited) Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 17.6% 20.3% 6.7% 3.1% 2.1% 2.1% 1.6% 0.7% 0.3% 0.1% The following table reconciles the above disclosures of undiscounted net incurred and paid claims development for significant short-duration contract liabilities to the liability for policy benefits and claims on the consolidated balance sheet (in thousands). December 31, 2019 Net outstanding balances: Specialty Health Segment $ 40,511 DBL/PFL 22,774 Group disability 67,139 Other short-duration insurance lines 7,712 Policy benefits and claims, net of reinsurance 138,136 Reinsurance recoverable on unpaid claims: Specialty Health Segment 1,717 DBL/PFL 664 Group disability 23,322 Other short-duration insurance lines 11,290 Reinsurance recoverable on unpaid claims 36,993 Insurance lines other than short-duration 55 Aggregate discount (10,382) Total policy benefit and claims $ 164,802

Income Tax Disclosure _Text Blo

Income Tax Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Income Tax Disclosure	Note 12. Income Taxes IHC and its subsidiaries file a consolidated Federal income tax return on a June 30 fiscal year. The provision for income tax expense (benefit) attributable to income from continuing operations, as shown in the Consolidated Statements of Income, is as follows for the years indicated (in thousands): 2019 2018 CURRENT: U.S. Federal $ 4,498 $ 3,897 State and Local 729 528 5,227 4,425 DEFERRED: U.S. Federal 8,334 4,077 State and Local (902) (14) 7,432 4,063 $ 12,659 $ 8,488 Taxes computed at the Federal statutory rate of 21% attributable to pretax income for the years ended December 31, 2019 and 2018, respectively, are reconciled to the Company's actual income tax expense (benefit) as follows for the years indicated (in thousands): 2019 2018 Tax computed at the statutory rate $ 5,323 $ 7,884 Dividends received deduction and tax exempt interest (128) (187) State and local income taxes, net of Federal effect (132) 406 Health insurer compensation limit 583 665 Impact of enacted tax reform - 1,190 AMIC valuation allowance adjustment 7,900 - Share-based compensation (993) (844) Other, net 106 (626) Income tax expense (benefit) $ 12,659 $ 8,488 In 2019, the Company increased AMIC’s valuation allowance by $7,900,000 to reflect a decrease in projected income and associated utilization of Federal net operating losses. This is largely due to the reorganization of the Specialty Health segment into specialty health and pet divisions, and the expansion of our D2C and tech-enabled operations in 2019, which reduced expected income over the remaining period that AMIC’s net operating loss carryforwards are available to offset income. As a result of IHC’s June 30 fiscal tax year, the Tax Cuts and Jobs Act (the “Tax Act”) subjected IHC to a blended tax rate of 28% for its fiscal tax year ended June 30, 2018 causing a difference of $1,190,000 in expected tax expense (calculated using a statutory rate of 21%) for the calendar year ended December 31, 2018. Temporary differences between the Consolidated Financial Statement carrying amounts and tax bases of assets and liabilities that give rise to the deferred tax assets and liabilities at December 31, 2019 and 2018 are summarized below (in thousands). The net deferred tax asset or liability is included in Other Assets or Other Liabilities, as appropriate, in the Consolidated Balance Sheets. 2019 2018 DEFERRED TAX ASSETS: Unrealized losses on investment securities $ - $ 2,210 Investment write-downs 48 48 Loss carryforwards 23,612 25,708 Other 3,323 2,005 Total gross deferred tax assets 26,983 29,971 Less AMIC valuation allowance (17,212) (9,394) Net deferred tax assets 9,771 20,577 DEFERRED TAX LIABILITIES: Insurance reserves (2,459) (2,801) Goodwill and intangible assets (2,341) (3,583) Unrealized gains on investment securities (338) - Other (688) (1,564) Total gross deferred tax liabilities (5,826) (7,948) Net deferred tax asset $ 3,945 $ 12,629 At December 31, 2019, AMIC and its subsidiaries had Federal net operating loss carryforwards of approximately $114,531,000, which expire in varying amounts through the year 2034, with a significant portion expiring in 2020, and are limited in their utilization to future taxable income earned on a separate company basis. AMIC’s valuation allowance at December 31, 2019 and 2018 is related to net operating loss carryforwards that, in the judgment of management, were not considered realizable. IHC and its subsidiaries, excluding AMIC and its subsidiaries, considered the reversal of deferred tax liabilities and projected future taxable income in determining that a valuation allowance was not necessary on their deferred tax assets at December 31, 2019 or 2018. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Management believes that it is more likely than not that IHC and its subsidiaries, including AMIC and its subsidiaries, will realize the benefits of these net deferred tax assets recorded at December 31, 2019. As of December 31, 2019, IHC and its subsidiaries, and AMIC and its subsidiaries, believe there were no material uncertain tax positions that would require disclosure under U.S. GAAP. Interest expense and penalties for the years ended December 31, 2019 and 2018 are insignificant. Tax years ending June 30, 2016 and forward are subject to examination by the Internal Revenue Service. The Internal Revenue Service has completed its review of the Company’s 2015 consolidated income tax return with no changes in the Company’s reported tax, however, the New York State Department of Taxation and Finance has recently selected the Company’s 2015 and 2016 income tax returns for audit. Net cash payments for income taxes were $966,000 and $1,303,000 in 2019 and 2018, respectively.

Stockholders' Equity Note Discl

Stockholders' Equity Note Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Stockholders' Equity Note Disclosure	Note 13. Stockholders’ Equity Treasury Stock IHC maintains a program of repurchasing shares of its common stock when the Company deems feasible. In August 2016, the Board of Directors increased the number of shares that can be repurchased to 3,000,000 shares of IHC common stock. At December 31, 2019, there were 1,747,101 shares still authorized to be repurchased under the plan authorized by the Board of Directors. In 2019 and 2018, the Company repurchased 108,646 and 135,311 shares, respectively, of its common stock for an aggregate cost of $4,051,000 and $4,019,000, respectively. The Company issued 95,339 and 123,274 shares from treasury stock in 2019 and 2018, respectively, as a result of option exercises and the vesting of restricted stock units during the period. Accumulated Other Comprehensive Income (Loss) Other comprehensive income (loss) includes the after-tax net unrealized gains and losses on fixed maturities available-for-sale, including the subsequent increases and decreases in fair value of fixed maturities available-for-sale securities previously impaired and the non-credit related component of other-than-temporary impairments of fixed maturities. Prior to January 1, 2018, the Company classified certain equity securities as available-for-sale and recorded changes in the fair value of those equity securities in other comprehensive income (loss). Upon the adoption of new accounting guidance on January 1, 2018, the Company recorded a cumulative-effect adjustment to reclassify the unrealized gains and losses on equity securities that were included in accumulated other comprehensive income to retained earnings. Changes in the balances for each component of accumulated other comprehensive income (loss), shown net of taxes, for the years indicated were as follows (in thousands): 2019 2018 Beginning balance $ (8,310) $ (4,598) Cumulative-effect of new accounting principles - (350) Other comprehensive income (loss): Other comprehensive income (loss) before reclassifications 12,246 (3,974) Less amounts reclassified from accumulated OCI (2,724) 612 Net other comprehensive income (loss) 9,522 (3,362) Ending balance $ 1,212 $ (8,310) Presented below are the amounts reclassified out of accumulated other comprehensive income (loss) and recognized in earnings for each of the years indicated (in thousands): 2019 2018 Unrealized gains (losses) on available-for-sale securities reclassified during the period to the following income statement line items: Net investment gains (losses) $ 4,105 $ (775) Net impairment losses recognized in earnings (646) - Income (loss) before income tax 3,459 (775) Tax effect 735 (163) Net income (loss) $ 2,724 $ (612)

Compensation and Employee Benef

Compensation and Employee Benefit Plans [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Compensation and Employee Benefit Plans	Note 14. Share-Based Compensation In November 2016, the stockholders approved the Independence Holding Company 2016 Stock Incentive Plan (the “2016 Plan"). The 2016 Plan permits grants of options, SARs, restricted shares, restricted share units, unrestricted shares, deferred share units and performance awards. Under the terms of the 2016 Plan: (i) the exercise price of an option may not be less than the fair market value of an IHC share on the grant date and the terms of an option may not exceed 10 years from the grant date; and (ii) the exercise price of a SAR may not be less than the fair market value of an IHC share on the grant date and SAR terms may not exceed 10 years from the date of grant. The fair value of an option award is estimated on the date of grant using the Black-Scholes option valuation model. In general, the vesting period for an option grant is 3 years. Restricted share units are valued at the quoted market price of the shares at the date of grant and generally vest over 3 years. Compensation costs for options and restricted share units are recognized over the stated vesting periods on a straight-line basis. The fair value of a SAR is calculated using the Black-Scholes valuation model at the grant date and each subsequent reporting period until settlement. Compensation cost is based on the proportionate amount of the requisite service that has been rendered to date. Once fully vested, changes in the fair value of a SAR continue to be recognized as compensation expense in the period of the change until settlement. The Company accounts for forfeitures of share-based compensation awards in the period that they occur. At December 31, 2019, there were 391,120 shares available for future stock-based compensation grants under the 2016 Plan. The following table summarizes share-based compensation expense, which is included in selling, general and administrative expenses on the Consolidated Statements of Income, applicable to the IHC plans (by award type) for each of the years indicated (in thousands): 2019 2018 IHC’s Share-based Compensation Plan: Stock options $ 1,940 $ 754 Restricted stock units 292 184 SARs 442 253 Share-based compensation expense, pre-tax 2,674 1,191 Tax benefits 720 358 Share-based compensation expense, net $ 1,954 $ 833 Stock Options The Company’s stock option activity during 2019 was as follows: Shares Weighted- Average Under Option Exercise Price December 31, 2018 567,384 $ 19.40 Granted 424,380 37.38 Exercised (202,717) 9.96 Forfeited (4,000) 22.20 December 31, 2019 785,047 $ 31.54 The weighted average grant-date fair-values of options granted during the years ended December 31, 2019 and 2018 were $8.31 and $9.05, respectively. The assumptions set forth in the table below were used to value the stock options granted during the periods indicated: 2019 2018 Weighted-average risk-free interest rate 2.32% 2.86% Expected annual dividend rate per share 1.22% 1.04% Expected volatility factor of the Company's common stock 28.97% 32.42% Weighted-average expected term of options 3.5 years 4.0 years In 2019, IHC received $269,000 in cash from the exercise of stock options with an aggregate intrinsic value of $5,207,000 and recognized $970,000 of tax benefits. Cash outflows in 2019 to satisfy employees’ income tax withholding obligations amounted to $2,397,000 for option exercises that were net settled in IHC shares. In 2018, IHC received $856,000 in cash from the exercise of stock options with an aggregate intrinsic value of $4,275,000 and recognized $810,000 of tax benefits. Cash outflows in 2018 to satisfy employees’ income tax withholding obligations amounted to $905,000 for option exercises that were net settled in IHC shares. The following table summarizes information regarding options outstanding and exercisable: December 31, 2019 Outstanding Exercisable Number of options 785,047 277,665 Weighted average exercise price per share $ 31.54 $ 23.57 Aggregate intrinsic value for all options (in thousands) $ 8,272 $ 5,140 Weighted average contractual term remaining 2.5 years 2.4 years At December 31, 2019, the total unrecognized compensation cost related to IHC’s non-vested stock options was $2,962,000 and it is expected to be recognized as compensation expense over a weighted average period of 1.6 years. Restricted Stock The Company’s restricted stock activity during 2019 was as follows: No. of Weighted-Average Non-vested Grant-Date Shares Fair Value December 31, 2018 19,800 $ 31.84 Granted 9,900 40.01 Vested (9,900) 28.61 December 31, 2019 19,800 $ 37.54 IHC granted 9,900 restricted stock units during each of the years ended December 31, 2019 and 2018 with weighted-average grant-date fair values of $40.01 and $38.49 per share, respectively. The total fair value of restricted stock units that vested in 2019 and 2018 was $389,000 and $350,000, respectively. At December 31, 2019, the total unrecognized compensation cost related to non-vested restricted stock unit awards was $699,000 which is expected to be recognized as compensation expense over a weighted average period of 2.2 years. SARs and Share-Based Performance Awards IHC had 64,900 SAR awards outstanding at both December 31, 2019 and 2018. No SAR awards were granted or exercised in either 2019 or 2018. Included in Other Liabilities in the Company’s Consolidated Balance Sheets at December 31, 2019 and December 31, 2018 are liabilities of $717,000 and $275,000, respectively, pertaining to SARs.

Contingencies Disclosure _Text

Contingencies Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Contingencies Disclosure	Note 15. Contingencies We are involved in legal proceedings and claims that arise in the ordinary course of our businesses. We have established reserves that we believe are sufficient given information presently available relating to our outstanding legal proceedings and claims. We do not anticipate that the result of any pending legal proceeding or claim will have a material adverse effect on our financial condition or cash flows, although there could be such an effect on our results of operations for any particular period. Third Party Administrator A third party administrator with whom we formerly did business (“Plaintiff” or “TPA”)) filed a Complaint dated May 17, 2017 in the United States District Court, Northern District of Texas, Dallas Division, naming IHC, Madison National Life, Standard Security Life, and Independence Brokerage Group, Inc. (formerly IHC Carrier Solutions, Inc.) (collectively referred to as “Defendants”). “Plaintiff” and “Defendants” are collectively referred to herein as the “Parties”. The Complaint concerned agreements entered into by Standard Security Life and Madison National Life with Plaintiff, as well as other allegations made by Plaintiff against Defendants. The Complaint seeks injunctive relief and damages in an amount exceeding $50,000,000, payments allegedly owed to Plaintiff under the agreements totaling at least $3,082,000 through 2014, plus additional amounts for 2015 and 2016, and exemplary and punitive damages as allowed by law and fees and costs. Defendants believe these claims to be without merit. Defendants moved to Compel Arbitration and Dismiss or Stay the original Complaint. Plaintiff filed an Amended Complaint on August 18, 2017. Defendants filed a Motion to Compel Arbitration or Stay the Amended Complaint. The Parties agreed to enter into an Order staying the action filed in Texas. The Parties’ disputed claims moved in part to arbitration. Standard Security Life and Madison National Life demanded arbitration against this TPA. The Arbitration Panel issued an Order splitting the hearing into two phases. Standard Security Life and Madison National Life successfully presented their claims in Phase I on September 25 through September 28, 2018 and were awarded $5,641,000 (“Arbitration Award”). The TPA’s counterclaims were heard during Phase II held on February 11, 2019 through February 15, 2019. Standard Security Life and Madison National Life successfully opposed the counterclaims asserted by the TPA as the Arbitration Panel denied all claims against Standard Security Life and Madison National Life. Standard Security Life and Madison National Life filed the Petition to Confirm the Arbitration Award. The TPA opposed this Motion. On June 17, 2019, the Court entered its Final Judgment and Order Confirming the Arbitration Award. On July 15, 2019, the TPA filed a Notice of Appeal to the United States Court of Appeals for the Seventh Circuit from the judgment entered on June 17, 2019. The TPA has filed its appeal and Standard Security and Madison National will submit a response. Since the arbitration is complete, the stay in the Texas litigation has been lifted. Defendants filed a Motion to Dismiss. On October 16, 2019, the Court granted in part and denied in part our Motion to Dismiss. Count I, which relates to the breach of contract, was denied without prejudice. Counts II-VI were granted in part. The Court found that an arbitration agreement, including an arbitration provision, exists between Plaintiff and Defendants. The arbitration provision incorporates the AAA Rules, evincing clear and unmistakable evidence of the parties’ intent to have the arbitrator decide whether a given claim must be arbitrated. Therefore, Counts II-VI were dismissed, without prejudice. The parties were directed to proceed with arbitration. In light of this holding, the action relating to Count I, breach of Contract, was stayed and administratively closed pending the outcome of another arbitration. On February 2, 2020, we received the TPA’s Demand for Arbitration. It is the Defendants' position that this demand for a new arbitration has no impact on the Arbitration Award discussed above. Multistate Market Conduct Examination As previously disclosed, our subsidiaries Standard Security Life, Madison National Life and Independence American have been selected for a multistate market conduct exam ("MCE") related to our short term medical, limited medical and fixed indemnity health insurance products for the period of January 1, 2014 through September 30, 2017. The insurance departments of five jurisdictions (Delaware, Wisconsin, District of Columbia, Kansas and South Dakota) are serving as leads, and the District of Columbia Department of Insurance, Securities and Banking and the Delaware Department of Insurance are serving as the managing lead states of the MCE. In addition to the five lead states, 36 other states are participating in the MCE. Each of Standard Security Life, Madison National Life and Independence American responded to inquiries and document production requests in the MCE and has proactively communicated and cooperated with the applicable regulatory agencies for the MCE. Each of these subsidiaries has also provided a detailed action plan to regulators that summarizes its enhanced compliance and control mechanisms. On July 18, 2019, each of Standard Security Life, Madison National Life and Independence American received a proposed Regulatory Settlement Agreement ("RSA") to resolve the MCE with respect to such company. The proposed RSAs provide for monetary penalties as well as requirements related to such subsidiaries' marketing activities and periodic reporting to regulators. Standard Security Life, Madison National Life and Independence American have exchanged correspondence regarding the proposed RSAs and are continuing to participate in confidential discussions with the insurance departments of the lead jurisdictions. At this time, the Company is not able to reasonably estimate any settlement amount or range of settlement amounts that may result from such discussions.

Concentration Risk Disclosure _

Concentration Risk Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Concentration Risk Disclosure	Note 16. Concentration of Credit Risk At December 31, 2019, the Company had no investment securities of any one issuer or in any one industry which exceeded 10% of stockholders' equity, except for investments in obligations of the U.S. Government and its agencies and mortgage-backed securities issued by GSEs, as summarized in Note 4. Fixed maturities with carrying values of $13,359,000 and $12,823,000 were on deposit with various state insurance departments at December 31, 2019 and 2018, respectively. At December 31, 2019, the Company had reinsurance recoverable from the following reinsurers that individually exceed 10% of stockholders’ equity (in thousands): AM Best Due from Reinsurer Rating Reinsurer National Guardian Life Insurance Company A- $ 215,724 Guggenheim Life and Annuity Company B++ 93,775 The Company believes that these receivables are fully collectible.

Dividend Payment Restrictions _

Dividend Payment Restrictions [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Dividend Payment Restrictions	Note 17. Dividend Payment Restrictions and Statutory Information Our insurance subsidiaries are restricted by state laws and regulations as to the amount of dividends they may pay to their parent without regulatory approval in any year. Any dividends in excess of limits are deemed “extraordinary” and require approval. Based on statutory results as of December 31, 2019, in accordance with applicable dividend restrictions, our insurance subsidiaries could pay dividends of approximately $31,287,000 in 2020 without obtaining regulatory approval. There are no regulatory restrictions on the ability of our holding company, IHC, to pay dividends. Under Delaware law, IHC is permitted to pay dividends from surplus or net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Dividends to shareholders are paid from funds available at the corporate holding company level. In 2019, upon receiving regulatory approvals, our insurance subsidiaries declared and paid extraordinary statutory dividends aggregating $165,472,000 to their parent company. The extraordinary dividends consisted of cash and the common and preferred shares issued by their affiliate, Madison Investors Corp., a wholly owned subsidiary of the Company. Non-“extraordinary” dividend payments were as follows: (i) Madison National Life declared and paid cash dividends of $0 and $12,035,000 to its parent in 2019 and 2018, respectively; (ii) Standard Security Life declared and paid dividends of $0 and $3,000,000 to its parent in 2019 and 2018, respectively; and (iii) Independence American declared and paid dividends of $18,000,000 and $8,400,000 to its parent in 2019 and 2018, respectively. IHC declared cash dividends of $0.40 per share or $5,963,000 in 2019 and $0.30 per share or $4,468,000 in 2018. The Company’s insurance subsidiaries are required to prepare statutory financial statements in accordance with statutory accounting practices prescribed or permitted by the insurance department of their state of domicile. Statutory accounting practices differ from U.S. GAAP in several respects causing differences in reported net income and stockholder’s equity. The Company’s insurance subsidiaries have no permitted accounting practices, which encompass all accounting practices not so prescribed that have been specifically allowed by the state insurance authorities. The statutory net income and statutory capital and surplus for each of the Company’s insurance subsidiaries are as follows for the periods indicated (in thousands): Years Ended December 31, 2019 2018 Statutory net income: Madison National Life $ 16,460 $ 16,050 Standard Security Life 5,246 8,291 Independence American 19,030 18,015 December 31, 2019 2018 Statutory capital and surplus: Madison National Life $ 83,256 $ 196,031 Standard Security Life 57,069 70,792 Independence American 84,533 82,986 The insurance subsidiaries are also required to maintain certain minimum amounts of statutory surplus to satisfy their various state insurance departments of domicile. Risk-based capital (“RBC”) requirements are designed to assess capital adequacy and to raise the level of protection that statutory surplus provides for policyholders. At December 31, 2019 and 2018, the statutory capital of our insurance subsidiaries is significantly in excess of their regulatory RBC requirements.

Segment Reporting Disclosure _T

Segment Reporting Disclosure [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Segment Reporting Disclosure	Note 18. Segment Reporting The Insurance Group principally engages in the life and health insurance business. Interest expense, taxes, and general expenses associated with parent company activities are included in Corporate. Identifiable assets by segment are those assets that are utilized in each segment and are allocated based upon the mean reserves and liabilities of each such segment. Corporate assets are composed principally of cash equivalents, resale agreements, fixed maturities, equity securities, partnership interests and certain other investments. Information by business segment is presented below for the years indicated (in thousands). 2019 2018 Revenues: Specialty Health $ 193,823 $ 202,938 Group disability, life, DBL and PFL 169,038 144,629 Individual life, annuities and other (A) 1,669 1,932 Medical Stop-Loss (A) 6 40 Corporate 5,853 2,269 370,389 351,808 Net investment gains (losses) 4,705 (1,033) Net impairment losses recognized in earnings (646) - Total revenues $ 374,448 $ 350,775 Income before income taxes Specialty Health (B) $ 7,757 $ 28,735 Group disability, life, DBL and PFL 21,809 18,863 Individual life, annuities and other (A) (C) (1,433) (436) Medical Stop-Loss (A) 304 177 Corporate (7,148) (8,765) 21,289 38,574 Net investment gains (losses) 4,705 (1,033) Net impairment losses recognized in earnings (646) - Income before income taxes $ 25,348 $ 37,541 (A) Substantially all of the business in the segment is coinsured. Activity in this segment primarily reflects income or expenses related to the coinsurance and the run-off of any remaining blocks that were not coinsured. (B) In 2019, the Specialty Health segment includes: (i) an other-than-temporary impairment loss of $3,712,000, a provision for losses on a note receivable of $1,773,000, and equity losses of $2,713,000, all in connection with the Company’s equity investment in Ebix Health Exchange (see Note 6 for more information); (ii) a provision for losses of $2,412,000 on other notes and receivables (primarily a note receivable from an unaffiliated lead generation company); and (iii) significant costs associated with hiring, training and licensing a significant number of new agents, as well as costs for system development in our marketing and administrative companies. (C) The Individual life, annuities and other segment includes amortization of deferred charges in connection with the assumptions of certain ceded life and annuity policies amounting to $788,000 and $888,000 for the years ended December 31, 2019 and 2018, respectively. December 31, 2019 2018 IDENTIFIABLE ASSETS AT YEAR END Specialty Health $ 223,679 $ 225,315 Group disability, life, DBL and PFL 324,139 308,183 Individual life, annuities and other 348,305 348,036 Medical Stop-Loss 13,161 23,983 Corporate 145,019 131,999 $ 1,054,303 $ 1,037,516

Subsequent Events _Text Block_

Subsequent Events [Text Block]	12 Months Ended
	Dec. 31, 2019
Notes
Subsequent Events	Note 19. Subsequent Events In January 2020, the Company acquired the remaining 56% membership units of The Abacus Group, LLC, for a purchase price of $2,464,000, subject to certain closing adjustments. The transaction will be accounted for as step-acquisition in 2020.

Summary of Investments, Other t

Summary of Investments, Other than Investments in Related Parties	12 Months Ended
	Dec. 31, 2019
Notes
Summary of Investments, Other than Investments in Related Parties	SCHEDULE I INDEPENDENCE HOLDING COMPANY AND SUBSIDIARIES SUMMARY OF INVESTMENTS – OTHER THAN INVESTMENTS IN RELATED PARTIES DECEMBER 31, 2019 (In thousands) AMOUNT SHOWN IN BALANCE TYPE OF INVESTMENT COST VALUE SHEET FIXED MATURITIES - AVAILABLE-FOR-SALE: Bonds: United States Government and Government agencies and authorities $ 56,570 $ 56,672 $ 56,672 States, municipalities and political subdivisions 153,439 154,008 154,008 Foreign governments 6,719 6,889 6,889 Public utilities 28,237 28,598 28,598 All other corporate bonds 138,460 138,807 138,807 TOTAL FIXED MATURITIES 383,425 384,974 384,974 EQUITY SECURITIES: Common stocks: Industrial, miscellaneous and all other 2,613 2,865 2,865 Non-redeemable preferred stocks 851 882 882 TOTAL EQUITY SECURITIES 3,464 3,747 3,747 Short-term investments and resale agreements 107,207 107,207 107,207 Other long-term investments 18,920 15,208 15,208 TOTAL INVESTMENTS $ 513,016 $ 511,136 $ 511,136

Condensed Financial Information

Condensed Financial Information of Parent Company Only Disclosure	12 Months Ended
	Dec. 31, 2019
Notes
Condensed Financial Information of Parent Company Only Disclosure	SCHEDULE II INDEPENDENCE HOLDING COMPANY CONDENSED BALANCE SHEETS (In thousands, except share data) (PARENT COMPANY ONLY) DECEMBER 31, 2019 2018 ASSETS: Cash and cash equivalents $ 895 $ 2,700 Securities purchased under agreements to resell 39,438 - Fixed maturities, available-for-sale 3,260 38,270 Investments in consolidated subsidiaries 428,014 456,304 Income tax receivable 9,307 - Deferred tax asset, net 1,517 - Other assets 461 281 TOTAL ASSETS $ 482,892 $ 497,555 LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES: Accounts payable and other liabilities $ 11,491 $ 10,005 Amounts due to consolidated subsidiaries, net 6,449 25,035 Income taxes payable - 6,645 Dividends payable 3,003 2,256 TOTAL LIABILITIES 20,943 43,941 Redeemable noncontrolling interest 2,237 2,183 STOCKHOLDERS' EQUITY: Preferred stock (none issued) (A) - - Common stock (B) 18,625 18,625 Paid-in capital 122,717 124,395 Accumulated other comprehensive loss 1,212 (8,310) Treasury stock, at cost (C) (69,724) (66,392) Retained earnings 386,864 380,431 TOTAL IHC’S STOCKHOLDERS' EQUITY 459,694 448,749 NONREDEEMABLE NONCONTROLLING INTERESTS 18 2,682 TOTAL EQUITY 459,712 451,431 TOTAL LIABILITIES AND EQUITY $ 482,892 $ 497,555 (A) (B) (C) The financial information of Independence Holding Company (Parent Company Only) should be read in conjunction with the Consolidated Financial Statements and Notes thereto. SCHEDULE II (Continued) INDEPENDENCE HOLDING COMPANY CONDENSED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (In thousands) (PARENT COMPANY ONLY) 2019 2018 REVENUES: Net investment income $ 738 $ 547 Net investment gains (losses) 130 (28) Other income 1,461 1,598 2,329 2,117 EXPENSES: General and administrative expenses 9,352 7,922 9,352 7,922 Loss before income tax benefits and equity in net income of subsidiaries (7,023) (5,805) Equity in net income of subsidiaries 19,061 32,459 Income before income tax benefits 12,038 26,654 Income tax (benefits) (651) (2,399) Net income 12,689 29,053 Less income from noncontrolling interests in subsidiaries (293) (571) Net income attributable to IHC $ 12,396 $ 28,482 Comprehensive Income: Net income $ 12,689 $ 29,053 Other comprehensive income (loss), net of tax: Unrealized gains (losses) on available-for-sale securities 164 (130) Equity in unrealized gains (losses) on available-for-sale securities of subsidiaries 9,358 (3,232) Other comprehensive income (loss), net of tax 9,522 (3,362) Comprehensive income, net of tax 22,211 25,691 Less: comprehensive income attributable to noncontrolling interests (293) (571) Comprehensive income, net of tax, attributable to IHC $ 21,918 $ 25,120 The financial information of Independence Holding Company (Parent Company Only) should be read in conjunction with the Consolidated Financial Statements and Notes thereto. SCHEDULE II (Continued) INDEPENDENCE HOLDING COMPANY CONDENSED STATEMENTS OF CASH FLOWS (In thousands) (PARENT COMPANY ONLY) 2019 2018 CASH FLOWS PROVIDED BY (USED BY) OPERATING ACTIVITIES: Net income $ 12,689 $ 29,053 Adjustments to net income: Equity in net income of subsidiaries (19,061) (32,459) Other 3,247 2,465 Change in current income tax liability (A) (17,793) 3,221 Changes in other assets and liabilities (48) (660) Net change in cash from operating activities (20,966) 1,620 CASH FLOWS PROVIDED BY (USED BY) INVESTING ACTIVITIES: Change in investments in and advances to subsidiaries (B) 34,544 17,779 Net purchases of securities under agreements to resell (39,438) - Purchases of fixed maturities (1,154) (16,000) Sales of fixed maturities 8,432 4,469 Maturities and other repayments of fixed maturities 28,193 429 Net change in cash from investing activities 30,577 6,677 CASH FLOWS PROVIDED BY (USED BY) FINANCING ACTIVITIES: Repurchases of common stock (4,057) (4,140) Dividends paid (5,231) (3,712) Proceeds from stock options exercised 269 856 Payments related to tax withholdings for share-based compensation (2,397) (905) Net change in cash from financing activities (11,416) (7,901) Net change in cash and cash equivalents (1,805) 396 Cash and cash equivalents, beginning of year (C) 2,700 2,304 Cash and cash equivalents, end of year (B) $ 895 $ 2,700 (A) (B) (C) The financial information of Independence Holding Company (Parent Company Only) should be read in conjunction with the Consolidated Financial Statements and Notes thereto.

Supplementary Insurance Informa

Supplementary Insurance Information, for Insurance Companies Disclosure	12 Months Ended
	Dec. 31, 2019
Notes
Supplementary Insurance Information, for Insurance Companies Disclosure	SCHEDULE III INDEPENDENCE HOLDING COMPANY SUPPLEMENTARY INSURANCE INFORMATION (in thousands) FUTURE POLICY INSURANCE AMORTIZATION SELLING DEFERRED BENEFITS, NET NET BENEFITS, OF DEFERRED GENERAL & NET ACQUISITION LOSSES & UNEARNED PREMIUMS INVESTMENT CLAIMS & ACQUISTION ADMINISTRATIVE PREMIUMS COSTS (1) CLAIMS PREMIUMS EARNED INCOME (2) RESERVES COSTS (1) EXPENSES (3) WRITTEN December 31, 2019 Specialty Health $ - 42,495 3,110 177,991 4,330 75,539 - 110,527 $ 177,438 Group disability, life, DBL and PFL - 146,080 4,000 160,702 7,774 97,335 - 49,894 162,972 Individual life, annuities and other - 318,236 172 48 1,294 1.382 - 1,720 48 Medical Stop-Loss - 147 - - 6 (135) - (163) - Corporate - - - - 2,239 - - 13,001 - $ - 506,958 7,282 338,741 15,643 174,121 - 174,979 $ 340,458 December 31, 2018 Specialty Health $ - 38,154 3,635 184,512 4,386 60,749 - 113,454 $ 184,513 Group disability, life, DBL and PFL - 148,012 1,737 136,709 7,029 82,948 - 42,818 135,662 Individual life, annuities and other - 324,063 185 27 1,535 796 - 1,572 27 Medical Stop-Loss - 431 - - 39 (287) - 150 - Corporate - - - - 2,032 - - 11,034 - $ - 510,660 5,557 321,248 15,021 144,206 - 169,028 $ 320,202 (1) (2) (3)

Supplemental Schedule of Reinsu

Supplemental Schedule of Reinsurance Premiums for Insurance Companies	12 Months Ended
	Dec. 31, 2019
Notes
Supplemental Schedule of Reinsurance Premiums for Insurance Companies	SCHEDULE IV INDEPENDENCE HOLDING COMPANY REINSURANCE (In thousands) PERCENTAGE ASSUMED CEDED OF AMOUNT GROSS FROM OTHER TO OTHER NET ASSUMED AMOUNT COMPANIES COMPANIES AMOUNT TO NET Life Insurance In-Force December 31, 2019 $ 14,935,361 $ 6,298 $ 6,553,251 $ 8,388,408 0.1% December 31, 2018 $ 14,486,642 $ 6,546 $ 7,528,651 $ 6,964,537 0.1% Premiums Earned December 31, 2019 Accident and health $ 287,529 $ 5 $ 22,538 $ 264,996 0.0% Life and annuity 54,825 998 33,061 22,762 4.4% Property and liability (1) 51,046 - 63 50,983 0.0% $ 393,400 $ 1,003 $ 55,662 $ 338,741 0.3% December 31, 2018 Accident and health $ 281,787 $ 112 $ 20,632 $ 261,267 0.0% Life and annuity 55,303 577 37,360 18,520 3.1% Property and liability (1) 41,846 - 385 41,461 0.0% $ 378,936 $ 689 $ 58,377 $ 321,248 0.2%

Organization, Consolidation, _2

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Basis of Accounting, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Basis of Accounting, Policy	The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (“GAAP”) and include the accounts of IHC and its consolidated subsidiaries. All significant intercompany transactions have been eliminated in consolidation. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect: (i) the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements; and (ii) the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Organization, Consolidation, _3

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Cash and Cash Equivalents, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Cash and Cash Equivalents, Policy	Cash equivalents are carried at cost which approximates fair value, and include principally interest-bearing deposits at brokers, money market instruments and U.S. Treasury securities with original maturities of less than 91 days. Investments with original maturities of 91 days to one year are considered short-term investments and are carried at cost, which approximates fair value.

Organization, Consolidation, _4

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Repurchase and Resale Agreements Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Repurchase and Resale Agreements Policy	Securities purchased under agreements to resell ("resale agreements") are carried at the amounts at which the securities will be subsequently resold as specified in the agreements. Resale agreements are utilized to invest excess funds on a short-term basis. At December 31, 2019, the Company had $107,157,000 invested in resale agreements, all of which settled on January 2 ,

Organization, Consolidation, _5

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Investment, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Investment, Policy	(F) Investment Securities (i) (a) (b) (ii) (iii) (iv) The Company periodically reviews and assesses the vendor’s qualifications and the design and appropriateness of its pricing methodologies. Management will on occasion challenge pricing information on certain individual securities and, through communications with the vendor, obtain information about the assumptions, inputs and methodologies used in pricing those securities, and corroborate it against documented pricing methodologies. Validation procedures are in place to determine completeness and accuracy of pricing information, including, but not limited to: (i) review of exception reports that (a) identify any zero or un-priced securities; (b) identify securities with no price change; and (c) identify securities with significant price changes; (ii) performance of trend analyses; (iii) periodic comparison of pricing to alternative pricing sources; and (iv) comparison of pricing changes to expectations based on rating changes, benchmarks or control groups. In certain circumstances, pricing is unavailable from the vendor and broker-pricing information is used to determine fair value. In these instances, management will assess the quality of the data sources, the underlying assumptions and the reasonableness of the broker quotes based on the current market information available. To determine if an exception represents an error, management will often have to exercise judgment. Procedures to resolve an exception vary depending on the significance of the security and its related class, the frequency of the exception, the risk of material misstatement, and the availability of information for the security. These procedures include, but are not limited to; (i) a price challenge process with the vendor; (ii) pricing from a different vendor; (iii) a reasonableness review; and (iv) a change in price based on better information, such as an actual market trade, among other things. Management considers all facts and relevant information obtained during the above procedures to determine the proper classification of each security in the Fair Value Hierarchy. (v) The Company reviews its investment securities regularly and determines whether other-than-temporary impairments have occurred. The factors considered by management in its regular review to identify and recognize other-than-temporary impairment losses on fixed maturities include, but are not limited to: the length of time and extent to which the fair value has been less than cost; the Company's intent to sell, or be required to sell, the debt security before the anticipated recovery of its remaining amortized cost basis; the financial condition and near-term prospects of the issuer; adverse changes in ratings announced by one or more rating agencies; subordinated credit support; whether the issuer of a debt security has remained current on principal and interest payments; current expected cash flows; whether the decline in fair value appears to be issuer specific or, alternatively, a reflection of general market or industry conditions including the effect of changes in market interest rates. If the Company intends to sell a debt security, or it is more likely than not that it would be required to sell a debt security before the recovery of its amortized cost basis, the entire difference between the security's amortized cost basis and its fair value at the balance sheet date would be recognized by a charge to total other-than-temporary impairment losses in the Consolidated Statement of Income. If a decline in fair value of a debt security is judged by management to be other-than-temporary and; (i) the Company does not intend to sell the security; and (ii) it is not more likely than not that it will be required to sell the security prior to recovery of the security’s amortized cost, the Company assesses whether the present value of the cash flows to be collected from the security is less than its amortized cost basis. To the extent that the present value of the cash flows generated by a debt security is less than the amortized cost basis, a credit loss exists. For any such security, the impairment is bifurcated into (a) the amount of the total impairment related to the credit loss, and (b) the amount of the total impairment related to all other factors. The amount of the other-than-temporary impairment related to the credit loss is recognized by a charge to total other-than-temporary impairment losses in the Consolidated Statement of Income, establishing a new cost basis for the security. The amount of the other-than-temporary impairment related to all other factors is recognized in other comprehensive income (loss). It is reasonably possible that further declines in estimated fair values of such investments, or changes in assumptions or estimates of anticipated recoveries and/or cash flows, may cause further other-than-temporary impairments in the near term, which could be significant. In assessing corporate debt securities for other-than-temporary impairment, the Company evaluates the ability of the issuer to meet its debt obligations and the value of the company or specific collateral securing the debt position. For mortgage-backed securities where loan level data is not available, the Company uses a cash flow model based on the collateral characteristics. Assumptions about loss severity and defaults used in the model are primarily based on actual losses experienced and defaults in the collateral pool. Prepayment speeds, both actual and estimated, are also considered. The cash flows generated by the collateral securing these securities are then determined with these default, loss severity and prepayment assumptions. These collateral cash flows are then utilized, along with consideration for the issue’s position in the overall structure, to determine the cash flows associated with the mortgage-backed security held by the Company. In addition, the Company evaluates other asset-backed securities for other-than-temporary impairment by examining similar characteristics referenced above for mortgage-backed securities. The Company evaluates U.S. Treasury securities and obligations of U.S. Government corporations, U.S. Government agencies, and obligations of states and political subdivisions for other-than-temporary impairment by examining the terms and collateral of the security. For the purpose of other-than-temporary impairment evaluations, redeemable preferred stocks are evaluated in a manner similar to debt securities. Subsequent increases and decreases, if not an other-than-temporary impairment, in the fair value of fixed maturities available-for-sale that were previously impaired, are recorded in other comprehensive income (loss). In certain circumstances, due to cash flow requirements, market conditions or changes in the condition of a specific security, the Company may deem it prudent to sell a security before the anticipated recovery of its remaining amortized cost basis. (G) Other Investments Other investments primarily consist of limited partnership interests carried on the equity method, which approximates the Company's equity in the underlying net assets of the partnership. Equity income or loss on partnership interests is credited or charged, as appropriate, to the Consolidated Statements of Income. Decreases in investment values are evaluated to determine if factors indicate the decrease is other than temporary. Evidence of a loss in value might include, but is not limited to, the absence of an ability to recover the carrying amount of the investment or the inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment. Impairment losses on equity method investments are recognized in the Consolidated Statements of Income in the period when evidence indicates a decrease in the value of the investment has occurred that is other than temporary. Other investments also include equity investments without readily determinable fair values which are carried at their cost minus impairment, if any. Impairment indicators the Company may consider in its evaluation of whether an impairment exists include, but are not limited to: (i) significant deterioration in earnings or performance of the investee; (ii) significant adverse changes in market, regulatory or economic conditions; (iii) a bona fide offer to purchase, or an offer by the investee to sell, for an amount less than the carrying amount of the investment; and (iv) factors that raise concerns about the investee’s ability to continue as a going concern. Dividends received from equity investments carried at cost are recognized in earnings.

Organization, Consolidation, _6

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Property, Plant and Equipment, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Property, Plant and Equipment, Policy	Improvements are capitalized while repair and maintenance costs are charged to operations as incurred. Depreciation of property and equipment has been provided on the straight-line method over the estimated useful lives of the respective assets. Amortization of leasehold improvements has been provided on the straight-line method over the shorter of the lease term or the estimated useful life of the asset. Any impairment of long-lived assets would be charged to expense. The Company had no impairments of long-lived assets in either 2019 or 2018.

Organization, Consolidation, _7

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Goodwill and Intangible Assets, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Goodwill and Intangible Assets, Policy	Goodwill carrying amounts are evaluated for impairment, at least annually on December 31 each year, at the reporting unit level that is equivalent to an operating segment. If the fair value of a reporting unit is less than its carrying amount, further evaluation is required to determine if a write-down of goodwill is required. In determining the fair value of each reporting unit, we used an income approach, applying a discounted cash flow method that included a residual value. Based on historical experience, we make assumptions as to: (i) expected future performance and future economic conditions, (ii) projected operating earnings, (iii) projected new and renewal business as well as profit margins on such business, and (iv) a discount rate that incorporated an appropriate risk level for the reporting unit. Any impairment of goodwill would be charged to expense. Other intangible assets are amortized to expense over their estimated useful lives and are subject to impairment testing. Any impairment of other intangible assets would be charged to expense.

Organization, Consolidation, _8

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Unpaid Policy Claims and Claims Adjustment Expense, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Unpaid Policy Claims and Claims Adjustment Expense, Policy	Policy Benefits and Claims The Company maintains loss reserves to cover its estimated liability for unpaid losses and loss adjustment expenses, where material, including legal, other fees, and costs not associated with specific claims but related to the claims payment function), for reported and unreported claims incurred as of the end of each accounting period. These loss reserves are based on actuarial assumptions. Many factors could affect these reserves, including economic and social conditions, frequency and severity of claims, medical trend resulting from the influences of underlying cost inflation, changes in utilization and demand for medical services, and changes in doctrines of legal liability and damage awards in litigation. Therefore, the Company’s reserves are necessarily based on estimates, assumptions and analysis of historical experience. The Company’s results depend upon the variation between actual claims experience and the assumptions used in determining reserves and pricing products. Reserve assumptions and estimates require significant judgment and, therefore, are inherently uncertain. The Company cannot determine with precision the ultimate amounts that will be paid for actual claims or the timing of those payments. The Company's estimate of loss represents management's best estimate of the Company's liability at the balance sheet date. All of the Company’s short-duration contracts are generated from its accident, health, disability and pet insurance business, and are accounted for based on actuarial estimates of the amount of loss inherent in that period’s claims, including losses incurred for which claims have not been reported. Short-duration contract loss estimates rely on actuarial observations of ultimate loss experience for similar historical events. Specialty Health For the Specialty Health business, incurred but not reported (“IBNR”) claims liabilities plus expected development on reported claims are calculated using standard actuarial methods and practices. The “primary” assumption in the determination of Specialty Health reserves is that historical Claim Development Patterns are representative of future Claim Development Patterns. Factors that may affect this assumption include changes in claim payment processing times and procedures, changes in time delay in submission of claims, and the incidence of unusually large claims. Liabilities for policy benefits and claims for specialty health medical and disability coverage are computed using completion factors and expected Net Loss Ratios derived from actual historical premium and claim data. The reserving analysis includes a review of claim processing statistical measures and large claim early notifications; the potential impacts of any changes in these factors are not material. The Company has business that is serviced by third-party administrators. From time to time, there are changes in the timing of claims processing due to any number of factors including, but not limited to, system conversions and staffing changes during the year. These changes are monitored by the Company and the effects of these changes are taken into consideration during the claim reserving process. Other than these considerations, there have been no significant changes to methodologies and assumptions from the prior year. While these calculations are based on standard methodologies, they are estimates based on historical patterns. To the extent that actual claim payment patterns differ from historical patterns, such estimated reserves may be redundant or inadequate. The effects of such deviations are evaluated by considering claim backlog statistics and reviewing the reasonableness of projected claim ratios. Other factors which may affect the accuracy of policy benefits and claim estimates include the proportion of large claims which may take longer to adjudicate, changes in billing patterns by providers and changes in claim management practices such as hospital bill audits. Disability and Paid Family Leave The Company’s disability business is primarily comprised of New York short-term disability (“DBL”) and group disability. With respect to DBL, the liability for policy benefits and claims for the most recent quarter of earned premium is established using a Net Loss Ratio methodology. The Net Loss Ratio is determined by applying the completed prior four quarters of historical Net Loss Ratios to the last quarter of earned premium. Policy benefits and claims associated with the premium earned prior to the last quarter are established using a completion factor methodology. The completion factors are developed using the historical payment patterns for DBL. The NYSDFS can order the Company to refund a portion of the premium, to each policyholder, to meet the mandated minimum loss ratio requirements. The Company adjusts this premium refund reserve each year based on its loss ratio in relation to the mandated minimum loss ratio requirements. With respect to PFL, policy benefits and claims associated with the premiums earned are established using a completion factor methodology. As this is the second year of this product, the completion factors used were based on the PFL payment patterns developed during 2018 and 2019. Since the NYSDFS established a risk adjustment program, the Company is required to record in its financial statements an accrual for a potential payment to, or recovery from, the risk adjustment program depending on how its loss ratio compares to the industry wide loss ratio. To determine the amount of this risk adjustment, knowledge of industry wide performance is necessary. The NYSDFS does not share the industry loss ratio data for the current reporting year until the following year. However, the Company uses available unaudited industry information to make its best estimate of its potential payment or refund under the risk adjustment program until actual information is available. Policy benefits and claims for the Company’s group disability products are developed using actuarial principles and assumptions that consider, among other things, future offsets and recoveries, elimination periods, interest rates, probability of rehabilitation or mortality, incidence and termination rates based on the Company’s experience. The liability for policy benefits and claims is made up of case reserves, IBNR and reopen reserves and Loss Adjustment Expenses (“LAE”). IBNR and reopen reserves are calculated by a hind-sight study, which takes historical experience and develops the reserve as a percentage of premiums from prior years. The two “primary” assumptions on which group disability reserves are based are: (i) morbidity levels; and (ii) recovery rates. If morbidity levels increase, for example due to an epidemic or a recessionary environment, the Company would increase reserves because there would be more new claims than expected. In regard to the assumed recovery rate, if disabled lives recover more quickly than anticipated then the existing claims reserves would be reduced; if less quickly, the existing claims reserves would be increased. Advancements in medical treatments could affect future recovery, termination, and mortality rates. Due to the long-term nature of LTD, in establishing the liability for policy benefits and claims, the Company must make estimates for case reserves, IBNR, and reserves for LAE. Case reserves generally equal the actuarial present value of the liability for future benefits to be paid on claims incurred as of the balance sheet date. The IBNR reserve is established based upon historical trends of existing incurred claims that were reported after the balance sheet date. The LAE reserve is calculated based on an actuarial expense study. There have been no significant changes to methodologies and assumptions from the prior year.

Organization, Consolidation, _9

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Future Policy Benefits Liability, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Future Policy Benefits Liability, Policy	Future Policy Benefits The liability for future policy benefits consists of the liabilities related to insured events for the Company’s long-duration contracts, primarily its life and annuity products. For traditional life insurance products, the Company computes the liability for future policy benefits primarily using the net premium method based on anticipated investment yield, mortality, and withdrawals. These methods are widely used in the life insurance industry to estimate the liabilities for future policy benefits. Inherent in these calculations are management and actuarial judgments and estimates that could significantly impact the ending reserve liabilities and, consequently, operating results. Actual results may differ, and these estimates are subject to interpretation and change. Management believes that the Company's methods of estimating the liabilities for future policy benefits provided appropriate levels of reserves at December 31, 2019. Changes in the Company's future policy benefits estimates are recorded through a charge or credit to its earnings.

Organization, Consolidation,_10

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Deposit Contracts, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Deposit Contracts, Policy	Funds received (net of mortality and expense charges) for certain long-duration contracts (principally deferred annuities and universal life policies) are credited directly to a policyholder liability account, funds on deposit. Withdrawals are recorded directly as a reduction of respective policyholders' funds on deposit. Amounts on deposit were credited at annual rates ranging from 3.0% to 6.0% in both 2019 and 2018.

Organization, Consolidation,_11

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Other Policyholders' Funds, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Other Policyholders' Funds, Policy	Other policyholders’ funds represent interest-bearing liabilities arising from the sale of products, such as universal life, interest-sensitive life and annuities. Policyholder funds are primarily comprised of deposits received and interest credited to the benefit of the policyholder less surrenders and withdrawals, mortality charges and administrative expenses. Interest credited to policyholder funds represents interest accrued or paid on interest-sensitive life policies and investment policies. These amounts are reported in insurance benefits, claims and reserves on the Consolidated Statements of Income. Credit rates for certain annuities and interest-sensitive life policies are adjusted periodically by the Company to reflect current market conditions, subject to contractually guaranteed minimum rates.

Organization, Consolidation,_12

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Income Tax, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Income Tax, Policy	The provision for deferred income taxes is based on the asset and liability method of accounting for income taxes. Under this method, deferred income taxes are recognized by applying enacted statutory tax rates to temporary differences between amounts reported in the Consolidated Financial Statements and the tax bases of existing assets and liabilities in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is recognized for the portion of deferred tax assets that, in management's judgment, is not likely to be realized. A liability for uncertain tax positions is recorded when it is more likely than not that a tax position will not be sustained upon examination by taxing authorities. The effect on deferred income taxes of a change in tax rates or laws is recognized in income tax expense in the period that includes the enactment date. The Company uses a portfolio approach to release income tax effects from accumulated other comprehensive income. The portfolio approach involves a strict period-by-period cumulative incremental allocation of income taxes to the change in unrealized gains and losses reflected in other comprehensive income. Under this approach, the net cumulative tax effect is ignored. The net change in unrealized gains or losses recorded in accumulated other comprehensive income under this approach would be eliminated only on the date the entire inventory of available-for-sale securities is sold or otherwise disposed of. Interest and penalties, if any, are included in income tax expense in the Consolidated Statements of Income.

Organization, Consolidation,_13

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Reinsurance Accounting Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Reinsurance Accounting Policy	Amounts paid for or recoverable under reinsurance contracts are included in total assets or total liabilities as due from reinsurers or due to reinsurers. The cost of reinsurance related to long-duration contracts is accounted for over the life of the underlying reinsured policies using assumptions consistent with those used to account for the underlying policies.

Organization, Consolidation,_14

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Insurance Premiums Revenue Recognition, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Insurance Premiums Revenue Recognition, Policy	Premiums from short-duration medical insurance contracts are intended to cover expected claim costs resulting from insured events that occur during a fixed period of short duration. The Company has the ability to not renew the contract or to revise the premium rates at the end of each annual contract period to cover future insured events. Insurance premiums from annual health contracts are collected monthly and are recognized as revenue evenly as insurance protection is provided. Premiums related to long-term and short-term disability contracts are recognized on a pro rata basis over the applicable contract term. Traditional life insurance products consist principally of products with fixed and guaranteed premiums and benefits, primarily term and whole life insurance products. Revenue from these products are recognized as premium when due. Policies that do not subject the Company to significant risk arising from mortality or morbidity are considered investment contracts. Deposits received for such contracts are reported as other policyholder funds. Policy charges for investment contracts consist of fees assessed against the policyholder account for maintenance, administration and surrender of the policy prior to contractually specified dates, and are recognized when assessed against the policyholder account balance.

Organization, Consolidation,_15

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Revenue (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Revenue	Fee income includes fees and commissions for various sales, marketing and administrative services provided by our marketing and administrative companies. Revenue is recognized as these services are performed. For these administrative service and other contracts, we have no material contract assets or contract liabilities on our consolidated balance sheet at December 31, 2019. Revenue recognized from performance obligations related to prior periods, and revenue expected to be recognized in future periods related to unfulfilled contractual performance obligations and contracts with variable consideration, is not material in 2019 and 2018.

Organization, Consolidation,_16

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Earnings Per Share, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Earnings Per Share, Policy	Income per common share is computed using the treasury stock method.

Organization, Consolidation,_17

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Share-based Compensation, Option and Incentive Plans Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
Share-based Compensation, Option and Incentive Plans Policy	Compensation costs for equity awards, such as stock options and non-vested restricted stock, are measured based on grant-date fair value and are recognized in the Consolidated Statements of Income over the requisite service period (which is usually the vesting period). For such awards with only service conditions, the Company recognizes the compensation cost on a straight-line basis over the requisite service period for the entire award. Compensation costs for liability-classified awards, such as share appreciation rights (“SARs”), are measured and accrued each reporting period in the Consolidated Statements of Income as the requisite service or performance conditions are met.

Organization, Consolidation,_18

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: New Accounting Pronouncements, Policy (Policies)	12 Months Ended
	Dec. 31, 2019
Policies
New Accounting Pronouncements, Policy	Recently Adopted Accounting Standards In July 2018, the FASB issued guidance to simplify several aspects of accounting for nonemployee share-based compensation. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In March 2017, the FASB issued guidance requiring premium amortization on callable debt securities to be amortized to the earliest call date to more closely align the amortization period with expectations incorporated in market pricing of the underlying securities. The adoption of this guidance did not have a material effect on the Company’s consolidated financial statements. In February 2016, the FASB issued guidance that requires lessees to recognize the assets and liabilities that arise from leases, including operating leases, on the statement of financial position. The Company elected the following practical expedients permitted within the new standard:  an accounting policy election to recognize the lease payments for short-term leases in profit or loss on a straight-line basis over the lease term and variable lease payments in the period in which the obligation for those payments is incurred;  practical expedients for leases that commenced before the effective date to not reassess: (i) whether any expired or existing contracts are or contain leases; (ii) the lease classification for any expired or existing leases; and (iii) initial direct costs for any existing leases;  a practical expedient to use hindsight in determining the lease term and in assessing impairment of the entity’s right-of-use assets.  an accounting policy election to not separate non-lease components from lease components and instead to account for them together as a single lease component. The Company selected the new transition method by applying the new lease requirements on January 1, 2019, without adjustment to the financial statements for periods prior to adoption. As a result, on January 1, 2019, the Company recognized right-of-use assets of $7,010,000 for operating leases, reduced other liabilities by $687,000 to reclassify the unamortized balances of previously deferred operating lease incentives, and recognized operating lease liabilities of $7,697,000 in its Consolidated Balance Sheet. The adoption of this guidance did not have a material effect on the Company’s consolidated results of operations or cash flows. Recently Issued Accounting Standards Not Yet Adopted In December 2019, the FASB issued guidance to simplify the accounting for income taxes. The guidance eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period, and the recognition of deferred tax liabilities related to changes in ownership of equity method investments and foreign subsidiaries. The guidance also simplifies aspects of accounting for franchise taxes, the requirement to allocate current and deferred tax expense to legal entities not subject to tax in its separate financial statements, enacted changes in tax laws or rates, and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The amendments in this guidance are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements. In October 2018, the FASB issued guidance for determining whether a decision making fee is a variable interest and requires reporting entities to consider indirect interests held through related parties under common control on a proportional basis rather than as the equivalent of a direct interest. The amendments in this guidance are effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments in this guidance should be applied retrospectively through a cumulative effect adjustment to retained earnings at the beginning of the earliest period presented. The adoption of this guidance is not expected to have a material effect on the Company’s consolidated financial statements. In August 2018, the FASB issued guidance to improve existing measurements, presentation and disclosure requirements for long-duration contracts issued by insurance entities. The amendments in this guidance requires an entity to (1) review and update assumptions used to measure cash flows at least annually as well as update the discount rate assumption at each reporting date; (2) measure market risk benefits associated with deposit contracts at fair value; (3) disclose liability rollforwards and information about significant inputs, judgements assumptions, and methods used in measurement. Additionally, it simplifies the amortization of deferred acquisition costs and other balances on a constant level basis over the expected term of the related contracts. In 2019, the FASB delayed the original effective dates. For smaller reporting companies, the amendments in this guidance are now effective for fiscal years beginning

Cash and Cash Equivalents Dis_2

Cash and Cash Equivalents Disclosure: Schedule of Cash and Cash Equivalents (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Cash and Cash Equivalents	December 31, 2019 2018 Cash and cash equivalents $ 21,094 $ 26,173 Restricted cash included in other assets 3,537 4,634 Total cash, cash equivalents and restricted cash $ 24,631 $ 30,807

Investments in Debt and Marke_2

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Debt Securities, Available-for-sale [Table Text Block] (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Debt Securities, Available-for-sale	December 31, 2019 GROSS GROSS AMORTIZED UNREALIZED UNREALIZED FAIR COST GAINS LOSSES VALUE FIXED MATURITIES AVAILABLE-FOR-SALE: Corporate securities $ 161,369 $ 1,832 $ (1,178) $ 162,023 CMOs – residential (1) 5,328 54 - 5,382 U.S. Government obligations 50,340 257 (48) 50,549 GSEs (3) 6,230 - (107) 6,123 States and political subdivisions 153,439 1,512 (943) 154,008 Foreign government obligations 6,719 172 (2) 6,889 Total fixed maturities $ 383,425 $ 3,827 $ (2,278) $ 384,974 December 31, 2018 GROSS GROSS AMORTIZED UNREALIZED UNREALIZED FAIR COST GAINS LOSSES VALUE FIXED MATURITIES AVAILABLE-FOR-SALE: Corporate securities $ 202,194 $ 701 $ (5,406) $ 197,489 CMOs - residential (1) 6,092 - (252) 5,840 U.S. Government obligations 63,231 1 (423) 62,809 Agency MBS - residential (2) 3 - - 3 GSEs (3) 6,596 - (110) 6,486 States and political subdivisions 172,860 302 (5,228) 167,934 Foreign government obligations 7,039 51 (46) 7,044 Redeemable preferred stocks 5,970 - (111) 5,859 Total fixed maturities $ 463,985 $ 1,055 $ (11,576) $ 453,464 (1) (2) (3)

Investments in Debt and Marke_3

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Investments Classified by Contractual Maturity Date (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Investments Classified by Contractual Maturity Date	AMORTIZED FAIR COST VALUE Due in one year or less $ 16,095 $ 16,094 Due after one year through five years 183,263 185,045 Due after five years through ten years 102,605 103,320 Due after ten years 69,904 69,010 Fixed maturities with no single maturity date 11,558 11,505 $ 383,425 $ 384,974

Investments in Debt and Marke_4

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value	December 31, 2019 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses Corporate securities $ 18,151 $ 455 $ 32,301 $ 723 $ 50,452 $ 1,178 U.S. Government obligations - - 7,167 48 7,167 48 GSEs - - 6,173 107 6,173 107 States and political subdivisions 29,872 114 29,462 829 59,334 943 Foreign government obligations - - 1,603 2 1,603 2 Fixed maturities in an unrealized loss position $ 48,023 $ 569 $ 76,706 $ 1,709 $ 124,729 $ 2,278 Number of fixed maturities in an unrealized loss position 18 43 61 December 31, 2018 Less than 12 Months 12 Months or Longer Total Fair Unrealized Fair Unrealized Fair Unrealized Value Losses Value Losses Value Losses Corporate securities $ 46,988 $ 1,045 $ 108,738 $ 4,361 $ 155,726 $ 5,406 CMOs - residential 847 37 4,993 215 5,840 252 U.S. Government obligations 6,138 15 31,693 408 37,831 423 GSEs - - 6,478 110 6,478 110 States and political subdivisions 33,021 522 113,297 4,706 146,318 5,228 Foreign government obligations - - 2,835 46 2,835 46 Redeemable preferred stocks 5,859 111 - - 5,859 111 Fixed maturities in an unrealized loss position $ 92,853 $ 1,730 $ 268,034 $ 9,846 $ 360,887 $ 11,576 Number of fixed maturities in an unrealized loss position 47 115 162

Investments in Debt and Marke_5

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Investment Income (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Investment Income	2019 2018 Fixed maturities $ 14,128 $ 13,826 Equity securities 386 595 Cash, cash equivalents and other short-term investments 1,004 308 Other 239 420 Investment income, gross 15,757 15,149 Investment expenses (114) (128) Net investment income $ 15,643 $ 15,021

Investments in Debt and Marke_6

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Realized Gain (Loss) on Investments (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Realized Gain (Loss) on Investments	2019 2018 Realized gains (losses): Fixed maturities available-for-sale $ 4,105 $ (775) Equity securities (13) (7) Total realized gains (losses) on debt and equity securities 4,092 (782) Unrealized gains (losses) on equity securities 613 (249) Gains (losses) on debt and equity securities 4,705 (1,031) Gains (losses) on other investments - (2) Net investment gains (losses) $ 4,705 $ (1,033)

Fair Value Disclosures _Text _2

Fair Value Disclosures [Text Block]: Fair Value, Assets Measured on Recurring Basis (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Fair Value, Assets Measured on Recurring Basis	December 31, 2019 Level 1 Level 2 Level 3 Total FINANCIAL ASSETS: Fixed maturities available-for-sale: Corporate securities $ - $ 162,023 $ - $ 162,023 CMOs - residential - 5,382 - 5,382 US Government obligations - 50,549 - 50,549 GSEs - 6,123 - 6,123 States and political subdivisions - 152,479 1,529 154,008 Foreign government obligations - 6,889 - 6,889 Total fixed maturities - 383,445 1,529 384,974 Equity securities: Common stocks 2,864 - - 2,864 Nonredeemable preferred stocks 883 - - 883 Total equity securities 3,747 - - 3,747 Total Financial Assets $ 3,747 $ 383,445 $ 1,529 $ 388,721 December 31, 2018 Level 1 Level 2 Level 3 Total FINANCIAL ASSETS: Fixed maturities available-for-sale: Corporate securities $ - $ 197,489 $ - $ 197,489 CMOs - residential - 5,840 - 5,840 US Government obligations - 62,809 - 62,809 Agency MBS - residential - 3 - 3 GSEs - 6,486 - 6,486 States and political subdivisions - 166,225 1,709 167,934 Foreign government obligations - 7,044 - 7,044 Redeemable preferred stocks 5,859 - - 5,859 Total fixed maturities 5,859 445,896 1,709 453,464 Equity securities: Common stocks 2,366 - - 2,366 Nonredeemable preferred stocks 2,800 - - 2,800 Total equity securities 5,166 - - 5,166 Total Financial Assets $ 11,025 $ 445,896 $ 1,709 $ 458,630

Fair Value Disclosures _Text _3

Fair Value Disclosures [Text Block]: Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation	2019 2018 States and Total States and Total Political Level 3 Political Level 3 Subdivisions Assets Subdivisions Assets Beginning balance $ 1,709 $ 1,709 $ 1,876 $ 1,876 Gains (losses) included in other comprehensive income (loss): Net unrealized gains (losses) (26) (26) (30) (30) Repayments and amortization of fixed maturities (154) (154) (137) (137) Balance at end of period $ 1,529 $ 1,529 $ 1,709 $ 1,709

Fair Value Disclosures _Text _4

Fair Value Disclosures [Text Block]: Fair Value, by Balance Sheet Grouping (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Fair Value, by Balance Sheet Grouping	December 31, 2019 December 31, 2018 Level 1 Level 2 Level 1 Level 2 Fair Fair Carrying Fair Fair Carrying Value Value Value Value Value Value FINANCIAL ASSETS: Short-term investments 50 - 50 1,050 - 1,050 Securities purchased under agreements to resell 107,157 - 107,157 12,063 - 12,063 FINANCIAL LIABILITIES: Funds on deposit $ - $ 141,010 $ 140,951 $ - $ 141,662 $ 141,635 Other policyholders’ funds - 12,049 12,049 - 10,939 10,939

Investments in and Advances t_2

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]: Other Investments, Including Variable Interest Entities Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Other Investments, Including Variable Interest Entities Table Text Block	December 31, 2019 2018 Equity method investments $ 10,171 $ 12,308 Equity investments carried at cost less impairments 5,000 850 Other investments and securities, at cost 37 34 $ 15,208 $ 13,192

Business Combination Disclosu_2

Business Combination Disclosure: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Tables)	12 Months Ended
	Dec. 31, 2019
Series of Individually Immaterial Business Acquisitions
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	Cash $ 582 Intangible assets 1,500 Other assets 1,341 Total identifiable assets 3,423 Other liabilities 3,637 Total liabilities 3,637 Net identifiable assets (liabilities) acquired $ (214)

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets Disclosure [Text Block]: Schedule of Finite-Lived Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Finite-Lived Intangible Assets	December 31, 2019 December 31, 2018 Gross Gross Carrying Accumulated Carrying Accumulated Amount Amortization Amount Amortization Finite-lived Intangible Assets: Agent and broker relationships $ 18,753 $ 14,474 $ 17,253 $ 13,419 Domain 1,000 325 1,000 225 Software systems 780 332 780 203 Total finite-lived $ 20,533 $ 15,131 $ 19,033 $ 13,847

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets Disclosure [Text Block]: Schedule of Indefinite-Lived Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Indefinite-Lived Intangible Assets	December 31, 2019 2018 Indefinite-lived Intangible Assets: Insurance licenses $ 7,977 $ 7,977 Total indefinite-lived $ 7,977 $ 7,977

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets Disclosure [Text Block]: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Amortization Year Expense 2020 $ 1,033 2021 848 2022 723 2023 623 2024 497

Lessee, Operating Leases_ Lease

Lessee, Operating Leases: Lease, Cost (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Lease, Cost	2019 Operating lease costs $ 2,277 Short-term lease costs 194 Variable lease costs 456 Total lease costs $ 2,927 Other information: Operating cash flows from operating leases $ (2,392) Right-of-use assets obtained for operating leases $ 1,688

Lessee, Operating Leases_ Lesse

Lessee, Operating Leases: Lessee, Operating Lease, Liability, Maturity (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Lessee, Operating Lease, Liability, Maturity	Due in the next year $ 2,381 Due in two years 1,750 Due in three years 1,715 Due in four years 889 Due in five years 619 Due in remaining years 1,079 Total payments due 8,433 Present value discount (1,190) Operating lease liability $ 7,243

Reinsurance _Text Block__ Effec

Reinsurance [Text Block]: Effects of Reinsurance (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Effects of Reinsurance	ASSUMED CEDED GROSS FROM OTHER TO OTHER NET AMOUNT COMPANIES COMPANIES AMOUNT Premiums Earned December 31, 2019 Accident and health $ 287,529 $ 5 $ 22,538 $ 264,996 Life and annuity 54,825 998 33,061 22,762 Property and liability 51,046 - 63 50,983 $ 393,400 $ 1,003 $ 55,662 $ 338,741 December 31, 2018 Accident and health $ 281,787 $ 112 $ 20,632 $ 261,267 Life and annuity 55,303 577 37,360 18,520 Property and liability 41,846 - 385 41,461 $ 378,936 $ 689 $ 58,377 $ 321,248 Insurance benefits, claims and reserves December 31, 2019 $ 215,477 $ 2,681 $ 44,037 $ 174,121 December 31, 2018 $ 188,319 $ 1,111 $ 45,224 $ 144,206

Liability for Future Policy B_2

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Schedule of Liability for Unpaid Claims and Claims Adjustment Expense (Tables)	12 Months Ended
	Dec. 31, 2019
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	2019 2018 Balance at beginning of year $ 160,115 $ 168,683 Less: reinsurance recoverable 38,122 42,136 Net balance at beginning of year 121,993 126,547 Amount incurred, related to: Current year 196,124 166,899 Prior years (20,294) (19,907) Total incurred 175,830 146,992 Amount paid, related to: Current year 115,319 97,168 Prior years 54,695 54,378 Total paid 170,014 151,546 Net balance at end of year 127,809 121,993 Plus: reinsurance recoverable 36,993 38,122 Balance at end of year $ 164,802 $ 160,115
Specialty Health Segment Member | Health Insurance Product Line
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense	Specialty Health Segment Health Insurance Claims 2019 2018 Balance at beginning of year $ 26,068 $ 32,904 Less: reinsurance recoverable 851 762 Net balance at beginning of year 25,217 32,142 Amount incurred, related to: Current year 51,479 47,143 Prior years (3,517) (9,000) Total incurred 47,962 38,143 Amount paid, related to: Current year 25,738 24,422 Prior years 17,295 20,646 Total paid 43,033 45,068 Net balance at end of year 30,146 25,217 Plus: reinsurance recoverable 1,113 851 Balance at end of year $ 31,259 $ 26,068

Liability for Future Policy B_3

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short-duration Insurance Contracts, Claims Development (Tables)	12 Months Ended
	Dec. 31, 2019
Specialty Health Segment Member
Short-duration Insurance Contracts, Claims Development	Specialty Health Segment –Claims Development December 31, 2019 Incurred Claims and Claim Adjustment Expenses, Net of Reinsurance Incurred But Cumulative For the years ended December 31, Not Reported Number of Accident 2015 2016 2017 2018 Plus Expected Reported Year (unaudited) (unaudited) (unaudited) (unaudited) 2019 Development Claims ( Actual ) 2015 $ 104,497 100,988 101,241 100,642 $ 101,260 $ 293 467,232 2016 85,426 86,446 86,244 85,399 1,161 538,382 2017 87,070 77,214 77,194 1,275 628,748 2018 74,652 69,206 4,259 661,819 2019 82,926 33,257 537,636 Total $ 415,985 Specialty Health Segment –Claims Development Cumulative Paid Claims and Claim Adjustment Expenses, Net of Reinsurance For the years ended December 31, Accident 2015 2016 2017 2018 Year (unaudited) (unaudited) (unaudited) (unaudited) 2019 2015 $ 70,090 94,757 97,603 99,364 $ 100,967 2016 45,454 78,611 82,983 84,238 2017 49,289 73,667 75,918 2018 46,574 64,947 2019 49,670 Total $ 375,740 Outstanding policy benefits and claims payable before 2015, net of reinsurance 266 Total policy benefits and claims, net of reinsurance $ 40,511
Group disability, life, DBL and PFL | NY Short-Term Disability Product Line
Short-duration Insurance Contracts, Claims Development	Group disability, life, DBL and PFL Segment – DBL/PFL Claims Development Incurred Claims and Claim Adjustment Expenses, Net of Reinsurance For the year ended December 31, Accident Year 2019 2019 Total $ 65,452 Group disability, life, DBL and PFL Segment – DBL/PFL Claims Development Cumulative Paid Claims and Claim Adjustment Expenses, Net of Reinsurance For the year ended December 31, Accident Year 2019 2019 Total $ 42,678 Total policy benefits and claims, net of reinsurance $ 22,774
Group disability, life, DBL and PFL | Group Disability Product Line
Short-duration Insurance Contracts, Claims Development	Group disability. Life, DBL and PFL Segment – Group Disability Claims Development December 31, 2019 Incurred Claims and Claim Adjustment Expenses, Net of Reinsurance Incurred But Cumulative For the years ended December 31, Not Reported Number of Accident 2010 2011 2012 2013 2014 2015 2016 2017 2018 Plus Expected Reported Year (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2019 Development Claims (Actual) 2010 $ 11,990 10,561 6,263 4,245 3,965 3,030 6,599 7,239 6,938 $ 6,857 $ - 2,311 2011 18,558 16,948 16,166 15,271 15,730 16,672 16,712 16,516 16,546 - 2,337 2012 15,356 13,708 12,187 12,177 12,585 12,472 12,161 11,883 - 2,263 2013 32,952 30,832 29,893 32,070 31,664 31,378 31,545 505 2,629 2014 16,314 13,322 14,792 14,414 14,311 14,488 165 2,783 2015 25,335 19,247 16,630 14,705 14,552 219 3,253 2016 28,450 28,568 27,359 25,988 331 3,498 2017 29,897 26,021 22,851 425 3,777 2018 29,766 26,610 1,603 3,997 2019 34,518 10,972 3,439 Total $ 205,838 Group disability, life, DBL and PFL Segment – Group Disability Claims Development Cumulative Paid Claims and Claim Adjustment Expenses, Net of Reinsurance For the years ended December 31, Accident 2010 2011 2012 2013 2014 2015 2016 2017 2018 Year (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) (unaudited) 2019 2010 $ 3,197 8,200 9,799 10,345 10,762 11,284 11,797 12,200 12,565 $ 12,902 2011 3,252 8,191 9,622 10,186 10,737 11,363 11,993 12,522 12,979 2012 3,069 7,003 8,033 8,591 8,997 9,509 9,924 10,177 2013 5,454 12,541 16,424 19,428 21,536 23,460 25,029 2014 3,663 8,466 9,919 10,623 11,142 11,661 2015 6,825 14,034 16,634 17,203 17,623 2016 8,333 16,379 19,269 20,261 2017 8,459 16,139 17,901 2018 8,417 16,109 2019 11,794 Total $ 156,436 Outstanding policy benefits and claims payable before 2010, net of reinsurance 17,737 Total policy benefits and claims, net of reinsurance $ 67,139

Liability for Future Policy B_4

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short-duration Insurance Contracts, Schedule of Historical Claims Duration (Tables)	12 Months Ended
	Dec. 31, 2019
Specialty Health Segment Member
Short-duration Insurance Contracts, Schedule of Historical Claims Duration	Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (unaudited) Year 1 Year 2 Year 3 Year 4 Year 5 Specialty Health Segment 62.7% 30.3% 3.6% 1.6% 1.6%
Group disability, life, DBL and PFL | Group Disability Product Line
Short-duration Insurance Contracts, Schedule of Historical Claims Duration	Group Disability Average Annual Percentage Payout of Incurred Claims by Age, Net of Reinsurance (unaudited) Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8 Year 9 Year 10 17.6% 20.3% 6.7% 3.1% 2.1% 2.1% 1.6% 0.7% 0.3% 0.1%

Liability for Future Policy B_5

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short Duration Insurance Contracts, Discounted Liabilities Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2019
Group disability, life, DBL and PFL | Group Disability Product Line
Short Duration Insurance Contracts, Discounted Liabilities Table Text Block	Carrying Value of Aggregate Amount Unpaid Claim Liabilities of Discount December 31, December 31 2019 2018 2019 2018 Group disability $ 56,756 $ 57,510 $ 10,382 $ 10,764

Liability for Future Policy B_6

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability	December 31, 2019 Net outstanding balances: Specialty Health Segment $ 40,511 DBL/PFL 22,774 Group disability 67,139 Other short-duration insurance lines 7,712 Policy benefits and claims, net of reinsurance 138,136 Reinsurance recoverable on unpaid claims: Specialty Health Segment 1,717 DBL/PFL 664 Group disability 23,322 Other short-duration insurance lines 11,290 Reinsurance recoverable on unpaid claims 36,993 Insurance lines other than short-duration 55 Aggregate discount (10,382) Total policy benefit and claims $ 164,802

Income Tax Disclosure _Text B_2

Income Tax Disclosure [Text Block]: Schedule of Components of Income Tax Expense (Benefit) (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	2019 2018 CURRENT: U.S. Federal $ 4,498 $ 3,897 State and Local 729 528 5,227 4,425 DEFERRED: U.S. Federal 8,334 4,077 State and Local (902) (14) 7,432 4,063 $ 12,659 $ 8,488

Income Tax Disclosure _Text B_3

Income Tax Disclosure [Text Block]: Schedule of Effective Income Tax Rate Reconciliation (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	2019 2018 Tax computed at the statutory rate $ 5,323 $ 7,884 Dividends received deduction and tax exempt interest (128) (187) State and local income taxes, net of Federal effect (132) 406 Health insurer compensation limit 583 665 Impact of enacted tax reform - 1,190 AMIC valuation allowance adjustment 7,900 - Share-based compensation (993) (844) Other, net 106 (626) Income tax expense (benefit) $ 12,659 $ 8,488

Income Tax Disclosure _Text B_4

Income Tax Disclosure [Text Block]: Schedule of Deferred Tax Assets and Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Deferred Tax Assets and Liabilities	2019 2018 DEFERRED TAX ASSETS: Unrealized losses on investment securities $ - $ 2,210 Investment write-downs 48 48 Loss carryforwards 23,612 25,708 Other 3,323 2,005 Total gross deferred tax assets 26,983 29,971 Less AMIC valuation allowance (17,212) (9,394) Net deferred tax assets 9,771 20,577 DEFERRED TAX LIABILITIES: Insurance reserves (2,459) (2,801) Goodwill and intangible assets (2,341) (3,583) Unrealized gains on investment securities (338) - Other (688) (1,564) Total gross deferred tax liabilities (5,826) (7,948) Net deferred tax asset $ 3,945 $ 12,629

Stockholders' Equity Note Dis_2

Stockholders' Equity Note Disclosure [Text Block]: Schedule of Accumulated Other Comprehensive Income (Loss) (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Accumulated Other Comprehensive Income (Loss)	2019 2018 Beginning balance $ (8,310) $ (4,598) Cumulative-effect of new accounting principles - (350) Other comprehensive income (loss): Other comprehensive income (loss) before reclassifications 12,246 (3,974) Less amounts reclassified from accumulated OCI (2,724) 612 Net other comprehensive income (loss) 9,522 (3,362) Ending balance $ 1,212 $ (8,310)

Stockholders' Equity Note Dis_3

Stockholders' Equity Note Disclosure [Text Block]: Reclassification out of Accumulated Other Comprehensive Income (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Reclassification out of Accumulated Other Comprehensive Income

Compensation and Employee Ben_2

Compensation and Employee Benefit Plans [Text Block]: Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan	2019 2018 IHC’s Share-based Compensation Plan: Stock options $ 1,940 $ 754 Restricted stock units 292 184 SARs 442 253 Share-based compensation expense, pre-tax 2,674 1,191 Tax benefits 720 358 Share-based compensation expense, net $ 1,954 $ 833

Compensation and Employee Ben_3

Compensation and Employee Benefit Plans [Text Block]: Schedule of Share-based Compensation, Stock Options, Activity (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Share-based Compensation, Stock Options, Activity	Shares Weighted- Average Under Option Exercise Price December 31, 2018 567,384 $ 19.40 Granted 424,380 37.38 Exercised (202,717) 9.96 Forfeited (4,000) 22.20 December 31, 2019 785,047 $ 31.54

Compensation and Employee Ben_4

Compensation and Employee Benefit Plans [Text Block]: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	2019 2018 Weighted-average risk-free interest rate 2.32% 2.86% Expected annual dividend rate per share 1.22% 1.04% Expected volatility factor of the Company's common stock 28.97% 32.42% Weighted-average expected term of options 3.5 years 4.0 years

Compensation and Employee Ben_5

Compensation and Employee Benefit Plans [Text Block]: Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding	December 31, 2019 Outstanding Exercisable Number of options 785,047 277,665 Weighted average exercise price per share $ 31.54 $ 23.57 Aggregate intrinsic value for all options (in thousands) $ 8,272 $ 5,140 Weighted average contractual term remaining 2.5 years 2.4 years

Compensation and Employee Ben_6

Compensation and Employee Benefit Plans [Text Block]: Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity	No. of Weighted-Average Non-vested Grant-Date Shares Fair Value December 31, 2018 19,800 $ 31.84 Granted 9,900 40.01 Vested (9,900) 28.61 December 31, 2019 19,800 $ 37.54

Concentration Risk Disclosure_2

Concentration Risk Disclosure [Text Block]: Ceded Credit Risk [Table Text Block] (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Ceded Credit Risk	AM Best Due from Reinsurer Rating Reinsurer National Guardian Life Insurance Company A- $ 215,724 Guggenheim Life and Annuity Company B++ 93,775

Dividend Payment Restrictions_2

Dividend Payment Restrictions [Text Block]: Statutory Accounting Practices Disclosure (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Statutory Accounting Practices Disclosure	Years Ended December 31, 2019 2018 Statutory net income: Madison National Life $ 16,460 $ 16,050 Standard Security Life 5,246 8,291 Independence American 19,030 18,015 December 31, 2019 2018 Statutory capital and surplus: Madison National Life $ 83,256 $ 196,031 Standard Security Life 57,069 70,792 Independence American 84,533 82,986

Segment Reporting Disclosure _2

Segment Reporting Disclosure [Text Block]: Schedule of Segment Reporting Information, by Segment (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Schedule of Segment Reporting Information, by Segment	2019 2018 Revenues: Specialty Health $ 193,823 $ 202,938 Group disability, life, DBL and PFL 169,038 144,629 Individual life, annuities and other (A) 1,669 1,932 Medical Stop-Loss (A) 6 40 Corporate 5,853 2,269 370,389 351,808 Net investment gains (losses) 4,705 (1,033) Net impairment losses recognized in earnings (646) - Total revenues $ 374,448 $ 350,775 Income before income taxes Specialty Health (B) $ 7,757 $ 28,735 Group disability, life, DBL and PFL 21,809 18,863 Individual life, annuities and other (A) (C) (1,433) (436) Medical Stop-Loss (A) 304 177 Corporate (7,148) (8,765) 21,289 38,574 Net investment gains (losses) 4,705 (1,033) Net impairment losses recognized in earnings (646) - Income before income taxes $ 25,348 $ 37,541 (A) Substantially all of the business in the segment is coinsured. Activity in this segment primarily reflects income or expenses related to the coinsurance and the run-off of any remaining blocks that were not coinsured. (B) In 2019, the Specialty Health segment includes: (i) an other-than-temporary impairment loss of $3,712,000, a provision for losses on a note receivable of $1,773,000, and equity losses of $2,713,000, all in connection with the Company’s equity investment in Ebix Health Exchange (see Note 6 for more information); (ii) a provision for losses of $2,412,000 on other notes and receivables (primarily a note receivable from an unaffiliated lead generation company); and (iii) significant costs associated with hiring, training and licensing a significant number of new agents, as well as costs for system development in our marketing and administrative companies. (C) The Individual life, annuities and other segment includes amortization of deferred charges in connection with the assumptions of certain ceded life and annuity policies amounting to $788,000 and $888,000 for the years ended December 31, 2019 and 2018, respectively. December 31, 2019 2018 IDENTIFIABLE ASSETS AT YEAR END Specialty Health $ 223,679 $ 225,315 Group disability, life, DBL and PFL 324,139 308,183 Individual life, annuities and other 348,305 348,036 Medical Stop-Loss 13,161 23,983 Corporate 145,019 131,999 $ 1,054,303 $ 1,037,516

Summary of Investments, Other_2

Summary of Investments, Other than Investments in Related Parties: Summary Of Investments Other Than Investments In Related Parties Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Summary Of Investments Other Than Investments In Related Parties Table Text Block	SCHEDULE I INDEPENDENCE HOLDING COMPANY AND SUBSIDIARIES SUMMARY OF INVESTMENTS – OTHER THAN INVESTMENTS IN RELATED PARTIES DECEMBER 31, 2019 (In thousands) AMOUNT SHOWN IN BALANCE TYPE OF INVESTMENT COST VALUE SHEET FIXED MATURITIES - AVAILABLE-FOR-SALE: Bonds: United States Government and Government agencies and authorities $ 56,570 $ 56,672 $ 56,672 States, municipalities and political subdivisions 153,439 154,008 154,008 Foreign governments 6,719 6,889 6,889 Public utilities 28,237 28,598 28,598 All other corporate bonds 138,460 138,807 138,807 TOTAL FIXED MATURITIES 383,425 384,974 384,974 EQUITY SECURITIES: Common stocks: Industrial, miscellaneous and all other 2,613 2,865 2,865 Non-redeemable preferred stocks 851 882 882 TOTAL EQUITY SECURITIES 3,464 3,747 3,747 Short-term investments and resale agreements 107,207 107,207 107,207 Other long-term investments 18,920 15,208 15,208 TOTAL INVESTMENTS $ 513,016 $ 511,136 $ 511,136

Condensed Financial Informati_2

Condensed Financial Information of Parent Company Only Disclosure: Condensed Balance Sheet (Tables)	12 Months Ended
	Dec. 31, 2019
Parent Company
Condensed Balance Sheet	SCHEDULE II INDEPENDENCE HOLDING COMPANY CONDENSED BALANCE SHEETS (In thousands, except share data) (PARENT COMPANY ONLY) DECEMBER 31, 2019 2018 ASSETS: Cash and cash equivalents $ 895 $ 2,700 Securities purchased under agreements to resell 39,438 - Fixed maturities, available-for-sale 3,260 38,270 Investments in consolidated subsidiaries 428,014 456,304 Income tax receivable 9,307 - Deferred tax asset, net 1,517 - Other assets 461 281 TOTAL ASSETS $ 482,892 $ 497,555 LIABILITIES AND STOCKHOLDERS' EQUITY LIABILITIES: Accounts payable and other liabilities $ 11,491 $ 10,005 Amounts due to consolidated subsidiaries, net 6,449 25,035 Income taxes payable - 6,645 Dividends payable 3,003 2,256 TOTAL LIABILITIES 20,943 43,941 Redeemable noncontrolling interest 2,237 2,183 STOCKHOLDERS' EQUITY: Preferred stock (none issued) (A) - - Common stock (B) 18,625 18,625 Paid-in capital 122,717 124,395 Accumulated other comprehensive loss 1,212 (8,310) Treasury stock, at cost (C) (69,724) (66,392) Retained earnings 386,864 380,431 TOTAL IHC’S STOCKHOLDERS' EQUITY 459,694 448,749 NONREDEEMABLE NONCONTROLLING INTERESTS 18 2,682 TOTAL EQUITY 459,712 451,431 TOTAL LIABILITIES AND EQUITY $ 482,892 $ 497,555 (A) (B) (C)

Condensed Financial Informati_3

Condensed Financial Information of Parent Company Only Disclosure: Condensed Income Statement (Tables)	12 Months Ended
	Dec. 31, 2019
Parent Company
Condensed Income Statement	SCHEDULE II (Continued) INDEPENDENCE HOLDING COMPANY CONDENSED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (In thousands) (PARENT COMPANY ONLY) 2019 2018 REVENUES: Net investment income $ 738 $ 547 Net investment gains (losses) 130 (28) Other income 1,461 1,598 2,329 2,117 EXPENSES: General and administrative expenses 9,352 7,922 9,352 7,922 Loss before income tax benefits and equity in net income of subsidiaries (7,023) (5,805) Equity in net income of subsidiaries 19,061 32,459 Income before income tax benefits 12,038 26,654 Income tax (benefits) (651) (2,399) Net income 12,689 29,053 Less income from noncontrolling interests in subsidiaries (293) (571) Net income attributable to IHC $ 12,396 $ 28,482 Comprehensive Income: Net income $ 12,689 $ 29,053 Other comprehensive income (loss), net of tax: Unrealized gains (losses) on available-for-sale securities 164 (130) Equity in unrealized gains (losses) on available-for-sale securities of subsidiaries 9,358 (3,232) Other comprehensive income (loss), net of tax 9,522 (3,362) Comprehensive income, net of tax 22,211 25,691 Less: comprehensive income attributable to noncontrolling interests (293) (571) Comprehensive income, net of tax, attributable to IHC $ 21,918 $ 25,120

Condensed Financial Informati_4

Condensed Financial Information of Parent Company Only Disclosure: Condensed Cash Flow Statement (Tables)	12 Months Ended
	Dec. 31, 2019
Parent Company
Condensed Cash Flow Statement	SCHEDULE II (Continued) INDEPENDENCE HOLDING COMPANY CONDENSED STATEMENTS OF CASH FLOWS (In thousands) (PARENT COMPANY ONLY) 2019 2018 CASH FLOWS PROVIDED BY (USED BY) OPERATING ACTIVITIES: Net income $ 12,689 $ 29,053 Adjustments to net income: Equity in net income of subsidiaries (19,061) (32,459) Other 3,247 2,465 Change in current income tax liability (A) (17,793) 3,221 Changes in other assets and liabilities (48) (660) Net change in cash from operating activities (20,966) 1,620 CASH FLOWS PROVIDED BY (USED BY) INVESTING ACTIVITIES: Change in investments in and advances to subsidiaries (B) 34,544 17,779 Net purchases of securities under agreements to resell (39,438) - Purchases of fixed maturities (1,154) (16,000) Sales of fixed maturities 8,432 4,469 Maturities and other repayments of fixed maturities 28,193 429 Net change in cash from investing activities 30,577 6,677 CASH FLOWS PROVIDED BY (USED BY) FINANCING ACTIVITIES: Repurchases of common stock (4,057) (4,140) Dividends paid (5,231) (3,712) Proceeds from stock options exercised 269 856 Payments related to tax withholdings for share-based compensation (2,397) (905) Net change in cash from financing activities (11,416) (7,901) Net change in cash and cash equivalents (1,805) 396 Cash and cash equivalents, beginning of year (C) 2,700 2,304 Cash and cash equivalents, end of year (B) $ 895 $ 2,700 (A) (B) (C)

Supplementary Insurance Infor_2

Supplementary Insurance Information, for Insurance Companies Disclosure: Supplementary Insurance Information For Insurance Companies Disclosure Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Supplementary Insurance Information For Insurance Companies Disclosure Table Text Block	SCHEDULE III INDEPENDENCE HOLDING COMPANY SUPPLEMENTARY INSURANCE INFORMATION (in thousands) FUTURE POLICY INSURANCE AMORTIZATION SELLING DEFERRED BENEFITS, NET NET BENEFITS, OF DEFERRED GENERAL & NET ACQUISITION LOSSES & UNEARNED PREMIUMS INVESTMENT CLAIMS & ACQUISTION ADMINISTRATIVE PREMIUMS COSTS (1) CLAIMS PREMIUMS EARNED INCOME (2) RESERVES COSTS (1) EXPENSES (3) WRITTEN December 31, 2019 Specialty Health $ - 42,495 3,110 177,991 4,330 75,539 - 110,527 $ 177,438 Group disability, life, DBL and PFL - 146,080 4,000 160,702 7,774 97,335 - 49,894 162,972 Individual life, annuities and other - 318,236 172 48 1,294 1.382 - 1,720 48 Medical Stop-Loss - 147 - - 6 (135) - (163) - Corporate - - - - 2,239 - - 13,001 - $ - 506,958 7,282 338,741 15,643 174,121 - 174,979 $ 340,458 December 31, 2018 Specialty Health $ - 38,154 3,635 184,512 4,386 60,749 - 113,454 $ 184,513 Group disability, life, DBL and PFL - 148,012 1,737 136,709 7,029 82,948 - 42,818 135,662 Individual life, annuities and other - 324,063 185 27 1,535 796 - 1,572 27 Medical Stop-Loss - 431 - - 39 (287) - 150 - Corporate - - - - 2,032 - - 11,034 - $ - 510,660 5,557 321,248 15,021 144,206 - 169,028 $ 320,202

Supplemental Schedule of Rein_2

Supplemental Schedule of Reinsurance Premiums for Insurance Companies: Supplemental Schedule Of Reinsurance Premiums For Insurance Companies Table Text Block (Tables)	12 Months Ended
	Dec. 31, 2019
Tables/Schedules
Supplemental Schedule Of Reinsurance Premiums For Insurance Companies Table Text Block	SCHEDULE IV INDEPENDENCE HOLDING COMPANY REINSURANCE (In thousands) PERCENTAGE ASSUMED CEDED OF AMOUNT GROSS FROM OTHER TO OTHER NET ASSUMED AMOUNT COMPANIES COMPANIES AMOUNT TO NET Life Insurance In-Force December 31, 2019 $ 14,935,361 $ 6,298 $ 6,553,251 $ 8,388,408 0.1% December 31, 2018 $ 14,486,642 $ 6,546 $ 7,528,651 $ 6,964,537 0.1% Premiums Earned December 31, 2019 Accident and health $ 287,529 $ 5 $ 22,538 $ 264,996 0.0% Life and annuity 54,825 998 33,061 22,762 4.4% Property and liability (1) 51,046 - 63 50,983 0.0% $ 393,400 $ 1,003 $ 55,662 $ 338,741 0.3% December 31, 2018 Accident and health $ 281,787 $ 112 $ 20,632 $ 261,267 0.0% Life and annuity 55,303 577 37,360 18,520 3.1% Property and liability (1) 41,846 - 385 41,461 0.0% $ 378,936 $ 689 $ 58,377 $ 321,248 0.2%

Organization, Consolidation,_19

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] (Details) - USD ($) $ in Thousands	1 Months Ended
	May 31, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 31, 2018
Stockholders' Equity Attributable to Noncontrolling Interest		$ 18	$ 2,682
Cumulative Effect of New Accounting Principle in Period of Adoption			(413)
RETAINED EARNINGS
Cumulative Effect of New Accounting Principle in Period of Adoption			34
RETAINED EARNINGS | Accounting Standards Update 2014-09
Cumulative Effect of New Accounting Principle in Period of Adoption				$ (306)
Other Assets
Property, Plant and Equipment, Net		7,582	3,947
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment		$ 6,689	$ 5,468
GeneveAffiliatedEntityMember
EntityCommonStockOutstandingOwnershipPercent		62.00%
HealthInsurance.Org Member
Business Combination, Consideration Transferred	$ 4,700
Stockholders' Equity Attributable to Noncontrolling Interest	2,380
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Changes, Purchase of Interest by Parent	$ 1,033

Organization, Consolidation,_20

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Repurchase and Resale Agreements Policy (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Details
Securities Purchased under Agreements to Resell	$ 107,157	$ 12,063
Resale Agreements Collateral Requirements, Percent	102.00%

Organization, Consolidation,_21

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Property, Plant and Equipment, Policy (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Other Asset Impairment Charges	$ 0	$ 0

Organization, Consolidation,_22

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: Deposit Contracts, Policy (Details)	Dec. 31, 2019	Dec. 31, 2018
Minimum
Liability for Policyholder Contract Deposits, Interest Rate	3.00%	3.00%
Maximum
Liability for Policyholder Contract Deposits, Interest Rate	6.00%	6.00%

Organization, Consolidation,_23

Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]: New Accounting Pronouncements, Policy (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Operating Lease, Right-of-Use Asset	$ 6,672
Other Liabilities	61,049	$ 53,133
Operating Lease, Liability	$ 7,243
Adjustments for New Accounting Pronouncement
Operating Lease, Right-of-Use Asset		7,010
Other Liabilities		(687)
Operating Lease, Liability		$ 7,697

Earnings Per Share _Text Bloc_2

Earnings Per Share [Text Block] (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements	73	292

Cash and Cash Equivalents Dis_3

Cash and Cash Equivalents Disclosure: Schedule of Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value	$ 21,094	$ 26,173
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents	24,631	30,807	$ 32,197
Other Assets
Restricted Cash	$ 3,537	$ 4,634

Investments in Debt and Marke_7

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Debt Securities, Available-for-sale [Table Text Block] (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale, Amortized Cost	$ 383,425	$ 463,985
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	3,827	1,055
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	2,278	11,576
Debt Securities, Available-for-sale	384,974	453,464
Corporate Debt Securities
Debt Securities, Available-for-sale, Amortized Cost	161,369	202,194
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	1,832	701
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	1,178	5,406
Debt Securities, Available-for-sale	162,023	197,489
Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale, Amortized Cost	5,328	6,092
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	54	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	0	252
Debt Securities, Available-for-sale	5,382	5,840
US Treasury Securities
Debt Securities, Available-for-sale, Amortized Cost	50,340	63,231
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	257	1
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	48	423
Debt Securities, Available-for-sale	50,549	62,809
US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale, Amortized Cost	6,230	6,596
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	0	0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	107	110
Debt Securities, Available-for-sale	6,123	6,486
US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale, Amortized Cost	153,439	172,860
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	1,512	302
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	943	5,228
Debt Securities, Available-for-sale	154,008	167,934
Debt Security, Government, Non-US
Debt Securities, Available-for-sale, Amortized Cost	6,719	7,039
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax	172	51
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax	2	46
Debt Securities, Available-for-sale	$ 6,889	7,044
US Government Agencies Debt Securities
Debt Securities, Available-for-sale, Amortized Cost		3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax		0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax		0
Debt Securities, Available-for-sale		3
Redeemable Preferred Stock
Debt Securities, Available-for-sale, Amortized Cost		5,970
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax		0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax		111
Debt Securities, Available-for-sale		$ 5,859

Investments in Debt and Marke_8

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Investments Classified by Contractual Maturity Date (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Details
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost	$ 16,095
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value	16,094
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Amortized Cost	183,263
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value	185,045
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Amortized Cost	102,605
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after Five Through Ten Years, Fair Value	103,320
Debt Securities, Available-for-sale, Allocated and Single Maturity Date, Maturity, after 10 Years, Amortized Cost	69,904
Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after 10 Years, Fair Value	69,010
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Amortized Cost	11,558
Debt Securities, Available-for-sale, Maturity, without Single Maturity Date, Fair Value	11,505
Debt Securities, Available-for-sale, Amortized Cost	383,425	$ 463,985
Debt Securities, Available-for-sale	$ 384,974	$ 453,464

Investments in Debt and Marke_9

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value (Details) $ in Thousands	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	$ 48,023	$ 92,853
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	569	1,730
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	76,706	268,034
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	1,709	9,846
Debt Securities, Available-for-sale, Unrealized Loss Position	124,729	360,887
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	$ 2,278	$ 11,576
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions	18	47
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions	43	115
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions	61	162
Corporate Debt Securities
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	$ 18,151	$ 46,988
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	455	1,045
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	32,301	108,738
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	723	4,361
Debt Securities, Available-for-sale, Unrealized Loss Position	50,452	155,726
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	1,178	5,406
US Treasury Securities
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	0	6,138
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0	15
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	7,167	31,693
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	48	408
Debt Securities, Available-for-sale, Unrealized Loss Position	7,167	37,831
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	48	423
US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	0	0
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0	0
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	6,173	6,478
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	107	110
Debt Securities, Available-for-sale, Unrealized Loss Position	6,173	6,478
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	107	110
US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	29,872	33,021
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	114	522
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	29,462	113,297
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	829	4,706
Debt Securities, Available-for-sale, Unrealized Loss Position	59,334	146,318
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	943	5,228
Debt Security, Government, Non-US
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months	0	0
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss	0	0
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer	1,603	2,835
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss	2	46
Debt Securities, Available-for-sale, Unrealized Loss Position	1,603	2,835
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss	$ 2	46
Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months		847
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss		37
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer		4,993
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss		215
Debt Securities, Available-for-sale, Unrealized Loss Position		5,840
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss		252
Redeemable Preferred Stock
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months		5,859
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss		111
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer		0
Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss		0
Debt Securities, Available-for-sale, Unrealized Loss Position		5,859
Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss		$ 111

Investments in Debt and Mark_10

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Investment Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Gross Investment Income, Operating	$ 15,757	$ 15,149
Investment Income, Investment Expense	114	128
Net Investment Income	15,643	15,021
Fixed Maturities
Gross Investment Income, Operating	14,128	13,826
Equity Securities
Gross Investment Income, Operating	386	595
Cash and Cash Equivalents
Gross Investment Income, Operating	1,004	308
Other Long-term Investments
Gross Investment Income, Operating	$ 239	$ 420

Investments in Debt and Mark_11

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]: Realized Gain (Loss) on Investments (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Debt Securities, Available-for-sale, Realized Gain (Loss), Excluding Other-than-temporary Impairment	$ 4,105	$ (775)
Equity Securities, FV-NI, Realized Gain (Loss)	(13)	(7)
Debt and Equity Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment	4,092	(782)
Equity Securities, FV-NI, Unrealized Gain (Loss)	613	(249)
Debt and Equity Securities, Gain (Loss)	4,705	(1,031)
Gain (Loss) on Sale of Other Investments	0	(2)
Gain (Loss) on Investments	$ 4,705	$ (1,033)

Investments in Debt and Mark_12

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Details
Available-for-sale Securities, Gross Realized Gains		$ 5,144	$ 531
Available-for-sale Securities, Gross Realized Losses	$ 1,039	1,306
Other than Temporary Impairment Losses, Investments, Portion Recognized in Earnings, Net, Available-for-sale Securities		$ 646	$ 0

Fair Value Disclosures _Text _5

Fair Value Disclosures [Text Block]: Fair Value, Assets Measured on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Debt Securities, Available-for-sale	$ 384,974	$ 453,464
Equity Securities, FV-NI	3,747	5,166
Corporate Debt Securities
Debt Securities, Available-for-sale	162,023	197,489
Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale	5,382	5,840
US Treasury Securities
Debt Securities, Available-for-sale	50,549	62,809
US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale	6,123	6,486
US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale	154,008	167,934
Debt Security, Government, Non-US
Debt Securities, Available-for-sale	6,889	7,044
US Government Agencies Debt Securities
Debt Securities, Available-for-sale		3
Redeemable Preferred Stock
Debt Securities, Available-for-sale		5,859
Fair Value, Recurring
Debt Securities, Available-for-sale	384,974	453,464
Equity Securities, FV-NI	3,747	5,166
Assets, Fair Value Disclosure	388,721	458,630
Fair Value, Recurring | Corporate Debt Securities
Debt Securities, Available-for-sale	162,023	197,489
Fair Value, Recurring | Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale	5,382	5,840
Fair Value, Recurring | US Treasury Securities
Debt Securities, Available-for-sale	50,549	62,809
Fair Value, Recurring | US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale	6,123	6,486
Fair Value, Recurring | US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale	154,008	167,934
Fair Value, Recurring | Debt Security, Government, Non-US
Debt Securities, Available-for-sale	6,889	7,044
Fair Value, Recurring | COMMON STOCK, AMOUNT
Equity Securities, FV-NI	2,864	2,366
Fair Value, Recurring | Nonredeemable Preferred Stock
Equity Securities, FV-NI	883	2,800
Fair Value, Recurring | US Government Agencies Debt Securities
Debt Securities, Available-for-sale		3
Fair Value, Recurring | Redeemable Preferred Stock
Debt Securities, Available-for-sale		5,859
Fair Value, Inputs, Level 1 | Fair Value, Recurring
Debt Securities, Available-for-sale	0	5,859
Equity Securities, FV-NI	3,747	5,166
Assets, Fair Value Disclosure	3,747	11,025
Fair Value, Inputs, Level 1 | Fair Value, Recurring | Corporate Debt Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | US Treasury Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | Debt Security, Government, Non-US
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | COMMON STOCK, AMOUNT
Equity Securities, FV-NI	2,864	2,366
Fair Value, Inputs, Level 1 | Fair Value, Recurring | Nonredeemable Preferred Stock
Equity Securities, FV-NI	883	2,800
Fair Value, Inputs, Level 1 | Fair Value, Recurring | US Government Agencies Debt Securities
Debt Securities, Available-for-sale		0
Fair Value, Inputs, Level 1 | Fair Value, Recurring | Redeemable Preferred Stock
Debt Securities, Available-for-sale		5,859
Fair Value, Inputs, Level 2 | Fair Value, Recurring
Debt Securities, Available-for-sale	383,445	445,896
Equity Securities, FV-NI	0	0
Assets, Fair Value Disclosure	383,445	445,896
Fair Value, Inputs, Level 2 | Fair Value, Recurring | Corporate Debt Securities
Debt Securities, Available-for-sale	162,023	197,489
Fair Value, Inputs, Level 2 | Fair Value, Recurring | Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale	5,382	5,840
Fair Value, Inputs, Level 2 | Fair Value, Recurring | US Treasury Securities
Debt Securities, Available-for-sale	50,549	62,809
Fair Value, Inputs, Level 2 | Fair Value, Recurring | US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale	6,123	6,486
Fair Value, Inputs, Level 2 | Fair Value, Recurring | US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale	152,479	166,225
Fair Value, Inputs, Level 2 | Fair Value, Recurring | Debt Security, Government, Non-US
Debt Securities, Available-for-sale	6,889	7,044
Fair Value, Inputs, Level 2 | Fair Value, Recurring | COMMON STOCK, AMOUNT
Equity Securities, FV-NI	0	0
Fair Value, Inputs, Level 2 | Fair Value, Recurring | Nonredeemable Preferred Stock
Equity Securities, FV-NI	0	0
Fair Value, Inputs, Level 2 | Fair Value, Recurring | US Government Agencies Debt Securities
Debt Securities, Available-for-sale		3
Fair Value, Inputs, Level 2 | Fair Value, Recurring | Redeemable Preferred Stock
Debt Securities, Available-for-sale		0
Fair Value, Inputs, Level 3 | Fair Value, Recurring
Debt Securities, Available-for-sale	1,529	1,709
Equity Securities, FV-NI	0	0
Assets, Fair Value Disclosure	1,529	1,709
Fair Value, Inputs, Level 3 | Fair Value, Recurring | Corporate Debt Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | Collateralized Mortgage Backed Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | US Treasury Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | US Government-sponsored Enterprises Debt Securities
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | US States and Political Subdivisions Debt Securities
Debt Securities, Available-for-sale	1,529	1,709
Fair Value, Inputs, Level 3 | Fair Value, Recurring | Debt Security, Government, Non-US
Debt Securities, Available-for-sale	0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | COMMON STOCK, AMOUNT
Equity Securities, FV-NI	0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | Nonredeemable Preferred Stock
Equity Securities, FV-NI	$ 0	0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | US Government Agencies Debt Securities
Debt Securities, Available-for-sale		0
Fair Value, Inputs, Level 3 | Fair Value, Recurring | Redeemable Preferred Stock
Debt Securities, Available-for-sale		$ 0

Fair Value Disclosures _Text _6

Fair Value Disclosures [Text Block]: Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance	$ 1,709	$ 1,876
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)	(26)	(30)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements	(154)	(137)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance	1,529	1,709
US States and Political Subdivisions Debt Securities
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Beginning Balance	1,709	1,876
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Other Comprehensive Income (Loss)	(26)	(30)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements	(154)	(137)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value, Ending Balance	$ 1,529	$ 1,709

Fair Value Disclosures _Text _7

Fair Value Disclosures [Text Block]: Fair Value, by Balance Sheet Grouping (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Short-term Investments	$ 50	$ 1,050
Securities Purchased under Agreements to Resell	107,157	12,063
Deposit Contracts, Liabilities	140,951	141,635
Policyholder Account Balance	12,049	10,939
Estimate of Fair Value, Fair Value Disclosure | Fair Value, Inputs, Level 1
Short-term Investments	50	1,050
Securities Purchased under Agreements to Resell	107,157	12,063
Deposit Contracts, Liabilities	0	0
Policyholder Account Balance	0	0
Estimate of Fair Value, Fair Value Disclosure | Fair Value, Inputs, Level 2
Short-term Investments	0	0
Securities Purchased under Agreements to Resell	0	0
Deposit Contracts, Liabilities	141,010	141,662
Policyholder Account Balance	12,049	10,939
Carrying (Reported) Amount, Fair Value Disclosure
Short-term Investments	50	1,050
Securities Purchased under Agreements to Resell	107,157	12,063
Deposit Contracts, Liabilities	140,951	141,635
Policyholder Account Balance	$ 12,049	$ 10,939

Investments in and Advances t_3

Investments in and Advances to Affiliates, Schedule of Investments [Text Block]: Other Investments, Including Variable Interest Entities Table Text Block (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Details
Equity Method Investments	$ 10,171	$ 12,308
Equity Securities without Readily Determinable Fair Value, Amount	5,000	850
Other Investments and Securities, at Cost	37	34
Other Investments	$ 15,208	$ 13,192

Investments in and Advances t_4

Investments in and Advances to Affiliates, Schedule of Investments [Text Block] (Details) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2019	Dec. 31, 2018
Income (Loss) from Equity Method Investments			$ 1,304,000	$ (2,111,000)
Equity Method Investments	$ 10,171,000	$ 12,308,000	10,171,000	12,308,000
Equity Method Investments Aggregate Distributions			1,772,000
Equity Securities without Readily Determinable Fair Value, Amount	5,000,000	850,000	5,000,000	850,000
Gain (Loss) on Disposition of Other Assets			3,589,000	0
Payments to Acquire Other Investments			8,000,000	0
Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount		2,275,000
Provision for Loan and Lease Losses			4,185,000	0
Ebix Health Exchange Member | Selling, General and Administrative Expenses
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party			2,180,000	7,779,000
Affiliated Lead Generation Company | Selling, General and Administrative Expenses
Related Party Transaction, Selling, General and Administrative Expenses from Transactions with Related Party			6,940,000
Other Assets | Ebix Health Exchange Member
Due from Related Parties	5,000	1,842,000	5,000	1,842,000
Accounts Payable and Accrued Liabilities | Ebix Health Exchange Member
Due to Related Parties	250,000	910,000	250,000	910,000
Variable Interest Entity, Not Primary Beneficiary, Aggregated Disclosure | Other Investments
Equity Method Investments	5,075,000	2,874,000	5,075,000	2,874,000
Variable Interest Entity, Reporting Entity Involvement, Maximum Loss Exposure, Amount	5,075,000		5,075,000
PetsBest Member
Equity Securities without Readily Determinable Fair Value, Amount		500,000		500,000
Gain (Loss) on Disposition of Other Assets			3,589,000
FIGO Pet Insurance LLC Member
Payments to Acquire Other Investments			5,000,000
Ebix Health Exchange Holdings Member
Income (Loss) from Equity Method Investments			(2,713,000)	(1,763,000)
Equity Method Investment, Other than Temporary Impairment	3,712,000		3,712,000
Equity Method Investments	0	$ 6,425,000	0	$ 6,425,000
Provision for Loan and Lease Losses	$ 1,773,000		1,773,000
Torchlight Technology Group Member
Payments to Acquire Equity Method Investments			$ 3,000,000

Business Combination Disclosu_3

Business Combination Disclosure (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 1,500
Revenues	374,448	$ 350,775
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	12,689	$ 29,053
Series of Individually Immaterial Business Acquisitions
Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value	720
Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Loss	237
Business Combination, Consideration Transferred	8,534
Goodwill, Acquired During Period	9,468
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1,500
Business Acquisition, Goodwill, Expected Tax Deductible Amount	10,921
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	(214)
Revenues	3,876
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ (838)

Business Combination Disclosu_4

Business Combination Disclosure: Schedule of Recognized Identified Assets Acquired and Liabilities Assumed (Details) $ in Thousands	Dec. 31, 2019USD ($)
Series of Individually Immaterial Business Acquisitions
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents	$ 582
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	1,500
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other	1,341
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets	3,423
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other	3,637
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities	3,637
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net	(214)
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 1,500

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets Disclosure [Text Block] (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Goodwill	$ 60,165	$ 50,697
Intangible Assets, Net (Excluding Goodwill)	13,379	13,163
Amortization of Intangible Assets	1,284	$ 1,506
Series of Individually Immaterial Business Acquisitions
Goodwill, Acquired During Period	$ 9,468
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life	17 years
Specialty Health Segment Member
Goodwill, Acquired During Period	$ 9,468
Finite-lived Intangible Assets Acquired	$ 1,500

Goodwill and Intangible Asset_6

Goodwill and Intangible Assets Disclosure [Text Block]: Schedule of Finite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Finite-Lived Intangible Assets, Gross	$ 20,533	$ 19,033
Finite-Lived Intangible Assets, Accumulated Amortization	15,131	13,847
Customer Relationships
Finite-Lived Intangible Assets, Gross	18,753	17,253
Finite-Lived Intangible Assets, Accumulated Amortization	14,474	13,419
Internet Domain Names
Finite-Lived Intangible Assets, Gross	1,000	1,000
Finite-Lived Intangible Assets, Accumulated Amortization	325	225
Computer Software, Intangible Asset
Finite-Lived Intangible Assets, Gross	780	780
Finite-Lived Intangible Assets, Accumulated Amortization	$ 332	$ 203

Goodwill and Intangible Asset_7

Goodwill and Intangible Assets Disclosure [Text Block]: Schedule of Indefinite-Lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 7,977	$ 7,977
Licensing Agreements
Indefinite-lived Intangible Assets (Excluding Goodwill)	$ 7,977	$ 7,977

Goodwill and Intangible Asset_8

Goodwill and Intangible Assets Disclosure [Text Block]: Schedule of Finite-Lived Intangible Assets, Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2019USD ($)
Details
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 1,033
Finite-Lived Intangible Assets, Amortization Expense, Year Two	848
Finite-Lived Intangible Assets, Amortization Expense, Year Three	723
Finite-Lived Intangible Assets, Amortization Expense, Year Four	623
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 497

Lessee, Operating Leases (Detai

Lessee, Operating Leases (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Operating Lease, Right-of-Use Asset	$ 6,672
Operating Lease, Liability	$ 7,243
Operating Lease, Weighted Average Discount Rate, Percent	6.70%
Lessee, Operating Lease, Renewal Term	5 years
Operating Lease, Weighted Average Remaining Lease Term	5 years
Operating Leases, Rent Expense, Net	$ 2,300
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	1,688
Series of Individually Immaterial Business Acquisitions
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 435
Minimum
Lessee, Operating Lease, Term of Contract	1 year
Maximum
Lessee, Operating Lease, Term of Contract	8 years

Lessee, Operating Leases_ Lea_2

Lessee, Operating Leases: Lease, Cost (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Details
Operating Lease, Cost	$ 2,277
Short-term Lease, Cost	194
Variable Lease, Cost	456
Lease, Cost	2,927
Operating Lease, Payments	2,392
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 1,688

Lessee, Operating Leases_ Les_2

Lessee, Operating Leases: Lessee, Operating Lease, Liability, Maturity (Details) $ in Thousands	Dec. 31, 2019USD ($)
Details
Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months	$ 2,381
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two	1,750
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three	1,715
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four	889
Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five	619
Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five	1,079
Lessee, Operating Lease, Liability, Payments, Due	8,433
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	(1,190)
Operating Lease, Liability	$ 7,243

Reinsurance _Text Block__ Eff_2

Reinsurance [Text Block]: Effects of Reinsurance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Direct Premiums Earned	$ 393,400	$ 378,936
Assumed Premiums Earned	1,003	689
Ceded Premiums Earned	55,662	58,377
Premiums Earned, Net	338,741	321,248
Policyholder Benefits and Claims Incurred, Direct	215,477	188,319
Policyholder Benefits and Claims Incurred, Assumed	2,681	1,111
Policyholder Benefits and Claims Incurred, Ceded	44,037	45,224
Policyholder Benefits and Claims Incurred, Net	174,121	144,206
Accident and Health Insurance Product Line
Direct Premiums Earned	287,529	281,787
Assumed Premiums Earned	5	112
Ceded Premiums Earned	22,538	20,632
Premiums Earned, Net	264,996	261,267
Life and Annuity Insurance Product Line
Direct Premiums Earned	54,825	55,303
Assumed Premiums Earned	998	577
Ceded Premiums Earned	33,061	37,360
Premiums Earned, Net	22,762	18,520
Property, Liability and Casualty Insurance Product Line
Direct Premiums Earned	51,046	41,846
Assumed Premiums Earned	0	0
Ceded Premiums Earned	63	385
Premiums Earned, Net	$ 50,983	$ 41,461

Liability for Future Policy B_7

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Schedule of Liability for Unpaid Claims and Claims Adjustment Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Liability for Claims and Claims Adjustment Expense, Beginning Balance	$ 160,115	$ 168,683
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments, Beginning Balance	38,122	42,136
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Beginning Balance	121,993	126,547
Current Year Claims and Claims Adjustment Expense	196,124	166,899
Prior Year Claims and Claims Adjustment Expense	(20,294)	(19,907)
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	175,830	146,992
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year	115,319	97,168
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years	54,695	54,378
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid	170,014	151,546
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Ending Balance	127,809	121,993
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments, Ending Balance	36,993	38,122
Liability for Claims and Claims Adjustment Expense, Ending Balance	164,802	160,115
Specialty Health Segment Member
Prior Year Claims and Claims Adjustment Expense	(5,879)	(10,716)
Specialty Health Segment Member | Health Insurance Product Line
Liability for Claims and Claims Adjustment Expense, Beginning Balance	26,068	32,904
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments, Beginning Balance	851	762
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Beginning Balance	25,217	32,142
Current Year Claims and Claims Adjustment Expense	51,479	47,143
Prior Year Claims and Claims Adjustment Expense	(3,517)	(9,000)
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims	47,962	38,143
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year	25,738	24,422
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years	17,295	20,646
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid	43,033	45,068
Liability for Unpaid Claims and Claims Adjustment Expense, Net, Ending Balance	30,146	25,217
Reinsurance Recoverable for Unpaid Claims and Claims Adjustments, Ending Balance	1,113	851
Liability for Claims and Claims Adjustment Expense, Ending Balance	$ 31,259	$ 26,068

Liability for Future Policy B_8

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block] (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Prior Year Claims and Claims Adjustment Expense	$ (20,294)	$ (19,907)
Specialty Health Segment Member
Prior Year Claims and Claims Adjustment Expense	(5,879)	(10,716)
Specialty Health Segment Member | Health Insurance Product Line
Prior Year Claims and Claims Adjustment Expense	(3,517)	(9,000)
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	30,146
Group disability, life, DBL and PFL
Prior Year Claims and Claims Adjustment Expense	(11,681)	(6,332)
Group disability, life, DBL and PFL | NY Short-Term Disability Product Line
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 22,774
Short-duration Insurance Contract, Cumulative Number of Reported Claims	18,000
Group disability, life, DBL and PFL | NY Short-Term Disability Product Line | Accrued Potential Risk Adjustment
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 10,000
Group disability, life, DBL and PFL | NY Short-Term Disability Product Line | Premium Refund Reserves
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	2,400
Group disability, life, DBL and PFL | Group Disability Product Line | Insurance Benefits, Claims And Reserves Member
Short-duration Insurance Contracts, Discounted Liabilities, Interest Accretion	$ 1,524	$ 1,617
Group disability, life, DBL and PFL | Group Disability Product Line | Minimum
Short-Duration Contract, Discounted Liability, Discount Rate	3.00%	3.00%
Group disability, life, DBL and PFL | Group Disability Product Line | Maximum
Short-Duration Contract, Discounted Liability, Discount Rate	6.00%	6.00%
Group disability, life, DBL and PFL | Group Disability Product Line | Short-duration Insurance Contracts, Accident Year 2013
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 505
Short-duration Insurance Contract, Cumulative Number of Reported Claims	2,629
Claims and Claims Adjustment Expenses Assumed	$ 15,384
Individual life annuities and other Segment Member
Prior Year Claims and Claims Adjustment Expense	(2,449)	$ (2,575)
Medical Stop-Loss Segment Member
Prior Year Claims and Claims Adjustment Expense	$ (285)	$ (284)

Liability for Future Policy B_9

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short-duration Insurance Contracts, Claims Development (Details) $ in Thousands	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)	Dec. 31, 2012USD ($)	Dec. 31, 2011USD ($)	Dec. 31, 2010USD ($)
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	$ 138,136
Specialty Health Segment Member
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	415,985
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	375,740
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented	266
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	40,511
Specialty Health Segment Member | Short-duration Insurance Contracts, Accident Year 2015
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	101,260	$ 100,642	$ 101,241	$ 100,988	$ 104,497
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 293
Short-duration Insurance Contract, Cumulative Number of Reported Claims	467,232
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 100,967	99,364	97,603	94,757	70,090
Specialty Health Segment Member | Short-duration Insurance Contracts, Accident Year 2016
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	85,399	86,244	86,446	85,426
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 1,161
Short-duration Insurance Contract, Cumulative Number of Reported Claims	538,382
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 84,238	82,983	78,611	45,454
Specialty Health Segment Member | Short-duration Insurance Contracts, Accident Year 2017
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	77,194	77,214	87,070
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 1,275
Short-duration Insurance Contract, Cumulative Number of Reported Claims	628,748
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 75,918	73,667	49,289
Specialty Health Segment Member | Short-duration Insurance Contracts, Accident Year 2018
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	69,206	74,652
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 4,259
Short-duration Insurance Contract, Cumulative Number of Reported Claims	661,819
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 64,947	46,574
Specialty Health Segment Member | Short-Duration Insurance Contract, Accident Year 2019
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	82,926
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 33,257
Short-duration Insurance Contract, Cumulative Number of Reported Claims	537,636
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 49,670
Group disability, life, DBL and PFL | NY Short-Term Disability Product Line
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 22,774
Short-duration Insurance Contract, Cumulative Number of Reported Claims	18,000
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	$ 22,774
Group disability, life, DBL and PFL | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	205,838
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	156,436
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net, Not Separately Presented	17,737
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	67,139
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2015 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	14,552	14,705	16,630	19,247	25,335
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 219
Short-duration Insurance Contract, Cumulative Number of Reported Claims	3,253
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 17,623	17,203	16,634	14,034	6,825
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2016 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	25,988	27,359	28,568	28,450
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 331
Short-duration Insurance Contract, Cumulative Number of Reported Claims	3,498
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 20,261	19,269	16,379	8,333
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2017 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	22,851	26,021	29,897
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 425
Short-duration Insurance Contract, Cumulative Number of Reported Claims	3,777
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 17,901	16,139	8,459
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2018 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	26,610	29,766
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 1,603
Short-duration Insurance Contract, Cumulative Number of Reported Claims	3,997
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 16,109	8,417
Group disability, life, DBL and PFL | Short-Duration Insurance Contract, Accident Year 2019 | NY Short-Term Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	65,452
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	42,678
Group disability, life, DBL and PFL | Short-Duration Insurance Contract, Accident Year 2019 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	34,518
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 10,972
Short-duration Insurance Contract, Cumulative Number of Reported Claims	3,439
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 11,794
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2010 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	6,857	6,938	7,239	6,599	3,030	$ 3,965	$ 4,245	$ 6,263	$ 10,561	$ 11,990
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 0
Short-duration Insurance Contract, Cumulative Number of Reported Claims	2,311
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 12,902	12,565	12,200	11,797	11,284	10,762	10,345	9,799	8,200	$ 3,197
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2011 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	16,546	16,516	16,712	16,672	15,730	15,271	16,166	16,948	18,558
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 0
Short-duration Insurance Contract, Cumulative Number of Reported Claims	2,337
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 12,979	12,522	11,993	11,363	10,737	10,186	9,622	8,191	$ 3,252
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2012 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	11,883	12,161	12,472	12,585	12,177	12,187	13,708	15,356
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 0
Short-duration Insurance Contract, Cumulative Number of Reported Claims	2,263
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 10,177	9,924	9,509	8,997	8,591	8,033	7,003	$ 3,069
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2013 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	31,545	31,378	31,664	32,070	29,893	30,832	32,952
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 505
Short-duration Insurance Contract, Cumulative Number of Reported Claims	2,629
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 25,029	23,460	21,536	19,428	16,424	12,541	$ 5,454
Group disability, life, DBL and PFL | Short-duration Insurance Contracts, Accident Year 2014 | Group Disability Product Line
Short-duration Insurance Contracts, Incurred Claims and Allocated Claim Adjustment Expense, Net	14,488	14,311	14,414	14,792	13,322	16,314
Short-duration Insurance Contracts, Incurred but Not Reported (IBNR) Claims Liability, Net	$ 165
Short-duration Insurance Contract, Cumulative Number of Reported Claims	2,783
Short-duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net	$ 11,661	$ 11,142	$ 10,623	$ 9,919	$ 8,466	$ 3,663

Liability for Future Policy _10

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short-duration Insurance Contracts, Schedule of Historical Claims Duration (Details)	Dec. 31, 2019
Specialty Health Segment Member
Short-duration Insurance Contracts, Historical Claims Duration, Year One	62.70%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	30.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	3.60%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	1.60%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	1.60%
Group disability, life, DBL and PFL | Group Disability Product Line
Short-duration Insurance Contracts, Historical Claims Duration, Year One	17.60%
Short-duration Insurance Contracts, Historical Claims Duration, Year Two	20.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Three	6.70%
Short-duration Insurance Contracts, Historical Claims Duration, Year Four	3.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Five	2.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Six	2.10%
Short-duration Insurance Contracts, Historical Claims Duration, Year Seven	1.60%
Short-duration Insurance Contracts, Historical Claims Duration, Year Eight	0.70%
Short-duration Insurance Contracts, Historical Claims Duration, Year Nine	0.30%
Short-duration Insurance Contracts, Historical Claims Duration, Year Ten	0.10%

Liability for Future Policy _11

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short Duration Insurance Contracts, Discounted Liabilities Table Text Block (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Short-duration Insurance Contract, Discounted Liability, Discount	$ 10,382
Group disability, life, DBL and PFL | Group Disability Product Line
Short-Duration Contracts, Discounted Liabilities, Amount	56,756	$ 57,510
Short-duration Insurance Contract, Discounted Liability, Discount	$ 10,382	$ 10,764

Liability for Future Policy _12

Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]: Short-duration Insurance Contracts, Reconciliation of Claims Development to Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	$ 138,136
Short Duration Insurance Insurance Contracts, Reinsurance Recoverable For Unpaid Claims And Claims Adjustments	36,993
Short-duration Insurance Contract, Discounted Liability, Discount	10,382
Liability for Claims and Claims Adjustment Expense	164,802	$ 160,115	$ 168,683
Short-Duration Insurance, OtherÂ
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	7,712
Short Duration Insurance Insurance Contracts, Reinsurance Recoverable For Unpaid Claims And Claims Adjustments	11,290
Long-Duration Insurance, OtherÂ
Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Other Reconciling Item	55
Specialty Health Segment Member
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	40,511
Short Duration Insurance Insurance Contracts, Reinsurance Recoverable For Unpaid Claims And Claims Adjustments	1,717
Group disability, life, DBL and PFL | NY Short-Term Disability Product Line
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	22,774
Short Duration Insurance Insurance Contracts, Reinsurance Recoverable For Unpaid Claims And Claims Adjustments	664
Group disability, life, DBL and PFL | Group Disability Product Line
Short-duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net	67,139
Short Duration Insurance Insurance Contracts, Reinsurance Recoverable For Unpaid Claims And Claims Adjustments	23,322
Short-duration Insurance Contract, Discounted Liability, Discount	$ 10,382	$ 10,764

Income Tax Disclosure _Text B_5

Income Tax Disclosure [Text Block]: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Details
Current Federal Tax Expense (Benefit)	$ 4,498	$ 3,897
Current State and Local Tax Expense (Benefit)	729	528
Current Income Tax Expense (Benefit)	5,227	4,425
Deferred Federal Income Tax Expense (Benefit)	8,334	4,077
Deferred State and Local Income Tax Expense (Benefit)	(902)	(14)
Deferred Income Tax Expense (Benefit)	7,432	4,063
Income Tax Expense (Benefit)	$ 12,659	$ 8,488

Income Tax Disclosure _Text B_6

Income Tax Disclosure [Text Block] (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018	Jun. 30, 2018
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		21.00%
Effective Income Tax Rate Reconciliation, Newly Enacted Federal Statutory Income Tax Rate, Fiscal Year Blended Rate, Percent				28.00%
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount		$ 0	$ 1,190
Income Taxes Paid, Net		966	$ 1,303
AMIC | Domestic Tax Authority
Operating Loss Carryforwards	[1]	114,531
AMICSubsidiariesMember
ValuationAllowance Deferred Tax Asset Change In Amount Due To Change In Projected NOL Utilization		$ (7,900)
[1]	Which expire in varying amounts through 2034, a significant portion expires in 2020.

Income Tax Disclosure _Text B_7

Income Tax Disclosure [Text Block]: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	$ 5,323	$ 7,884
Income Tax Reconciliation, Tax Exempt Income and Dividends Received Deduction	128	187
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	(132)	406
Effective Income Tax Rate Reconciliation, Health Insurer Compensation Limit	583	665
Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount	0	1,190
Income Tax Reconciliation Deductions for Sharebased Compensation	993	844
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	106	(626)
Income Tax Expense (Benefit)	12,659	8,488
AMICSubsidiariesMember
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$ 7,900	$ 0

Income Tax Disclosure _Text B_8

Income Tax Disclosure [Text Block]: Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred Tax Assets, Investments	$ 0	$ 2,210
Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Impairment Losses	48	48
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	23,612	25,708
Deferred Tax Assets, Other	3,323	2,005
Deferred Tax Assets, Gross	26,983	29,971
Deferred Tax Assets, Net of Valuation Allowance	9,771	20,577
Deferred Tax Liabilities, Tax Deferred Expense, Reserves and Accruals, Policyholder Liabilities	2,459	2,801
Deferred Tax Liabilities, Goodwill and Intangible Assets	2,341	3,583
Deferred Tax Liabilities, Investments	338	0
Deferred Tax Liabilities, Other	688	1,564
Deferred Tax Liabilities, Gross	5,826	7,948
Deferred Tax Assets, Net	3,945	12,629
AMICSubsidiariesMember
Deferred Tax Assets, Valuation Allowance	$ 17,212	$ 9,394

Stockholders' Equity Note Dis_4

Stockholders' Equity Note Disclosure [Text Block] (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Aug. 31, 2016
Treasury Stock, Shares, Acquired	108,646	135,311
Treasury Stock, Value, Acquired, Cost Method	$ 4,051	$ 4,019
TREASURY STOCK, AT COST
Treasury Stock, Shares, Acquired	108,646	135,311
Treasury Stock, Value, Acquired, Cost Method	$ 4,051	$ 4,019
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture	95,339	123,274
IhcShareRepurchaseProgramMember
Stock Repurchase Program, Number of Shares Authorized to be Repurchased			3,000,000
Stock Repurchase Program, Remaining Number of Shares Authorized to be Repurchased	1,747,101

Stockholders' Equity Note Dis_5

Stockholders' Equity Note Disclosure [Text Block]: Schedule of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accumulated Other Comprehensive Income (Loss), Net of Tax	$ (8,310)
Cumulative Effect of New Accounting Principle in Period of Adoption		$ (413)
Other Comprehensive Income (Loss), Net of Tax	9,522	(3,362)
Accumulated other comprehensive income (loss)	1,212	(8,310)
Accumulated Net Unrealized Investment Gain (Loss)
Accumulated Other Comprehensive Income (Loss), Net of Tax	(8,310)	(4,598)
Other Comprehensive Income (Loss), before Reclassifications, Net of Tax	12,246	(3,974)
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax	2,724	(612)
Other Comprehensive Income (Loss), Net of Tax	9,522	(3,362)
Accumulated other comprehensive income (loss)	1,212	(8,310)
Accumulated Net Unrealized Investment Gain (Loss) | Accounting Standards Update 2016-01
Cumulative Effect of New Accounting Principle in Period of Adoption	$ 0	$ (350)

Stockholders' Equity Note Dis_6

Stockholders' Equity Note Disclosure [Text Block]: Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Gain (Loss) on Investments	$ 4,705	$ (1,033)
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings	646	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	25,348	37,541
Income Tax Expense (Benefit)	12,659	8,488
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	12,689	29,053
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Unrealized Investment Gain (Loss)
Gain (Loss) on Investments	4,105	(775)
Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Recognized in Earnings	(646)	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	3,459	(775)
Income Tax Expense (Benefit)	735	(163)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 2,724	$ (612)

Compensation and Employee Ben_7

Compensation and Employee Benefit Plans [Text Block] (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	391,120
Proceeds from Stock Options Exercised	$ 269	$ 856
Payment, Tax Withholding, Share-based Payment Arrangement	$ 2,397	$ 905
Share-based Payment Arrangement, Option
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 8.31	$ 9.05
Proceeds from Stock Options Exercised	$ 269	$ 856
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	5,207	4,275
Share-based Payment Arrangement, Exercise of Option, Tax Benefit	970	810
Payment, Tax Withholding, Share-based Payment Arrangement	2,397	$ 905
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount	$ 2,962
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	1 year 7 months 6 days
Share-based Payment Arrangement, Option | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number	64,900	64,900
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted	0	0
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised	0	0
Stock Appreciation Rights (SARs) | Accounts Payable and Accrued Liabilities
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent	$ 717	$ 275
Stock Appreciation Rights (SARs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition	2 years 2 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	9,900	9,900
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 40.01	$ 38.49
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value	$ 389	$ 350
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount	$ 699

Compensation and Employee Ben_8

Compensation and Employee Benefit Plans [Text Block]: Schedule of Compensation Cost for Share-based Payment Arrangements, Allocation of Share-based Compensation Costs by Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Payment Arrangement, Expense, Tax Benefit	$ 720	$ 358
Share-based Payment Arrangement, Expense, after Tax	1,954	833
Selling, General and Administrative Expenses
Share-based Payment Arrangement, Expense	2,674	1,191
Share-based Payment Arrangement, Option | Selling, General and Administrative Expenses
Share-based Payment Arrangement, Expense	1,940	754
Restricted Stock Units (RSUs) | Selling, General and Administrative Expenses
Share-based Payment Arrangement, Expense	292	184
Stock Appreciation Rights (SARs) | Selling, General and Administrative Expenses
Share-based Payment Arrangement, Expense	$ 442	$ 253

Compensation and Employee Ben_9

Compensation and Employee Benefit Plans [Text Block]: Schedule of Share-based Compensation, Stock Options, Activity (Details) - Share-based Payment Arrangement, Option	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Beginning Balance | shares	567,384
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 19.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	424,380
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares	$ 37.38
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares	202,717
Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | $ / shares	$ 9.96
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | shares	4,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price | $ / shares	$ 22.20
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance | shares	785,047
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance | $ / shares	$ 31.54

Compensation and Employee Be_10

Compensation and Employee Benefit Plans [Text Block]: Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) - Share-based Payment Arrangement, Option	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	2.32%	2.86%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	1.22%	1.04%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate	28.97%	32.42%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years 6 months	4 years

Compensation and Employee Be_11

Compensation and Employee Benefit Plans [Text Block]: Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding (Details) - Share-based Payment Arrangement, Option $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | shares	785,047
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | shares	277,665
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares	$ 31.54
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price | $ / shares	$ 23.57
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value | $	$ 8,272
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $	$ 5,140
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	2 years 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term	2 years 4 months 24 days

Compensation and Employee Be_12

Compensation and Employee Benefit Plans [Text Block]: Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity (Details) - Restricted Stock Units (RSUs) - $ / shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number	19,800	19,800
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value	$ 37.54	$ 31.84
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	9,900	9,900
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 40.01	$ 38.49
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period	9,900
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value	$ 28.61

Contingencies Disclosure _Tex_2

Contingencies Disclosure [Text Block] (Details) - USD ($) $ in Thousands	Oct. 16, 2019	May 31, 2017
Arbitration Award	$ 5,641
Pending Litigation | Loss Contingency, Nature, Injunctive Relief and Damages Member
Loss Contingency, Damages Sought, Value		$ 50,000
Pending Litigation | Loss Contingency, Nature, Amounts Allegedly Owed To Plaintiff Member
Loss Contingency, Damages Sought, Value		$ 3,082

Concentration Risk Disclosure_3

Concentration Risk Disclosure [Text Block] (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2019	Dec. 31, 2018
Assets Held by Insurance Regulators		$ 13,359	$ 12,823
Credit Concentration Risk
Fair Value, Concentration of Risk, Investments	[1]	$ 0
Credit Concentration Risk | Stockholders' Equity, Total
Concentration Risk, Percentage		10.00%
Reinsurer Concentration Risk | Stockholders' Equity, Total
Concentration Risk, Percentage		10.00%
[1]	Except for investments in obligations of the U.S. Government and its agencies and mortgage-backed securities issued by GSEs.

Concentration Risk Disclosure_4

Concentration Risk Disclosure [Text Block]: Ceded Credit Risk [Table Text Block] (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Reinsurance Recoverables, Including Reinsurance Premium Paid	$ 362,969	$ 368,731
CededCreditRiskReinsurerNationalGuardianLifeInsuranceCompanyMember | AM Best, A- Rating
Reinsurance Recoverables, Including Reinsurance Premium Paid	215,724
CededCreditRiskReinsurerGuggenheimLifeAndAnnuityCompanyMember | AM Best, B++ Rating
Reinsurance Recoverables, Including Reinsurance Premium Paid	$ 93,775

Dividend Payment Restrictions_3

Dividend Payment Restrictions [Text Block] (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Statutory Accounting Practices, Statutory Amount Available for Dividend Payments without Regulatory Approval	$ 31,287
Statutory Accounting Practices, Dividends Paid with Approval of Regulatory Agency	$ 165,472
Common Stock, Dividends, Per Share, Declared	$ 0.40	$ 0.30
Dividends, Common Stock, Cash	$ 5,963	$ 4,468
MadisonNationalLifeSubsidiariesMember
Payments of Dividends	0	12,035
StandardSecurityLifeSubsidiariesMember
Payments of Dividends	0	3,000
IndependenceAmericanSubsidiariesMember
Payments of Dividends	$ 18,000	$ 8,400

Dividend Payment Restrictions_4

Dividend Payment Restrictions [Text Block]: Statutory Accounting Practices Disclosure (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
MadisonNationalLifeSubsidiariesMember
Statutory Accounting Practices, Statutory Net Income Amount	$ 16,460	$ 16,050
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	83,256	196,031
StandardSecurityLifeSubsidiariesMember
Statutory Accounting Practices, Statutory Net Income Amount	5,246	8,291
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	57,069	70,792
IndependenceAmericanSubsidiariesMember
Statutory Accounting Practices, Statutory Net Income Amount	19,030	18,015
Statutory Accounting Practices, Statutory Capital and Surplus, Balance	$ 84,533	$ 82,986

Segment Reporting Disclosure _3

Segment Reporting Disclosure [Text Block]: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2019	Dec. 31, 2018
Revenues		$ 374,448,000	$ 350,775,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		25,348,000	37,541,000
Provision for Loan and Lease Losses		4,185,000	0
Income (Loss) from Equity Method Investments		1,304,000	(2,111,000)
Assets, Total	$ 1,054,303,000	1,054,303,000	1,037,516,000
Unaffiliated Company
Provision for Loan and Lease Losses		2,412,000
Ebix Health Exchange Holdings Member
Equity Method Investment, Other than Temporary Impairment	3,712,000	3,712,000
Provision for Loan and Lease Losses	1,773,000	1,773,000
Income (Loss) from Equity Method Investments		(2,713,000)	(1,763,000)
Operating Segments
Revenues		370,389,000	351,808,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		21,289,000	38,574,000
Segment Reconciling Items | Gain (Loss) on Investments
Revenues		4,705,000	(1,033,000)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		4,705,000	(1,033,000)
Segment Reconciling Items | Net Impairment Losses Recognized In Earnings
Revenues		(646,000)	0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		(646,000)	0
Specialty Health Segment Member
Revenues		193,823,000	202,938,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		7,757,000	28,735,000
Assets, Total	223,679,000	223,679,000	225,315,000
Group disability, life, DBL and PFL
Revenues		169,038,000	144,629,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		21,809,000	18,863,000
Assets, Total	324,139,000	324,139,000	308,183,000
Individual life annuities and other Segment Member
Revenues		1,669,000	1,932,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		(1,433,000)	(436,000)
Amortization of Other Deferred Charges		788,000	888,000
Assets, Total	348,305,000	348,305,000	348,036,000
Medical Stop-Loss Segment Member
Revenues		6,000	40,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		304,000	177,000
Assets, Total	13,161,000	13,161,000	23,983,000
Corporate
Revenues		5,853,000	2,269,000
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest		(7,148,000)	(8,765,000)
Assets, Total	$ 145,019,000	$ 145,019,000	$ 131,999,000

Subsequent Events _Text Block_

Subsequent Events [Text Block] (Details) - The Abacus Group,LLC $ in Thousands	Jan. 01, 2020USD ($)
Business Acquisition, Percentage of Voting Interests Acquired	56.00%
Business Combination, Consideration Transferred	$ 2,464

Summary of Investments, Other_3

Summary of Investments, Other than Investments in Related Parties: Summary Of Investments Other Than Investments In Related Parties Table Text Block (Details) $ in Thousands	Dec. 31, 2019USD ($)
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	$ 513,016
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	511,136
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	511,136
US Treasury and Government
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	56,570
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	56,672
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	56,672
US States and Political Subdivisions Debt Securities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	153,439
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	154,008
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	154,008
Foreign Government Debt
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	6,719
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	6,889
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	6,889
Public Utility, Bonds
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	28,237
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	28,598
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	28,598
Other Corporate Bonds
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	138,460
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	138,807
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	138,807
Fixed Maturities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	383,425
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	384,974
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	384,974
Industrial, Miscellaneous, and All Others
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	2,613
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	2,865
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	2,865
Nonredeemable Preferred Stock
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	851
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	882
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	882
Equity Securities
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	3,464
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	3,747
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	3,747
Short-term Investments
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	107,207
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	107,207
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	107,207
Other Long-term Investments
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Cost	18,920
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Fair Value	15,208
SEC Schedule, 12-15, Insurance Companies, Summary of Investments, Other than Investments in Related Parties, Amount	$ 15,208

Condensed Financial Informati_5

Condensed Financial Information of Parent Company Only Disclosure: Condensed Balance Sheet (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value	$ 21,094	$ 26,173
Securities Purchased under Agreements to Resell	107,157	12,063
Debt Securities, Available-for-sale	384,974	453,464
Equity Method Investments	10,171	12,308
Other Assets	72,695	82,568
Assets, Total	1,054,303	1,037,516
Other Liabilities	61,049	53,133
Liabilities	592,354	583,902
Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount	2,237	2,183
Preferred Stock, Value, Issued	0	0
Common Stock, Value, Issued	18,625	18,625
Additional Paid in Capital, Common Stock	122,717	124,395
Accumulated Other Comprehensive Income (Loss), Net of Tax	1,212	(8,310)
Treasury stock, at cost; 3,760,517 and 3,747,210 shares	(69,724)	(66,392)
Retained Earnings (Accumulated Deficit)	386,864	380,431
TOTAL IHC STOCKHOLDERS' EQUITY	459,694	448,749
Stockholders' Equity Attributable to Noncontrolling Interest	18	2,682
TOTAL EQUITY	459,712	451,431	$ 434,243
TOTAL LIABILITIES AND EQUITY	$ 1,054,303	$ 1,037,516
Preferred Stock, Par or Stated Value Per Share	$ 1	$ 1
Preferred Stock, Shares Authorized	100,000	100,000
Common Stock, Par or Stated Value Per Share	$ 1	$ 1
Common Stock, Shares Authorized	23,000,000	23,000,000
Common Stock, Shares, Issued	18,625,458	18,625,458
Common Stock, Shares, Outstanding	14,864,941	14,878,248
Treasury Stock, Shares	3,760,517	3,747,210
Parent Company
Cash and Cash Equivalents, at Carrying Value	$ 895	$ 2,700	$ 2,304
Securities Purchased under Agreements to Resell	39,438	0
Debt Securities, Available-for-sale	3,260	38,270
Equity Method Investments	428,014	456,304
Income Taxes Receivable	9,307	0
Deferred Income Tax Assets, Net	1,517	0
Other Assets	461	281
Assets, Total	482,892	497,555
Other Liabilities	11,491	10,005
Due to Affiliate	6,449	25,035
Accrued Income Taxes	0	6,645
Dividends Payable	3,003	2,256
Liabilities	20,943	43,941
Redeemable Noncontrolling Interest, Equity, Common, Carrying Amount	2,237	2,183
Preferred Stock, Value, Issued	0	0
Common Stock, Value, Issued	18,625	18,625
Additional Paid in Capital, Common Stock	122,717	124,395
Accumulated Other Comprehensive Income (Loss), Net of Tax	1,212	(8,310)
Treasury stock, at cost; 3,760,517 and 3,747,210 shares	(69,724)	(66,392)
Retained Earnings (Accumulated Deficit)	386,864	380,431
TOTAL IHC STOCKHOLDERS' EQUITY	459,694	448,749
Stockholders' Equity Attributable to Noncontrolling Interest	18	2,682
TOTAL EQUITY	459,712	451,431
TOTAL LIABILITIES AND EQUITY	$ 482,892	$ 497,555
Preferred Stock, Par or Stated Value Per Share	$ 1	$ 1
Preferred Stock, Shares Authorized	100,000	100,000
Preferred Stock, Shares Issued	0	0
Common Stock, Par or Stated Value Per Share	$ 1	$ 1
Common Stock, Shares Authorized	23,000,000	23,000,000
Common Stock, Shares, Issued	18,625,458	18,625,458
Common Stock, Shares, Outstanding	14,864,941	14,878,248
Treasury Stock, Shares	3,760,517	3,747,210

Condensed Financial Informati_6

Condensed Financial Information of Parent Company Only Disclosure: Condensed Income Statement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net Investment Income	$ 15,643	$ 15,021
Gain (Loss) on Investments	4,705	(1,033)
Other Income	2,002	(3,361)
Revenues	374,448	350,775
Income (Loss) from Equity Method Investments	1,304	(2,111)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	25,348	37,541
Income Tax Expense (Benefit)	12,659	8,488
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	12,689	29,053
Net Income (Loss) Attributable to Noncontrolling Interest	(293)	(571)
Net Income (Loss) Attributable to Parent	12,396	28,482
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	9,522	(3,362)
Other Comprehensive Income (Loss), Net of Tax	9,522	(3,362)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	22,211	25,691
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	(293)	(571)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	21,918	25,120
Parent Company
Net Investment Income	738	547
Gain (Loss) on Investments	130	(28)
Other Income	1,461	1,598
Revenues	2,329	2,117
General and Administrative Expense	9,352	7,922
Operating Expenses	9,352	7,922
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	(7,023)	(5,805)
Income (Loss) from Equity Method Investments	19,061	32,459
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	12,038	26,654
Income Tax Expense (Benefit)	(651)	(2,399)
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	12,689	29,053
Net Income (Loss) Attributable to Noncontrolling Interest	(293)	(571)
Net Income (Loss) Attributable to Parent	12,396	28,482
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax	164	(130)
Equity in unrealized gains (losses) on available-for-sale securities of subsidiaries	9,358	(3,232)
Other Comprehensive Income (Loss), Net of Tax	9,522	(3,362)
Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest	22,211	25,691
Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest	(293)	(571)
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	$ 21,918	$ 25,120

Condensed Financial Informati_7

Condensed Financial Information of Parent Company Only Disclosure: Condensed Cash Flow Statement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	$ 12,689	$ 29,053
Income (Loss) from Equity Method Investments	(1,304)	2,111
Other Noncash Income (Expense)	8,261	6,644
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable	2,285	1,112
Increase (Decrease) in Other Operating Assets and Liabilities, Net	(1,956)	(7,599)
Net Cash Provided by (Used in) Operating Activities	39,174	36,017
Proceeds from (Payments for) Securities Purchased under Agreements to Resell	(95,094)	(1,794)
Payments to Acquire Debt Securities, Available-for-sale	(168,540)	(126,529)
Proceeds from Sale of Debt Securities, Available-for-sale	161,239	72,905
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	86,460	32,813
Net Cash Provided by (Used in) Investing Activities	(27,137)	(27,690)
Payments for Repurchase of Common Stock	(4,057)	(4,140)
Payments of Ordinary Dividends, Common Stock	(5,231)	(3,712)
Proceeds from Stock Options Exercised	269	856
Payment, Tax Withholding, Share-based Payment Arrangement	(2,397)	(905)
Net Cash Provided by (Used in) Financing Activities	(18,213)	(9,717)
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	26,173
Cash and Cash Equivalents, at Carrying Value, Ending Balance	21,094	26,173
Parent Company
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest	12,689	29,053
Income (Loss) from Equity Method Investments	(19,061)	(32,459)
Other Noncash Income (Expense)	3,247	2,465
Increase (Decrease) in Income Taxes Payable, Net of Income Taxes Receivable	(17,793)	3,221
Increase (Decrease) in Other Operating Assets and Liabilities, Net	(48)	(660)
Net Cash Provided by (Used in) Operating Activities	(20,966)	1,620
Change In Investments In and Advances To Subsidiaries	34,544	17,779
Proceeds from (Payments for) Securities Purchased under Agreements to Resell	(39,438)	0
Payments to Acquire Debt Securities, Available-for-sale	(1,154)	(16,000)
Proceeds from Sale of Debt Securities, Available-for-sale	8,432	4,469
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	28,193	429
Net Cash Provided by (Used in) Investing Activities	30,577	6,677
Payments for Repurchase of Common Stock	(4,057)	(4,140)
Payments of Ordinary Dividends, Common Stock	(5,231)	(3,712)
Proceeds from Stock Options Exercised	269	856
Payment, Tax Withholding, Share-based Payment Arrangement	(2,397)	(905)
Net Cash Provided by (Used in) Financing Activities	(11,416)	(7,901)
Cash and Cash Equivalents, Period Increase (Decrease)	(1,805)	396
Cash and Cash Equivalents, at Carrying Value, Beginning Balance	2,700	2,304
Cash and Cash Equivalents, at Carrying Value, Ending Balance	895	2,700
SEC Schedule, 12-04, Cash Dividends Paid to Registrant, Consolidated Subsidiaries	53,129	17,833
Restricted Cash	0	0
Parent Company | Subsidiaries
Increase (Decrease) in Income Taxes Payable	$ (17,086)	$ 5,778

Supplementary Insurance Infor_3

Supplementary Insurance Information, for Insurance Companies Disclosure: Supplementary Insurance Information For Insurance Companies Disclosure Table Text Block (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost	$ 0	$ 0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense	506,958,000	510,660,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium	7,282,000	5,557,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue	338,741,000	321,248,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income	15,643,000	15,021,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses	174,121,000	144,206,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense	174,979,000	169,028,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written	340,458,000	320,202,000
Selling, General and Administrative Expenses
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	1,036,000	982,000
Specialty Health Segment Member
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense	42,495,000	38,154,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium	3,110,000	3,635,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue	177,991,000	184,512,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income	4,330,000	4,386,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses	75,539,000	60,749,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense	110,527,000	113,454,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written	177,438,000	184,513,000
Group disability, life, DBL and PFL
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense	146,080,000	148,012,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium	4,000,000	1,737,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue	160,702,000	136,709,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income	7,774,000	7,029,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses	97,335,000	82,948,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense	49,894,000	42,818,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written	162,972,000	135,662,000
Individual life annuities and other Segment Member
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense	318,236,000	324,063,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium	172,000	185,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue	48,000	27,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income	1,294,000	1,535,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses	1,382	796,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense	1,720,000	1,572,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written	48,000	27,000
Medical Stop-Loss Segment Member
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense	147,000	431,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income	6,000	39,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses	(135,000)	(287,000)
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense	(163,000)	150,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written	0	0
Corporate
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Liability for Future Policy Benefit, Loss, Claim and Loss Expense	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Unearned Premium	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Revenue	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Net Investment Income	2,239,000	2,032,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Benefit, Claim, Loss and Settlement Expenses	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Amortization of Deferred Policy Acquisition Cost	0	0
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Other Operating Expense	13,001,000	11,034,000
SEC Schedule, 12-16, Insurance Companies, Supplementary Insurance Information, Premium Written	$ 0	$ 0

Supplemental Schedule of Rein_3

Supplemental Schedule of Reinsurance Premiums for Insurance Companies: Supplemental Schedule Of Reinsurance Premiums For Insurance Companies Table Text Block (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Life Insurance in Force, Gross	$ 14,935,361	$ 14,486,642
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Life Insurance in Force, Assumed	6,298	6,546
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Life Insurance in Force, Ceded	6,553,251	7,528,651
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Life Insurance in Force, Net	$ 8,388,408	$ 6,964,537
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Life Insurance in Force, Percentage Assumed to Net	0.10%	0.10%
Direct Premiums Earned	$ 393,400	$ 378,936
Assumed Premiums Earned	1,003	689
Ceded Premiums Earned	55,662	58,377
Premiums Earned, Net	$ 338,741	$ 321,248
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net	0.30%	0.20%
Accident and Health Insurance Product Line
Direct Premiums Earned	$ 287,529	$ 281,787
Assumed Premiums Earned	5	112
Ceded Premiums Earned	22,538	20,632
Premiums Earned, Net	$ 264,996	$ 261,267
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net	0.00%	0.00%
Life and Annuity Insurance Product Line
Direct Premiums Earned	$ 54,825	$ 55,303
Assumed Premiums Earned	998	577
Ceded Premiums Earned	33,061	37,360
Premiums Earned, Net	$ 22,762	$ 18,520
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net	4.40%	3.10%
Property, Liability and Casualty Insurance Product Line
Direct Premiums Earned	$ 51,046	$ 41,846
Assumed Premiums Earned	0	0
Ceded Premiums Earned	63	385
Premiums Earned, Net	$ 50,983	$ 41,461
SEC Schedule, 12-17, Insurance Companies, Reinsurance, Premium, Percentage Assumed to Net	0.00%	0.00%